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ABSTRACT 
With the onset of the rapidly increasing population, the impact of age related 
neurodegenerative diseases including Amyotrophic lateral sclerosis, Alzheimer’s disease, 
Creutzfeldt-Jakob disease, Parkinson’s disease, Huntington’s disease and frontotemporal 
dementia is becoming a predominant health and economic concern. Amyotrophic lateral 
sclerosis (ALS) is a devastating neuromuscular degenerative disease that currently has no 
effective treatment or therapeutics. ALS is characterised by a focal onset of motor neuron 
loss, followed by contiguous outward spreading of pathology throughout the nervous system, 
resulting in paralysis and death generally within a few years after diagnosis. The mechanisms 
underlying neurodegeneration of motor neurons and disease progression are currently 
unknown; however, current evidence implicates a range of cellular mechanisms. These 
mechanisms include, deficient protein quality control, aberrant RNA metabolism, oxidative 
stress, endoplasmic reticulum stress, glutamate excitotoxicity, mitochondrial dysfunction, 
fragmentation of the Golgi apparatus, activated glia, axonal transport defects and 
neuroinflammation. These dysfunctional cellular pathways may be associated with the 
protein aggregates that are hallmarks of ALS pathology. However, the dysfunction in several 
cellular processes does not explain the spreading of pathology, here the aberrant release and 
uptake of toxic proteins including SOD1 and TDP-43 and their subsequent accumulation and 
deposition in motor neurons may contribute. Given this hypothesis, the work presented in this 
thesis aimed to further examine the role of SOD1 and TDP-43 in the propagation of 
neurodegeneration in ALS, and investigate whether the proteins exhibit prion-like properties. 
The term “Prion-like” as used here refers to the misfolding and aggregation of a disease 
specific protein that subsequently escapes the cellular environment and seeds aggregation in a 
naïve cell. 
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The main aims of this thesis were to: investigate the mechanisms underpinning the uptake of 
SOD1 aggregates into murine NSC-34 cells (Chapter 2); Examine the subsequent release of 
SOD1 into the cytosol, detect released extracellular SOD1, and observe for secreted SOD1 
internalisation into NSC‐34 motor neurons, then identify and quantify seeding activity in 
recipient cells expressing SOD1 and characterise this interaction using a novel flow 
cytometry method to quantify protein aggregation; Flow cytometric characterisation of 
inclusions and trafficking (FloIT) (Chapter 3); determine whether exogenous recombinant 
SOD1 protein aggregates can induce and/or contribute to TDP-43 pathology (Chapter 4); 
determine if SOD1 aggregates can enter humanised models of motor neurons via the same 
mechanism of action using both iPSC derived motor neurons and primary neurons (Chapter 
5).  
In Chapter 2, the aggregation and internalisation of SOD1 proteins, inhibition of SOD1 
aggregates; macropinocytosis-associated membrane protrusions, fluid-phase uptake and 
activation of RAC1 in NSC-34 motor neurons were investigated using transmission electron 
microscopy, pharmacological inhibitors, flow cytometric measurements, confocal 
microscopy, field emission scanning electron microscopy and enzyme‐linked immunosorbent 
assays (ELISAs). Flow cytometric measurements indicated that SOD1 aggregates could enter 
into naïve NSC‐34 cells in vivo. Furthermore, internalisation of SOD1 aggregates into NSC-
34 cells was shown to be mediated via a macropinocytosis pathway. SOD1-induced the 
activation of macropinocytosis in NSC-34 cells, which was dependent on the activation of 
RAC1 as assessed by ELISA. This in turn triggered the formation of ruffles and blebs in the 
plasma membrane as assessed by field emission scanning electron microscopy and 
fluorescent measurements of the FM1-43FX membrane binding dye. This resulted in the 
uptake of SOD1 aggregates and fluid from the extracellular environment as assessed by 
fluorescent measurements of 10 kDa dextran conjugated to Alexa Fluor. Significant cell 
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death in NSC-34 motor neurons was not observed during this process. Collectively, this data 
suggests that SOD1 aggregates are capable of mediating the activation of macropinocytosis-
like pathways to facilitate their entry into in NSC-34 cells.  
In chapter 3, spontaneous aggregation of SOD1
WT
 and mutant SOD1
G93A
-EGFP proteins in 
NSC-34 motor neurons was measured using the flow cytometric characterisation of 
inclusions and trafficking (FloIT) technique. The transient expression of SOD1
WT
 and mutant 
SOD1
G93A
-EGFP in NSC-34 motor neurons was shown to correlate with cell death over time, 
indicative of toxicity. SOD1 aggregate release from transiently transfected NSC-34 cells was 
examined by immunoblotting pelletable fractions of conditioned media from these cells at 
end point (72 h). Although the mechanisms of release were not confirmed, an increase in cell 
death was observed concomitant with inclusion formation; consistent with a possible role for 
passive release from SOD1 transfected NSC-34 cells. The now extracellular (released) SOD1 
aggregates were internalised into naïve NSC-34 cells as demonstrated by confocal 
microscopy and immunoblotting of cell lysates. Next, the transfer of SOD1
WT
 tdTomato and 
mutant SOD1
G93A
-EGFP from transfected NSC-34 cells was assessed by flow cytometry and 
the FloIT technique. The transfer of SOD1
WT
 tdTomato and mutant SOD1
G93A
-EGFP proteins 
was confirmed by the detection of dual fluorescent NSC-34 cells, indicating the presence of 
both proteins. Furthermore, immunoblotting and microscopic observations following the 
uptake of SOD1 aggregates suggested that recombinant WT and mutant SOD1 aggregates 
were found to escape membrane bound vesicles and enter into the cytosol; a similar process 
has previously been observed during virus entry. The ability of SOD1 to rupture membrane 
bound compartments was confirmed by haemoglobin red blood cell assay, the use of 
liposomes, and fluorescent measurements of the Galectin-3 protein. The seeding activity of 
mutant SOD1 was assessed by co-culturing NSC-34 cells expressing either SOD1
WT
 
tdTomato or mutant SOD1
G93A
-EGFP. Flow cytometric analysis and FloIT measurements 
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indicated that mutant SOD1
G93A
-EGFP induced the aggregation of SOD1
WT
 tdTomato 
proteins at 72 h, in a prion like fashion. The FloIT analysis of two colour aggregates also 
demonstrates that SOD1
G93A
-EGFP and SOD1
WT
 tdTomato are co-aggregating. The seeding 
activity of mutant SOD1 was further confirmed, when recombinant mutant SOD1 G93A 
aggregates were found to enhance the number of inclusion bodies containing SOD1
WT
 
tdTomato red aggregates as assessed by flow cytometric analysis and FloIT measurements. 
Together, this data supports a role for SOD1 in the infectious prion-like spread of protein 
aggregation in neuronal cells. 
In Chapter 4, spontaneous aggregation of TDP-43
WT
 tdTomato and mutant TDP-43
G124A
-
EGFP fusion proteins in NSC-34 motor neurons was demonstrated using flow cytometry and 
measured using the flow cytometric characterisation of inclusions and trafficking (FloIT) 
technique. However, a significant reduction in the number of inclusions was observed at 72 h, 
indicating loss of cells containing inclusions, likely through cell death. The transfer of TDP-
43
WT
 tdTomato and mutant TDP-43
G124A
-EGFP from transfected donor to recipient NSC-34 
cells was assessed by flow cytometry and the FloIT technique. The transfer of TDP-43
WT
 
tdTomato and mutant TDP-43
G124A
-EGFP proteins was confirmed by the detection of dual 
fluorescent NSC-34 cells, indicating the presence of both proteins. Furthermore, the seeding 
activity of mutant TDP-43 was assessed by co-culturing NSC-34 cells expressing either TDP-
43
WT
 tdTomato or mutant TDP-43
G124A
-EGFP. Flow cytometric analysis and FloIT 
measurements indicated that mutant TDP-43
G124A 
induced the aggregation of TDP-43
WT
 from 
48 to 72 h. These data also demonstrate that TDP-43
G124A 
and TDP-43
WT
 tdTomato are co-
aggregating. Incubation of TDP-43
WT
 tdTomato transfected NSC-34 cells with recombinant 
SOD1 aggregates was found to induce the mislocalisation and aggregation of TDP-43
WT
 into 
the cytosol at 2 h and 72 h. To confirm these results, flow cytometric analysis and FloIT 
measurements were used to quantify inclusion formation. Recombinant mutant SOD1 G93A 
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aggregates were found to significantly enhance the number of inclusion bodies containing 
TDP-43
WT
 tdTomato red aggregates. Furthermore, confocal microscopy demonstrated that 
recombinant SOD1 aggregates could induce the same TDP-43 pathology in TDP-43
WT
 
tdTomato transfected human embryonic kidney (HEK-293) cells. Collectively, this data 
suggests that TDP-43 can spontaneously form aggregates, transfer between cultured motor 
neuron cells and induce the aggregation of TDP-43
WT
 mediated by mutant TDP-43
G124A
. This 
is similar to those observed for SOD1. Furthermore, this study suggests a role for the 
interplay between SOD1 and TDP-43 where SOD1 aggregates may contribute to TDP-43 
pathology.  
In Chapter 5, a role for macropinocytosis in humanised models was studied. Human iPSC 
derived motor neurons and human primary neurons were both used to confirm the ability of 
protein aggregates to stimulate macropinocytosis using confocal microscopy and flow 
cytometry. Incubation of human iPSC derived motor neurons and neurons with WT and 
mutant G93A SOD1 recombinant aggregates were found to internalise into these cells, and 
this could be significantly inhibited by pre-incubation with inhibitors of macropinocytosis 
including EIPA and RAC1W56. Furthermore, confocal microscopy observations 
demonstrated that SOD1 aggregate internalisation into these cells induced the formation of 
membrane ruffling and blebbing, as assessed by field emission scanning electron microscopy 
and fluorescent measurements of the FM1-43FX membrane binding dye. In addition, the 
internalisation of SOD1 aggregates was shown to coincide with the uptake of extracellular 
fluid as assessed by fluorescent measurements of 10 kDa dextran conjugated to Alexa Fluor. 
This data supports a role for SOD1 aggregate mediated activation of macropinocytosis in 
human neurons, demonstrating that similar mechanisms are possible in vivo. Moreover, the 
role of macropinocytosis in other protein aggregates including recombinant TDP-43, 
Huntingtin (Httex146Q) and α-synuclein associated with ALS/FTLD, Huntington’s and 
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Parkinson’s disease was assessed in NSC-34 motor neurons. Incubation of NSC-34 motor 
neurons with TDP-43, Huntingtin (Httex146Q) and α-synuclein recombinant aggregates was 
found to result in aggregate internalisation, which could be significantly inhibited by pre-
incubation with inhibitors of macropinocytosis including EIPA (exception in the case of α-
synuclein). Furthermore, internalisation of these aggregates into these NSC-34 motor neurons 
induced the formation of membrane perturbations as assessed by field emission scanning 
electron microscopy; this coincided with the activation of RAC1 as assessed by ELISA and 
the uptake of extracellular fluid as assessed by fluorescent measurements of 10 kDa dextran 
conjugated to Alexa Fluor. Furthermore, the model proteins α-lactalbumin reduced and 
carboxymethylated (RCM) and amorphous proteins were also able to internalize into NSC-34 
motor neurons, induce membrane perturbations and fluid uptake from the extracellular 
environment, in a similar manner to that of SOD1, however, this occurred in the absence of 
the activation of RAC1 suggesting that a broad range of aggregated proteins, both amorphous 
and amyloid-like, may be able to induce varied macropinocytosis-like pathways to facilitate 
their cellular uptake. Overall, this data suggests that activation of macropinocytosis-like 
pathways induced by a range of protein aggregates including SOD1, TDP-43, Huntingtin 
(Httex146Q) and α-synuclein aggregates may facilitate their entry into motor neurons in vivo, 
similar to those observed during the propagation of aggregation during ALS progression.  
Collectively, this thesis demonstrated that SOD1 and TDP-43 protein aggregates, as well as 
other protein aggregates including Huntingtin (Httex146Q) and α-synuclein aggregates are 
capable of being internalising by neuronal cells, through stimulating the activation of 
macropinocytosis, an endocytic pathway also commonly employed by viruses during 
infection. Once internalised, SOD1 and TDP-43 aggregates were shown to behave in a prion-
like manner, propagating aggregation between motor neuron cells in culture, a mechanism 
that potentially contributes to the progression of disease in ALS. However, given that an 
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array of other genes have been recently implicated in disease pathogenesis and the multi-
systemic and multifactorial nature of ALS, findings from this thesis may only represent one 
pathway which may act in concert with other pathways and mechanisms to induce motor 
neuron degeneration. Given this, further research into the pathological mechanisms 
underlying the progressive cycle of disease progression of ALS is necessary for viable 
therapeutic treatments of ALS. 
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1.1 Amyotrophic Lateral sclerosis: A common motor neuron disorder 
Amyotrophic lateral sclerosis (ALS) was first described by Jean-Martin Charcot in 1869, as a 
paralytic disorder associated with lesions observed in the central nervous system (CNS) 
(Goetz, 2000). ALS is the most common form of motor neuron disease with adult onset. It is 
a progressive and fatal neurodegenerative disease characterised by the selective degeneration 
of both the upper and lower motor neurons which extend through the brainstem and spinal 
cord to innervate skeletal muscle (Boillée et al., 2006) (Figure 1.1). Premature degeneration 
and death of these motor neurons leads to progressive spasticity, exaggerated reflexes of 
facial muscles (bulbar onset) or limbs (spinal onset), muscle weakness and atrophy that 
affects the muscles of mobility, speech, swallowing and respiration, eventually resulting in 
paralysis and death of the patient generally within 3-5 years from clinical onset (Cleveland 
and Rothstein, 2001; Tandan and Bradley, 1985). Although in general cell loss in ALS is 
specific for motor neurons, thus sparing cognitive ability, in approximately 5-10% of ALS 
cases, patients also develop frontotemporal lobar dementia (FTLD) (Lomen-Hoerth et al., 
2002). 
1.2 Clinical features and disease course in ALS  
Diagnosis of ALS is achieved by clinical examination and electromyography (EMG) analysis 
(Redler and Dokholyan, 2012). ALS is a heterogeneous disorder, characterised by variations 
in i) the region(s) of onset, ii) contribution of upper and lower motor neuron deficits and iii) 
the rate of disease progression between affected individuals (Ravits and Spada, 2009). 
Irrespective of this, the majority of ALS cases are defined by a focal site of clinical onset of 
motor neuron degeneration, followed by outward spreading of pathology through adjacent 
contiguous anatomic paths, affecting motor neurons that are proximal to the region of onset, 
followed by more distal pools of motor neurons and other cells within the interconnected 
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regions (Ravits et al., 2007; Ravits and Spada, 2009). Recent evidence however, suggests that 
onset of motor neuron degeneration can start at one or more focal points (multifocal) (Braak 
et al., 2013), followed by local propagation of pathology from these regions (Sekiguchi et al., 
2014). Although contiguous propagation of pathology through the neuroaxis is considered the 
most significant clinical feature of ALS (Ravits and Spada, 2009), the molecular mechanisms 
underlying anatomical spread are currently unknown. Given the progression and spread 
observed in ALS cases, it is likely disease pathology is spread cell to cell and region to region 
by a yet to be understood mechanism.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 ALS disease onset and regional spread of pathology involves the anatomy of 
the motor system. The functional motor system consists of upper motor neurons (UMNs), lower motor 
neurons (LMNs), and regional skeletal muscles. Upper motor neurons (solid red line) are located in the primary 
motor cortex of the brain with their axons projecting to the brainstem or spinal cord to form synapses with LMN 
cell bodies (blue dots). LMN axons then extend from the brainstem or the spinal cord to communicate with 
target muscles of the head and neck or trunk and proximal limb muscles through synaptic connectivity 
respectively (blue line). At the initiation of disease in ALS, pathology is observed to have propagated and 
distributed within the functional motor system, followed by propagation of pathology by regional contiguous 
spread (Ravits, 2014; Ravits and Spada, 2009), affecting muscle tissues responsible for controlling voluntary 
movements (Rowland and Shneider, 2001), and therefore resulting in the progressive paralysis. 
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1.3 Incidence, Risk factors and therapeutics 
ALS has an incidence of approximately 2-3 people per 100,000 (Logroscino et al., 2010; 
Strong and Rosenfeld, 2003), with a slight male predominance in Caucasian populations 
(Logroscino et al., 2010), although the incidence between men and women is relatively 
similar in familial ALS (Kiernan et al., 2011). The major risk factors for ALS are age, with 
onset commonly occurring at 45-65 years, and family history of the disease (Kiernan et al., 
2011). There is increasing evidence to suggest that specific environmental factors may have a 
role in the etiology of some ALS cases. Such environmental factors thought to increase the 
risk of developing ALS include engaging in a lifetime of intensive physical activity 
(Scarmeas et al., 2002; Veldink et al., 2005) and geographically limited populations including 
Gulf War veterans (Haley, 2003) and Italian soccer players (Chio et al., 2005). The overall 
population-based lifetime risk of ALS is 1:350 and 1:400 for men and women respectively 
(Kiernan et al., 2011), with a rapid decrease in incidence after the age of 80 (Logroscino et 
al., 2010).  
Currently, ALS is managed by limited pharmacological treatments which have prioritised the 
symptoms rather than the causes of ALS, with more potentially supportive therapies being 
investigated, such as Tauroursodeoxycholic acid (Elia et al., 2016; Lu et al., 2016). Despite 
this, there are no definitive treatment options to cure or even significantly slow ALS disease 
progression. Riluzole is the only clinically approved disease-modifying therapeutic treatment 
available (Orsini et al., 2015). However this drug only provides modest improvement in 
survival (3-6 months) attributed to its transient effects on modulating excitotoxicity 
(Geevasinga et al., 2016). Consequently, understanding the pathological mechanisms of 
neurodegeneration in ALS disease progression is necessary for better treatment options that 
aim to improve disease course and potentially lead to preventative treatments for ALS that 
will act as specific disease targets.  
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1.4 Disease Aetiology 
The aetiology of ALS is currently unknown, however, it is suggested that the complexity of 
ALS is attributed to the multi-factorial and multi-systemic nature of the disease, some of 
which will be outlined below. Previous findings from studies of ALS patients, transgenic 
animal models and in vivo cell culture systems implicate several pathological processes that 
may potentially be responsible for, or contribute to, the pathogenesis of ALS resulting in it 
being classed as either a proteinopathy, a ribonucleopathy, an axonopathy, or a disease 
related to the neuronal microenvironment (Riancho et al., 2016).  
There are currently multiple and interconnected molecular and pathological mechanisms 
implicated in ALS. These mechanisms include, deficient protein quality control, aberrant 
RNA metabolism, oxidative stress, endoplasmic reticulum stress, glutamate excitotoxicity, 
mitochondrial dysfunction, fragmentation of the Golgi apparatus, axonal transport defects and 
neuroinflammation (reviewed in Harikrishnareddy et al., 2015; Redler and Dokholyan, 2012). 
However, recent work presents convincing evidence to suggest that these mechanisms are 
occurring simultaneously, rather than individually, to mediate motor neuron degeneration and 
death (reviewed in Soo et al., 2011), and therefore are potential targets for therapeutic 
intervention. 
1.5 Protein misfolding and aggregation 
Neurodegenerative diseases are closely linked to the formation and deposition of protein 
aggregates, quite often fibrillar, that accumulate intracellularly, such as α-synuclein in 
Parkinson’s disease, or extracellularly, such as the Aβ peptide plaques associated with 
Alzheimer’s disease (Chiti and Dobson, 2006). Although the peptides and proteins that 
aggregate are seemingly unrelated in terms of primary or tertiary structure, often the resulting 
deposits are remarkably similar, often sharing a rope-like fibrillar morphology, a common 
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cross-β core structure, and the ability to bind specific dyes such as thioflavin T and Congo 
red (Dobson, 2003).  
Protein aggregation, or more specifically fibril formation, can be described as a nucleated 
self-assembly reaction. In this context, misfolded monomeric proteins or peptides must first 
aggregate to form stable nuclei from which fibril growth can occur via addition of further 
monomer. In vivo, using bulk measurements such as light scattering or thioflavin T 
fluorescence, protein aggregation reactions display sigmoidal growth kinetics (Figure 1.2). 
Initially, there is a lag phase which is thought to reflect the time it takes for the nuclei to 
form, and throughout which time the formation of fibrils is below the threshold of detection 
(Pedersen et al., 2004; Serio et al., 2000). In solution, there are two predominant species; 
monomer and fibrils (Figure 1.2A), while oligomeric aggregates are thought to be present in 
small amounts (< 2% of total species). However, during the elongation phase the 
concentration of fibrils increases dramatically as the monomer concentration decreases. This 
is thought to be due to increasing numbers of actively growing fibrils via fragmentation of 
fibrils creating new ‘growing ends’ and/or secondary nucleation (Figure 1.2B; where 
available sites on existing fibrils catalyse the nucleation of new aggregates)(Arosio et al., 
2014; Knowles et al., 2014). This rapid growth proceeds until such time as the process 
reaches a plateau where the equilibrium between available monomer and fibrillar protein is 
reached (Figure 1.2A) (Chiti and Dobson, 2006; Wilson et al., 2008). The lag phase can be 
circumvented by the addition of exogenous nuclei or ‘seed’ in the form of preformed fibrils 
(Jarrett and Lansbury, 1993). As a consequence of seeding, the lag time is eliminated (Jarrett 
et al., 1993) resulting in a first-order growth polymerisation (Figure 1.2C).  
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Figure 1.2 Schematic representation of amyloid fibril formation.   (A-B) Fibril formation can be 
characterised by a lag phase where nucleation events occur, following critical nucleation a growth/elongation 
phase is observed which can proceed via primary (monomer addition) or secondary (fragmentation/secondary 
nucleation) events. During the latter stages, mature fibrils are formed which often display strong ThT emission 
signals. (C) Addition of fibrils or other functional seeds to the start of the reaction allows elongation to proceed 
without the requirement for primary nucleation removing the lag phase. 
 
1.6 Genetic factors  
While the majority of clinical ALS is sporadic (sALS; 90-95%) with no known obvious 
cause, the remainder of cases are familial or inheritable in nature (fALS; 10%) (Haverkamp 
et al., 1995) and are predominantly associated with Mendelian-inherited mutations in genes 
encoding Cu/ Zn superoxide dismutase (SOD1), 43-kDa trans-activating response region 
DNA-binding protein (TDP-43), fused in sarcoma/translocated in liposarcoma (FUS/TLS), 
and C9ORF72 (Belzil et al., 2009; Brettschneider et al., 2012; Mackenzie et al., 2007; Rosen, 
1993). Familial ALS is commonly inherited in an autosomal dominant pattern (Li and Wu, 
2016). Furthermore, some gene mutations have been identified in sALS cases including the 
ataxin-2 repeat expansions (Elden et al., 2010) and more recently loss-of-function NEK1 
variants have been associated with approximately 3% of ALS cases (Kenna et al., 2016). In 
addition, there is accumulating evidence to suggest that that mutations in these genes 
associated with fALS are also identified in sALS cases (Al-Chalabi et al., 2012). Given the 
similarities in pathological and clinical features between sporadic and familial forms of ALS, 
it is suggested that similar downstream pathogenic mechanisms are involved in the final 
 
8 
 
pathway for ALS (Al-Chalabi et al., 2012; Kabashi et al., 2007), and therefore information 
into mechanistic insights and therapeutic advances may be translatable to all forms of ALS 
and increase our understanding of the aetiology of ALS. 
To date, at least 19 major genes with mutations and various functions including DNA and/or 
RNA processing, and protein transport, trafficking and degradation have been directly linked 
to fALS, in which a summary of these main genes are outlined in Table 1.1 (see Li and Wu, 
2016). Although other studies and genome wide analysis databases have reported 
approximately 125 genes as potential modifiers of ALS susceptibility (ALS Online Genetics 
Database; http://alsod.iop.kcl.ac.uk), mutations in most of these genes are only identified in a 
small fraction of ALS patients and therefore contribute minimally to the development of ALS 
disease (Li and Wu, 2016). Furthermore, some polymorphisms identified in ALS patients 
may represent genetic risk factors rather than causative mutations including mutations in the 
neurofilament-heavy subunit (NFH), vascular endothelial growth factor (VEGF) and ciliary 
neurotrophic factor (CNTF) (see Redler and Dokholyan, 2012). 
The first causative gene was identified in 1993 as Cu
2+
, Zn
2+
 superoxide dismutase 1 (SOD1) 
(Rosen, 1993). SOD1, a well-studied gene linked with several variants of familial ALS, and 
has contributed significantly to the current understanding of the molecular mechanisms of 
other forms of ALS. Mutations in SOD1 are very common, accounting for approximately 
20% fALS and 1-2 % sALS cases (Deng et al., 1993; Rosen, 1993). The majority of these 
SOD1 mutations are missense mutations, with an autosomal dominant inheritance, with the 
exception of the D90A polymorphism, which can also result in a recessive inheritance pattern 
(Al-Chalabi et al., 1998). In addition to SOD1, TDP-43, which binds RNA and DNA, is an 
additional key player in ALS, with mutations in TDP-43 identified in approximately 5% 
sALS and 3% fALS (Rutherford et al., 2008; Sreedharan et al., 2008).  
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Table 1.1 The genetics of familial amyotrophic lateral sclerosis 
Mode types: AD, autosomal dominant; AR, autosomal recessive; DN, de novo; (‐) unknown information at current. 
Information obtained from ALSoD database (http://alsod.iop.kcl.ac.uk/) and from the following literature (Al-Chalabi et al., 
2012; Chen et al., 2013; Li and Wu, 2016; Marangi and Traynor, 2015; Webster et al., 2016; Williams et al., 2016). 
Gene Protein Clinical presentations Function Mode of 
Inheritance 
ALS 2 Alsin UMN, LMN, Bulbar DNA/RNA processing AR 
ANG Angiogenin UMN, LMN, Bulbar DNA/RNA processing AD 
ATXN2 Ataxin 2 UMN, LMN DNA/RNA processing AD 
C9orf72 Chromosome 9 open 
reading frame 72 
UMN, LMN, Bulbar Protein degradation  AD 
CHMP2B Charged multivesicular 
body protein 2B 
UMN, LMN, Bulbar DNA/RNA processing AD 
CHMP2B Charged multivesicular 
body protein 2B 
UMN, LMN, Bulbar DNA/RNA processing AD 
CCNF cyclin F UMN Protein degradation AD 
DCTN1 Dynactin UMN, LMN, Bulbar Axonal transport and 
vesicle trafficking 
- 
FUS Fused in sarcoma UMN, LMN, Bulbar DNA/RNA processing AD,AR,DN 
NEFH Neurofilament heavy chain UMN, LMN, Bulbar Cytoskeletal network AD 
OPTN Optineurin UMN, LMN Protein degradation 
(autophagy)- 
AD, AR 
PRPH Peripherin LMN, Bulbar Cytoskeletal network - 
PFN1 Profilin 1 LMN, Bulbar Cytoskeletal network AD 
SETX Senataxin UMN, LMN, Bulbar DNA/RNA processing AD 
SOD1 Cu2+, Zn2+ superoxide 
dismutase 1 
UMN, LMN, Bulbar Antioxidant AD,AR,DN 
SQSTM1 Sequestosome 1 UMN, LMN, Bulbar Protein degradation - 
TAF15 TAF15 RNA polymerase II,  UMN, LMN DNA/RNA processing AD, AR 
TARDBP TAR DNA binding protein UMN, LMN, Bulbar DNA/RNA processing AD, AR 
UBQLN2 Ubiquilin 2 UMN, LMN, Bulbar Protein degradation SD 
VAPB Vesicle‐associated 
membraneprotein‐
associated protein B 
UMN, LMN, Bulbar Axonal transport and 
vesicle trafficking 
AD 
VCP Valosin‐containing protein UMN, LMN, Bulbar Protein degradation AD 
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1.6.1 Superoxide dismutase 1 (SOD1) in ALS 
SOD1 is a ubiquitously expressed, cytosolic 32 kDa homodimeric enzyme, which plays an 
important role as a cellular antioxidant to prevent oxidative stress. The primary function of 
SOD1 is to convert (dismutase) the highly reactive free-radical superoxide formed during 
biological processes, to a less damaging species (hydrogen peroxide) (Beckman and 
Koppenol, 1996). More than 180 disease-associated mutations have been described in ALS 
patients, mainly identified as point mutations present throughout all 5 exons of the SOD1 
gene (http://alsod.iop.kcl.ac.uk/; Tortelli et al., 2013). Although some of these SOD1 
mutations can impair enzymatic function, others are not associated with a loss of dismutase 
function, rather they retain enzymatic activity comparatively similar to wild-type levels 
(Bruijn et al., 1997; Gurney et al., 1994). However, these mutations may result in varying 
dimer stability, aggregation propensity, metal ion binding affinity, intracellular protein 
trafficking and rates of disease progression (Kaur et al., 2016). 
Some of the most common SOD1-ALS mutations include G93A, G37R, G85R, A4V and 
D90A (Al-Chalabi et al., 1998; Bruijn et al., 1997; Polling et al., 2014; Robertson et al., 
2007; Weisberg et al., 2012). To further characterise the role of SOD1 in ALS, in vivo models 
including transgenic mice and rats have been engineered to over-express fALS associated 
mutated forms of either the human or murine SOD1. These genetically engineered 
(transgenic) animal models subsequently develop progressive motor neuron degeneration, 
reminiscent of human ALS disease, and are therefore used as in vivo experimental ALS 
models (reviewed in Turner and Talbot, 2008). To more accurately analyse SOD1 behaviour 
in vivo, recent studies have developed mice expressing both human WT and mutant SOD1 
protein, since most patients with familial ALS exhibit heterozygous mutations (Fukada et al., 
2001; Jaarsma et al., 2000). Interestingly, co-expression of WT SOD1 accelerated disease 
phenotypes of mutant SOD1 expressing mice (Deng et al., 2006; Wang et al., 2009). 
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Increasing evidence implicates a toxic gain of function acquired by mutant forms of SOD1, 
which is directly responsible for motor neuron death (Andersen et al., 1995; Gurney et al., 
1994; Yim et al., 1996). This idea was initially supported by observations that transgenic 
mice lacking SOD1 do not develop an ALS-like motor neuron disease or do not die 
prematurely at least up to 6 months of age (Reaume et al., 1996). Conversely, rodents 
expressing mutant SOD1 develop a progressive motor neuron disease, recapitulating many 
features of ALS including motor neuron loss, deficient axonal transport, mitochondrial 
dysfunction as well as pathological hallmarks (Gurney et al., 1994; Nagai et al., 2001; Ripps 
et al., 1995) similar to that observed in human ALS patients (Dal Canto and Gurney, 1997). 
However, the development of ALS-like symptoms in these mice varies depending on the type 
of SOD1 mutation; transgene expression level, gender and genetic background (Heiman-
Patterson et al., 2011; Mancuso et al., 2012). Although it is widely accepted that different 
mutants of SOD1 exert their toxicity through a gain of function, the precise cytotoxicity of 
mutant SOD1 and its specificity for motor neurons remain to be elucidated.  
A common feature that nearly all forms of mutant SOD1 exhibit is a higher propensity to 
misfold and/or aggregate compared to WT SOD1 (Andersen et al., 1995; Furukawa and 
O’Halloran, 2005; Gurney et al., 1994). Indeed, the relative aggregation propensities among 
variants of mutant SOD1 has been reported to vary significantly in culture (Prudencio et al., 
2009), with certain mutations in SOD1 that exhibit aggressive clinical phenotypes having a 
higher propensity to aggregate (Radunovic and Leigh, 1996). Although protein aggregation is 
central to mutant SOD1 pathogenesis, it is unclear how mutation in SOD1 results in protein 
misfolding and thus disease. However, aggregation-prone segments that interact to induce 
aggregation in SOD1 have recently been identified, indicating that protein destabilisation of 
the native fold may play a role in SOD1 mutant pathogenicity (Ivanova et al., 2014). 
Furthermore, dimer disassociation has been reported to be a critical step for triggering SOD1 
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aggregation, thus making aggregation prone residues more accessible (Rakhit et al., 2004). 
However, additional factors such as RNA granule dysregulation and dysfunction of protein 
degradation pathways may also underlie aggregation more generally in ALS (see Blokhuis et 
al., 2013). Using in vivo analysis of mutant SOD1 aggregation profiles and survival time of 
fALS patients, it has been reported that a higher protein instability and aggregation rate 
correlate inversely with survival time (Bystrom et al., 2010; Wang et al., 2008). In addition, 
under certain denaturing conditions, WT SOD1 has also been shown to form aggregates in 
vivo (Chia et al., 2010), suggesting that aberrant oligomerisation of SOD1 could be a shared 
pathogenic feature of ALS, irrespective of genotype (Redler and Dokholyan, 2012). 
1.6.2 TDP-43 in ALS 
In addition to SOD1, pathogenic forms of TDP-43, that are mislocalised to the cytoplasm, 
hyperphosphorylated, and ubiquitinated within protein inclusions are a significant 
pathological characteristic of motor neurons in ALS where SOD1 mutations are excluded. 
TDP-43 is a heterogeneous RNA/DNA binding protein that is ubiquitously expressed and 
involved in a range of processes in RNA metabolism including mRNA splicing and 
localisation and gene regulation (Ayala et al., 2008; Johnson et al., 2009). Specifically, TDP-
43 has been implicated in ALS as a key player due to its presence in neuronal cytoplasmic 
inclusions found in the spinal cord of sporadic ALS patients (Arai et al., 2006; Neumann et 
al., 2006). In addition, mutations in TDP-43 have been associated with both familial and 
sporadic ALS disease (Kabashi et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 
2008). Of note, most mutations identified in the TARDBP gene are located in the exon 
encoding the C-terminal domain (Rutherford et al., 2008; Sreedharan et al., 2008), which has 
been suggested to be highly aggregation prone (Zhang et al., 2009). It remains to be 
determined if mutations in TDP-43 cause a gain or loss of function, with current evidence 
suggesting both a toxic gain of function, a loss of function or a combination thereof (Lee et 
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al., 2012). Similar to other misfolding disease related proteins, a gain of toxic function may 
result from the mislocalisation of TDP-43 from the nucleus to the cytosol, where it fragments, 
aggregates and forms inclusions (Johnson et al., 2009). However, it has been proposed that 
the sequestration of functional TDP-43 into cytoplasmic inclusions may deplete nuclear TDP-
43 and result in the toxic loss of function of nuclear TDP-43 (Budini et al., 2015).  
 
1.7 Cytoplasmic inclusion bodies in ALS 
1.7.1 Overview 
The central pathological hallmark of ALS is the presence of cytoplasmic proteinaceous 
deposits known as inclusion bodies in degenerating motor neurons and neighbouring cells 
(Blokhuis et al., 2013). The most common types of aggregates identified in ALS patients are 
ubiquitinated aggregates in the form of Lewy body-like hyaline inclusions, skein-like, or 
round ubiquitin positive inclusions (Kato, 1999; Murayama et al., 1989). In addition, Bunina 
bodies and round hyaline inclusions (without a halo) are also found is ALS (Mizusawa, 1993; 
Okamoto et al., 2008). Multiple proteins have been found associated with these inclusions 
including; SOD1, TDP‐43, FUS/TLS, optineurin (OPTN), Ubiquilin‐2 (UBQLN2) and 
C9ORF72 (reviewed in Blokhuis et al., 2013). Of note, TDP-43 is thought to be the major 
component of ubiquitinated inclusions in most cases of ALS and many cases of FTLD (Arai 
et al., 2006; Neumann et al., 2006). Therefore, not only are these misfolded protein 
aggregates a significant pathological hallmark of ALS, but also have an important role in 
mediating disease initiation and progression (see section 1.4).  
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1.7.2 Misfolded SOD1 in inclusion bodies  
Inclusion bodies containing aggregated SOD1 have been detected in human most-mortem 
spinal cord tissues from both familial and to a lesser extent sporadic ALS patients (Bosco et 
al., 2010; Forsberg et al., 2010; Shibata et al., 1994) and in spinal cord tissues from SOD1 
ALS mouse (Bruijn et al., 1997; Shibata et al., 1994; Watanabe et al., 2001). However, these 
cytoplasmic inclusions are not limited to the spinal cord, rather are found in other brain 
regions including the hippocampus, cerebellum and frontal and temporal cortices (reviewed 
in Al-Chalabi et al., 2012). The appearance of these inclusion bodies coincide with disease 
onset in mouse models and are therefore thought to be an early pathological event in ALS, 
which then accumulate progressively throughout the course of the disease (Turner et al., 
2003; Wang et al., 2002). Furthermore, recent studies have used conformation specific 
antibodies to show that misfolded WT SOD1 can be detected in human post-mortem tissues 
from non-SOD1 sporadic ALS individuals (Bosco et al., 2010; Forsberg et al., 2010; 
Pokrishevsky et al., 2012). 
While SOD1 misfolding and/or aggregation are features of pathogenesis in both familial and 
sporadic ALS, including non-SOD1 linked familial and sporadic ALS (Matias-Guiu et al., 
2008), the role of SOD1 misfolding in motor neuron death has not yet been conclusively 
determined. A study of transgenic familial ALS mice over time reported that soluble 
misfolded SOD1 is concentrated in motor neurons from birth (Rakhit et al., 2007; Zetterstrom 
et al., 2007), and that large insoluble aggregates are detected primarily in the later stages of 
disease (Karch et al., 2009). Its thus appears that smaller soluble or misfolded SOD1 species 
may be responsible for initial toxicity, and eventually begin to cause symptoms once a 
disease-specific threshold has been reached. However, the relative toxicities of small soluble 
oligomers and large-scale aggregates of SOD1 remain to be directly proven. It has been 
postulated that oligomeric species present in solution prior to the appearance of fibrils are 
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more likely to be responsible for cellular toxicity more generally (Kayed et al., 2003). 
However, it is probable that all aggregate species provoke some level of cellular stress. One 
potential mechanism of toxicity is through exposed hydrophobic residues found on protein 
aggregates that have been shown to interact with cell receptors and membranes (Bolognesi et 
al., 2010; Stefani and Dobson, 2003), leading to membrane disruption and inappropriate 
signaling cascades. Moreover, the toxicity exerted by misfolded and aggregated SOD1 has 
been reportedly linked with a range of pathological cellular effects including organelle 
dysfunction (mitochondria, endoplasmic reticulum and the Golgi), cytoskeletal disruption, 
caspase activation and dysfunction of proteasomal and autophagic pathways (Bendotti et al., 
2012). 
Evidence from post mortem tissue demonstrates that protein aggregation is linked closely to 
motor neuron death in ALS (Brettschneider et al., 2014).However, nucleation of protein 
aggregation appears to be a stochastic process (Hortschansky et al., 2005), suggesting that 
protein aggregation alone should cause a random pattern of cell death. In contrast, cell death 
in ALS occurs in an ordered and progressive manner in human ALS patients, and therefore 
protein aggregation contained within individual cells is not likely the sole cause of this 
spread. Rather, one way to explain such an ordered progression is the prion-like propagation 
of protein misfolding and aggregation between adjacent cells. 
1.8 Patterns of Neurodegenerative Pathology in Humans 
Major neurodegenerative diseases, such as ALS, Alzheimer’s disease, Tauopathies such as 
Frontotemporal Dementia, Parkinson’s disease, Huntington’s disease, and transmissible 
spongiform encephalopathies (TSEs), have common pathological changes such as loss of 
neurons and the presence of pathological protein aggregates into either intracellular 
inclusions bodies or extracellular plaques. However, generally speaking, the main 
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aggregating protein is disease specific; for example SOD1, β-amyloid, α-synuclein, 
Huntingtin and the prion protein (PrP) aggregate in ALS, Alzheimer’s disease, Parkinson’s 
disease, Huntington’s disease and Creutfeldt-Jakob disease respectively (reviewed in Brundin 
et al., 2010). Distinctive anatomical patterns of disease spread are consistent with a spreading 
of pathology from one part of the brain to another in all of these neurodegenerative diseases 
(Brundin et al., 2010).  
The progression of these disorders, which is also associated with increasing clinical severity, 
has enabled the development of several staging systems based on location of protein 
aggregates (Braak et al., 2006; Braak et al., 2003; Brettschneider et al., 2014; Brettschneider 
et al., 2013). The resulting patterns suggest that pathology is not only propagated between 
nearby cells, but that it also remotely connects regions of the brain along axonal pathways 
(Brettschneider et al., 2015; Brundin et al., 2010). Together these data are consistent with a 
propagation of protein misfolding and aggregation reminiscent of those underpinning prion 
diseases (reviewed in Zeineddine and Yerbury, 2015).  
1.9 Prion-like propagation of aggregation in neurodegenerative diseases 
1.9.1 Prion Disease 
Over 30 years ago, a significant development in the field of infectious diseases and protein 
biochemistry research was made, it was identified that “infectious” proteins known as prions, 
could transmit disease between organisms without the requirement of nucleic acid (Prusiner, 
1998). The mammalian prion protein is a self-propagating transmissible agent that mainly 
consists of the abnormal misfolded/aggregated form of the prion protein (Prion Protein 
Scrapie; PrP
Sc
), known to transmit between cells and between individuals of the same species 
(species barriers) (Diener et al., 1982; Prusiner, 1984). Prions can exhibit multiple 
phenotypes (prion strains) and are responsible for a spectrum of aggressive 
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neurodegenerative diseases in humans including Kuru and Creutzfeldt-Jakob disease (CJD), 
and in animal populations in the form of scrapie in sheep and bovine spongiform 
encephalopathy (BSE), also known as mad cow disease in cattle, and several other species 
have their own version of prion-opathies (Diener et al., 1982; Prusiner, 1982). In these prion 
diseases, the PrP
Sc
 protein can replicate by inducing the misfolding and aggregation of the 
recruited natively folded cellular prion protein (PrP
C
), resulting in the aggregation of the 
newly formed pathological prion protein converting it the protease resistant and insoluble 
state. Therefore, prions act as abnormal templates that induce template-directed protein 
misfolding and progressive aggregation (Prusiner, 1998).  
There are two hypotheses on the molecular mechanisms of PrP
Sc
-induced conversion of PrP
C
, 
including template-directed refolding or nucleated polymerisation. Template-directed 
misfolding involves a cyclical propagation whereby PrP
Sc
 induces PrP
C
 (substrate) formation, 
and these newly formed pathogenic proteins go on to convert subsequent PrP
C
 proteins, thus 
amplifying infectious agents (Aguzzi and Calella, 2009). The nucleated polymerisation 
hypothesis suggests that the misfolding of PrP
C
 to PrP
Sc
 is a reversible process and the PrP
Sc
 
can be stabilised by contact with PrP
Sc
 protein aggregates (Aguzzi and Calella, 2009). 
1.9.2 Prion-like activity in neurodegenerative disease 
1.9.2.1 Overview 
Misfolded proteins associated with common neurodegenerative diseases are thought to be 
capable of propagating the misfolding and aggregation of their natively folded counterparts, 
potentially contributing to the transmission and spread of pathology from cell to cell within 
and between tissues beyond the site of original protein conversion (reviewed in 
Brettschneider et al., 2015). Mounting evidence has implicated a ‘prion-like’ mechanism in 
the propagation of a pathology associated with common neurodegenerative diseases also 
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known collectively as proteinopathies including; ALS, Alzheimer’s, Parkinson’s and 
Huntington’s disease. Proteins known to aggregate in these disorders including SOD1, 𝛽-
amyloid, tau, α-synuclein and fibrillar polyQ aggregates (K2Q44K2), a model for polyQ 
expansion, are all thought to share a “prion-like” mechanism of cell to cell spread, to 
propagate misfolding (see Aguzzi and Calella, 2009; Brundin et al., 2010).  
Prion-like propagation involves these protein aggregates entering into cells, crossing cellular 
membranes to transmit pathogenic proteins in a ‘prion-like’ manner through the triggering of 
the misfolding of their normally structured counterparts in cells, tissues, and animal models 
(Brettschneider et al., 2015). The precise mechanism by which pathogenic proteins gain 
access to the cytoplasmic compartment to propagate misfolding and aggregation remains 
incompletely understood (Clavaguera et al., 2009; Desplats et al., 2009; Grad et al., 2014; 
Ren et al., 2009). 
These non-infectious proteopathies do not involve the prion protein but typically their disease 
specific misfolded protein (Marciniuk et al., 2013). However, it is useful to model the 
progression of neurodegenerative diseases associated with protein aggregation on the spread 
of prion diseases within a host. It may provide an explanation for the apparent clinically 
observed patterns of pathology in ALS, Parkinson’s, Alzheimer’s and Huntington’s disease. 
There is indeed evidence amassing that suggests this might be the case (Table1.2). 
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Table 1.2 Evidence of Prion-like mechanisms of disease specific proteins in models of 
common neurodegenerative disorders. 
 
Disease Disease 
specific 
protein 
Cellular location 
of misfolded 
protein 
Cell to cell 
spread 
*
Self-
propagation 
Disease 
transmission 
Transmissible 
prion 
encephalopathie
s 
Prion Intracellular  
(Yamasaki et al., 
2012) 
Extracellular 
(Fevrier et al., 
2004) 
Yes 
 
Yes Yes 
Parkinson’s 𝛼- 
Synuclei
n 
Intracellular 
(Bick et al., 2008; 
Eisbach and 
Outeiro, 2013) 
Extracellular 
(Desplats et al., 
2009; Gustafsson et 
al., 2016; Loov et 
al., 2016; Ren et 
al., 2016) 
Yes 
 (Luk et al., 
2012a) 
Yes 
(Desplats et al., 
2009; Ibrahim 
and McLaurin, 
2016; Pinotsi et 
al., 2016) 
Yes 
(Li et al., 2008; 
Luk et al., 2012a; 
Luk et al., 
2012b) 
 
Alzheimer’s 𝛽-
amyloid 
Intracellular 
(Moon et al., 2012) 
Extracellular 
(Kumar et al., 
2011) 
Yes  
(Nath et al., 
2012; Tasaki et 
al., 2010) 
Yes 
(Kane et al., 
2000; Tjernberg 
et al., 1999) 
Yes 
(Kane et al., 
2000; Meyer-
Luehmann et al., 
2006) 
Alzheimer’s Tau Extracellular 
(Schwab et al., 
1998; Yamaguchi 
et al., 1991) 
Yes 
(Kfoury et al., 
2012; 
Mohamed et 
al., 2013; 
Saman et al., 
2012) 
Yes 
(Frost et al., 
2009; Stancu et 
al., 2015; Stohr 
et al., 2012; 
Vasconcelos et 
al., 2016) 
Yes 
(Iba et al., 2013; 
Lasagna-Reeves 
et al., 2012) 
 
Huntington’s Huntingti
n (Poly 
Q) 
Intracellular 
(Petrasch-Parwez et 
al., 2007) 
Yes 
(Herrera et al., 
2011; Pearce et 
al., 2015) 
Yes 
(Ren et al., 
2009; Yang et 
al., 2002) 
No 
ALS SOD1 Intracellular 
(Cereda et al., 
2013) 
Extracellular 
(Grad et al., 2011; 
Turner et al., 
2005a; Urushitani 
et al., 2006) 
Yes 
(Grad et al., 
2014; Münch et 
al., 2011) 
Yes 
(Chia et al., 
2010; Grad et 
al., 2011; Grad 
et al., 2014; 
Münch et al., 
2011) 
Yes 
(Ayers et al., 
2014; Ayers et 
al., 2016) 
ALS TDP-43 Intracellular 
(Nonaka et al., 
2009b) 
Yes 
(Feiler et al., 
2015; Nonaka 
et al., 2013) 
Yes 
(Feiler et al., 
2015; Furukawa 
et al., 2011; 
Nonaka et al., 
2013; 
Shimonaka et 
al., 2016) 
Yes 
(Nonaka et al., 
2013) 
* Self propagation refers to the ability of the disease proteins to seed the aggregation of soluble 
endogenous proteins. 
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1.9.2.2 Parkinson’s Disease 
Parkinson’s disease is a movement disorder characterised by the formation of Lewy bodies 
and Lewy neurite inclusions, containing predominately α-synuclein, which has been 
implicated as a key mediator in vesicular transport (Braak et al., 2003; Uversky, 2007). 
Mutations within the α-synuclein gene is linked with inherited forms of Parkinson’s disease 
and over expression of the wild-type form of α-synuclein has been reported to induce 
toxicity, similar to that observed in the disease (Dauer and Przedborski, 2003).  
Similar to ALS, in Parkinson’s disease α-synuclein aggregates have been reported to spread 
in a topographically predictable manner as disease pathology progresses through the CNS 
(Braak et al., 2006; Braak et al., 2003). Furthermore, previous studies have observed the 
propagation of α-synuclein aggregates from cell to cell in human cultured human neurons and 
in animal models, initiating the formation of Lewy body- like aggregates in naïve cells 
(Desplats et al., 2009; Hansen et al., 2011; Lee et al., 2010). Cell culture studies have shown 
that extracellular α-synuclein in various forms (fibrils, oligomers, and monomers) can be 
internalised by cultured neuronal cells (Lee et al., 2010). Furthermore, mouse cortical 
neuronal stem cells were shown to internalise extracellular aggregated α-synuclein either 
applied as recombinantly produced protein aggregates or from co-culture with cells 
overexpressing and subsequently releasing α-synuclein aggregates (Steiner et al., 2011). In 
addition, CNS injections of brain homogenates derived from mice exhibiting α-synuclein 
pathology or recombinant 𝛼-synuclein amyloid fibrils induced the formation of intracellular 
inclusions and the onset of Parkinson’s symptoms in recipient transgenic and wild-type non-
transgenic mice (Luk et al., 2012a; Luk et al., 2012b).  
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The most startling evidence for a prion-like mechanism of α-synuclein involves the 
observation that healthy tissue transplants grafted into the brains of people with Parkinson’s 
disease acquire (as early as four years) intracellular deposits of α-synuclein, known as Lewy 
bodies (Li et al., 2008). This was further demonstrated in post mortem studies that showed 
that approximately 2-5% of normal embryonic neurons transplanted in the brains of 
Parkinson’s disease patients acquired α-synuclein rich Lewy bodies over a period of 5 years 
(Brundin et al., 2008; Hansen et al., 2011). The host to graft pathological 𝛼- synuclein cell-to-
cell transfer and seeding aggregation in recipient neurons (neuroblastoma cell line) and in 
vivo in mice, where α-synuclein was shown to propagate from a mouse host brain cells to 
grafted dopaminergic neurons (Hansen et al., 2011) and demonstrates the transmissibility of 
𝛼- synuclein. A more recent study has been able to show, using more advanced imaging 
techniques including super resolution microscopy, that 𝛼- synuclein can be taken up in its 
monomeric form into neuronal cells, and nucleate the aggregation of endogenous 𝛼- 
synuclein (Pinotsi et al., 2016).  
1.9.2.3 Alzheimer’s Disease 
Alzheimer’s disease is characterised by the formation of amyloid plaques which are 
extracellular deposits composed primarily of insoluble β-amyloid aggregates and cytoplasmic 
inclusion bodies containing hyperphosphorylated tau protein (Alonso et al., 1996). β-amyloid 
is a proteolytic cleavage product of amyloid precursor protein (APP) which is a 
transmembrane protein which may act as a signaling nexus, transducing information about 
extracellular conditions (van der Kant and Goldstein, 2015). Cytoplasmic inclusion bodies 
containing hyperphosphorylated tau protein aggregates or tangles are known to progressively 
spread through the brain in an anatomically stereotypical manner (Alonso et al., 1996; 
Goedert et al., 2006). 
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In a similar paradigm to α-synuclein in Parkinson’s disease models, the transmissibility of 𝛽-
amyloid (A𝛽) peptide plaques have been initially shown to resemble a prion-like mechanism 
in a study in which non-human primates were injected with human brain tissue derived from 
AD patient (Baker et al., 1993; 1994). Similarly, injection of autopsy-derived brain extracts 
from Alzheimer’s disease patients in to transgenic mouse models of Alzheimer’s disease 
engineered to produce large amounts of APP, induces 𝛽-amyloid (A𝛽) peptide plaque 
formation around the injection site indicating that a single inoculation of brain extract can 
initiate β-amyloid plaque formation in vivo (Kane et al., 2000). In addition, one study 
implanted steel wires coated with brain extracts derived from human Alzheimer’s disease 
patients and demonstrated plaque formation which were observed to spread from the point of 
seeding into neighbouring tissues (Eisele et al., 2009). This transmissibility was shown to be 
inhibited by neutralising antibodies specific for 𝛽- amyloid, therefore indicating that the 
agent responsible for this self-propagation mechanism is 𝛽-amyloid (Meyer-Luehmann et al., 
2006). Furthermore, intraperitoneal injections of β-amyloid rich transgenic brain 
homogenates into transgenic mice induced widespread cerebral 𝛽-amyloidosis and associated 
pathologies (Eisele et al., 2010), which was confirmed in another study which traced in vivo 
A𝛽 propagation using bioluminescence imaging (Stohr et al., 2012). 
 
In addition to 𝛽-amyloid, tau protein aggregates have been shown to self-propagate from cell 
to cell in cultured cells (Kfoury et al., 2012). Similar to 𝛽-amyloid, injected brain extracts 
containing misfolded tau into the brains of transgenic mice can seed the propagation of tau 
misfolding and transmit this misfolding from the site of injection into neighbouring regions 
of the brain (Clavaguera et al., 2009). More recently, pre-aggregated 𝛽-amyloid aggregates 
were shown to directly induce Tau aggregation by cross-seeding in a prion-like manner and 
therefore propagating Tau pathology in vivo (Vasconcelos et al., 2016).  
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1.9.2.4 Huntington’s Disease 
Huntington’s disease is a genetic autosomal dominantly inherited disease associated with 
mutations in the gene encoding huntingtin and is characterised mainly by involuntary 
movements and dementia. Huntingtin protein has been implicated in DNA transcription, 
vesicle and axonal transport and synaptic function (Cattaneo et al., 2005). Mutations in the 
huntingtin protein associated with disease are in the form of variable expansions within a 
polyglytamine repeat (CAG) in exon 1 and induce the misfolding and aggregation of 
Huntingtin resulting in the formation of inclusion bodies (Duyao et al., 1993). A direct 
correlation between the extent of polyQ expansion with the propensity to misfold or 
aggregate, disease severity and initiation of onset has been suggested (Davies et al., 1997; 
Duyao et al., 1993; Scherzinger et al., 1997). Like α-synuclein, 𝛽-amyloid and tau, 
Huntingtin has also been reported to exhibit prion-like mechanisms of propagation. 
Aggregates of pathogenic polyQ expansion peptides have been shown to resemble scrapie 
prions (fibrillar or ribbon-like morphology) (Scherzinger et al., 1997) and transmit from cell 
to cell (Ren et al., 2009; Yang et al., 2002). Importantly, large aggregates of huntingtin 
peptides have been shown to self-propagate through a seeding nucleation mechanism that 
persists for several passages following the initial incubation of the cells with the extracellular 
aggregates (Ren et al., 2009).  
1.10 Regional spread of disease in ALS 
1.10.1 Overview 
It has been known for decades that fibril formation can be seeded in vivo through addition of 
preformed fibrils, removing the rate limiting lag phase (see Figure 1.2). Just as in vivo fibril 
formation of purified proteins is a nucleation dependent process, recent work using 2-photon 
imaging demonstrates that Aβ plaque formation in the brain is also a nucleation dependent 
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process (Burgold et al., 2014). This propagation is easily understandable given that Aβ 
aggregates do not have to cross plasma membranes to seed further aggregation as amyloid 
plaques are present outside of cells. It may be less likely that aggregates formed 
intracellularly such as SOD1, could propagate aggregation inside another cell. However, 
there is a wave of research that demonstrates that this is possible. At present, two major 
proteins associated with pathogenesis of ALS have demonstrated intermolecular requirements 
of prion-like activity: including SOD1 and TDP-43 (see Grad et al., 2015). In SOD1-ALS 
disease models, the propagation of SOD1 protein aggregates from cell to cell in neuronal and 
other cell lines and the template-directed seeding of SOD1 has been suggested as a possible 
explanation for the toxic intercellular spread of pathology. (Furukawa et al., 2013; Grad et al., 
2014; Münch et al., 2011).  
Given that ALS associated inclusions are intracellular, there are two vital steps that must 
occur in order to propagate aggregation between cells; aggregates must first be released from 
the originating neuron to the extracellular space and then the aggregates must cross the cell 
membrane barriers to be taken up by neighbouring neuron cells to seed further aggregation in 
the cytosol of naïve cells.  
1.10.2 SOD1 
1.10.2.1 SOD1 aggregates can be released from neurons 
Misfolded SOD1 aggregates that are suggested to exhibit thermodynamic and conformational 
stability are able to better thrive in the hostile extracellular environments (Grad et al., 2015). 
SOD1 aggregates are generally found to be intracellular in human ALS patient samples, 
however both WT and mutant SOD1 have been detected in the cerebrospinal fluid of ALS 
patients (Zetterstrom et al., 2011) and in spinal cord cultured derived from transgenic SOD1 
mouse models (Urushitani et al., 2006), suggesting that release of SOD1 occurs in vivo. In 
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addition, SOD1 can also be secreted from motor neuron like-cells in culture (Gomes et al., 
2007). Although the mechanism of release of protein aggregates is incompletely understood, 
SOD1 secretion can occur in both a passive manner associated with cell death or actively 
through exocytosis pathways (Gomes et al., 2007; Grad et al., 2014). In addition, SOD1 
associates with secretory chaperone-like proteins, including chromogranins which are 
components of neurotransmitter enriched secretory vesicles, facilitating the release of SOD1 
(Huttner et al., 1991; Urushitani et al., 2006). Of note, prior to secretion, mutant SOD1 
aggregates can accumulate in the endoplasmic reticulum-Golgi compartments of the 
endocytic pathways (Urushitani et al., 2008). Misfolded WT and mutant SOD1 have been 
shown to be secreted from neuron-like cells in association with exosomes (Basso et al., 
2013), which are subsequently taken up by neuron-like cells in culture (Grad et al., 2014). 
Furthermore, exosomes obtained from mouse astrocytes were observed to transfer mutant 
SOD1 to spinal neurons, resulting in the selective death of motor neurons (Basso et al., 
2013). Collectively these data leaves open the possibility that both cell death and active 
secretion mechanisms are acting in concert to promote aggregate release in vivo.  
1.10.2.2 SOD1 uptake 
In order to facilitate the propagation of intracellular aggregation in neurodegenerative 
diseases, such as ALS, Parkinson’s, Alzheimer’s and Huntington’s diseases, active aggregate 
nuclei or seeds must internalise into cells and gain access to the cytosol of naïve cells. Indeed, 
a number of recent studies have observed that exogenously applied SOD1 aggregates derived 
recombinantly or from conditioned media can be taken up efficiently and rapidly into living 
cells (Furukawa et al., 2013), such as motor neuron like cells in a time dependant manner, 
followed by localisation of SOD1 to the cytosol of neurons (Münch et al., 2011) and cultured 
glial cells (Roberts et al., 2013). However, it is currently unknown how exogenous SOD1 
aggregates gain access to the cytosol and subsequently accumulate in cytosolic inclusions 
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(Sundaramoorthy et al., 2013). Moreover, exogenously added aggregated WT and mutant 
SOD1 have been shown to be taken up into mouse NSC-34 and human SH-SY5Y neuronal 
cells (Sundaramoorthy et al., 2013).  
1.10.2.3 Prion-like action of SOD1 
Increasing experimental evidence now indicate that misfolded SOD1 has the ability to induce 
conformational changes from one molecule, seeding aggregation to another analogous to that 
of prion-like propagation (Chia et al., 2010; Grad et al., 2011; Grad et al., 2014; Münch et al., 
2011).  
Furthermore, similar to prions, there is evidence to suggest that propagation of misfolding 
and aggregation of both mutant and WT SOD1 occurs via two mechanisms including, 
nucleated polymerisation and template-directed misfolding (Grad et al., 2015). Given the 
highly stable conformation of native SOD1 and its ability to stabilise mutant misfolded SOD1 
(Prudencio et al., 2010), it has been suggested that this may enable native SOD1 to act as a 
thermodynamically favourable substrate for template directed seeded polymerisation (Grad et 
al., 2015). Furthermore, another study has also demonstrated that the intracellular conversion 
of WT SOD1 potentially occurs via template-directed misfolding, using surface plasmon 
resonance (Grad et al., 2011). However, it is possible that mutant SOD1 that is highly 
aggregation prone may utilise both seeded polymerisation and template directed misfolding. 
Moreover, newly formed misfolded SOD1 can act as template for propagation of misfolding, 
given that the misfolding of SOD1 can persist in the absence of the misfolded seed in cell 
culture (Grad et al., 2014).  
Misfolded and aggregated forms of SOD1 derived from recombinant protein or from 
homogenates of spinal cords of transgenic mice expressing human mutant SOD1 have been 
observed to trigger the formation of SOD1 protein aggregates in naïve cells, thus acting as 
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seeds (Figure 1.3) (Chia et al., 2010). In addition, the co-aggregation of mutant and WT 
SOD1 have been detected in post-mortem tissue derived from familial ALS patients, 
indicative of intermolecular conversion of protein misfolding (Bruijn et al., 1998). Supporting 
this, familial associated mutations in SOD1 (G127X and G85R) expressed in human 
mesenchymal and neural cell lines were observed to trigger the conversion of endogenous 
wild-type native SOD1 to a misfolded form, revealed by conformation-specific antibodies 
specific for epitopes present in SOD1 only when it is in a misfolded state. The conversion of 
human WT SOD1 to a misfolded form was shown to be dependent on a tryptophan (Trp) 
amino acid residue at position 32 (Grad et al., 2011). Interestingly, the same study showed 
that SOD1 mutations containing a serine substitution at position 32 failed to trigger the 
misfolding of WT SOD1 in human cell lines. Similarly, expression of these human SOD1 
mutants in cells lines did not induce the misfolding of endogenous murine WT SOD1 which 
inherently exhibits a serine at position 32, indicating species specific barriers. Similarly, 
prions also have species specific barriers that limit their transmission of disease between 
different species (Raymond et al., 2000), therefore further supporting the prion-like behaviour 
of SOD1 ALS. 
 
 
 
 
 
 
 
 
 
 
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Proposed model of the role of SOD1 propagation of aggregation in amyotrophic 
lateral sclerosis.  Protein aggregates form in neurons (primary nucleation) and have the potential to further 
nucleate the aggregation of other proteins. These protein aggregates can transfer directly from cell to cell 
through synaptic transfer, or be actively released via secretion mechanisms (e.g. exosomes) or in their naked 
forms from newly dying/dead motor neurons which is suggested to occur in the easily stages of the diseases to 
neighbouring interconnecting neurons. The uptake of such aggregates nucleates aggregation in naïve cells, a 
process that resembles the prion-like propagation of aggregation. 
 
To further support this, murine SOD1 protein is not associated with inclusions of human 
mutant SOD1 in SOD1 mice (Deng et al., 2006; Prudencio et al., 2009; Wang et al., 2009). 
Furthermore, human WT SOD1 does not exacerbate motor neuron disease in mice expressing 
murine mutant SOD1 G86R (Audet et al., 2010). In addition, recombinant G127X aggregates 
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were able to trigger the misfolding of recombinant human WTSOD1 in a cell-free system 
under reducing conditions, supporting the idea of “protein-only” conversion. This therefore 
provides direct evidence of intermolecular conversion of natively structured WT SOD1 by 
misfolded SOD1 in a physiological intracellular environment (Grad et al., 2011). 
Furthermore, other work has observed that exogenously applied mutant SOD1 aggregates can 
induce the misfolding of soluble transgenically expressed mutant protein in mouse 
neuroblastoma cells, transmitting the pathology from cell to cell, indicative of self-
propagation of aggregation, similar to the disease mechanics in prion diseases (Münch et al., 
2011). Similarly, exogenously applied recombinant human mutant SOD1 fibrils can 
internalise into mouse neuroblastoma cells that are engineered to express the same human 
SOD1 mutant and subsequently induce intracellular aggregation (Furukawa et al., 2013) 
These findings are supported by the results of two other studies which demonstrate for the 
first time, in vivo evidence for prion-like transmission of SOD1 toxic aggregate species in 
mediating pathology in ALS. Recently, it has been demonstrated that spinal cord 
homogenates derived from symptomatic (paralysed) SOD1G93A mice when injected into the 
spinal cords of genetically vulnerable mice (newborn) expressing low amounts of another 
form of mutant SOD1 (SOD1G85R-YFP) triggered a spinal inclusion pathology and ALS-like 
disease phenotype (Ayers et al., 2014). Interestingly, when second passage homogenates 
derived from these mice were injected into new SOD1G85R mice, an early onset of clinical 
disease was observed, again featuring abundant SOD1G85R inclusion‐like pathology (Ayers et 
al., 2014). Furthermore, it was observed in this study that spinal cord homogenates derived 
from WT SOD1 transgenic mice injected into transgenic mice triggered widespread 
SOD1G85R containing inclusion‐like pathology in one third of inoculated SOD1G85R mice, 
implicating WT SOD1 in the pathogenesis of disease progression in sporadic ALS. In a more 
recent study that extends these findings, spinal homogenates from paralysed mutant 
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SOD1G93A mice were injected into the sciatic nerves of adult SOD1G85R expressing mice 
(rather than newborn) (Ayers et al., 2016). Similar to the previous study above, these mice 
developed ALS-like disease characterised by rapidly spreading SOD1G85R containing 
inclusion pathology and motor neuron loss, similar to clinical and pathological findings in 
human ALS. 
1.10.3 TDP-43 
In addition to SOD1, propagation of TDP-43 aggregation has also been suggested to resemble 
that of a prion-like seeding mechanism. TDP-43 pathology in ALS is clinically similar to 
SOD1 pathology in SOD1 familial ALS, with ubiquitinated inclusions throughout the spinal 
cord and motor cortex. There is also evidence of regional spreading of TDP-43 associated 
pathology occurring in a sequential pattern through the neuroaxis (Brettschneider et al., 
2013). Recent evidence suggests that phosphorylated and ubiquitinated TDP-43 aggregates 
may be able to propagate from cell to cell in cultured neuroblastoma cells and induce TDP-43 
aggregation in the cells expressing human TDP-43 in a self-templating fashion (Nonaka et 
al., 2013). Similar to SOD1, TDP-43 and its C-terminal fragments have a high propensity to 
misfold in vivo (Johnson et al., 2009) with mutations enhancing aggregation (Guo et al., 
2011; Johnson et al., 2009). Furthermore, aggregated full length TDP-43 has been detected in 
exosome fractions derived from conditioned media of human neuroblastoma cells treated 
with seeds from ALS disease patient brain extracts, similar to prions and therefore this gives 
evidence for the prion-like properties of pathological TDP-43 aggregates from diseased 
brains (Nonaka et al., 2013). It has been suggested that TDP-43 contains a yeast prion-like 
domain in the C-terminal region which is highly aggregation prone (Mousavi and Hotta, 
2005). Specifically, one study has reported that the prion-like domain of TDP-43 is critical 
for aggregation, cytoplasmic mislocalisation and toxicity (Johnson et al., 2008). Pathological 
aggregates of TDP-43 also contains aggregates of its C-terminal fragment (Arai et al., 2006) 
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which have been characterised as fibril-like structures (Hasegawa et al., 2008). Other studies 
have demonstrated that recombinant exogenously applied fibrillar aggregates of full-length 
TDP-43 can internalise into human embryonic kidney cells, and triggered the mislocalisation 
of endogenous nuclear TDP-43 to the cytoplasm, where it is found to co-localise with the 
seeding aggregates and form inclusions via prion-like nucleated polymerisation (Furukawa et 
al., 2011). These induced aggregates are ubiquitinated, similar to that observed in ALS 
disease and therefore supporting an important role for pathological TDP-43 in disease 
progression. More recently, it was observed that TDP-43 fibrils triggered the seed-dependant 
aggregation of WT TDP-43 or TDP-43 lacking a nuclear localisation signal, and different 
peptides sequences of TDP-43 were able to produce fibrils that induced different TDP-43 
associated pathologies (Shimonaka et al., 2016).  
A role for a prion-like propagation of WT SOD1 misfolding induced by toxic TDP-43 has 
recently been reported. Aberrant accumulation of mislocalised cytosolic TDP-43 has been 
shown to induce the misfolding of SOD1 (Pokrishevsky et al., 2012). Misfolding-specific 
antibodies revealed misfolded SOD1 in both spinal cord tissue derived from SOD1-familial 
ALS and in sporadic ALS with cytoplasmic TDP-43 inclusions. In addition, this was also 
supported by in vivo evidence using human neuroblastoma SH-SY5Y cells and murine spinal 
neural cultured cells transgenic for human WT SOD1. However, misfolded SOD1 was not 
co-localised with cytosolic TDP-43, suggesting an indirect induction of SOD1 misfolding, 
followed by the propagation of SOD1 misfolding (Pokrishevsky et al., 2012). Similar to the 
prion protein, tissue-derived TDP-43 aggregates are resistant to protease digestion, heat and 
formic acid (Nonaka et al., 2013), however, it remains to be determined whether propagated 
aggregation persists in the absence of the seed. In addition, induced aggregates of TDP-43 are 
toxic to cultured neuroblastoma cells (Nonaka et al., 2013). 
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1.11 Endocytosis  
The mechanisms involved in the propagation of misfolded proteins from cell to cell or from 
region to region in CNS tissues are not completely understood. However, there may be 
several mechanisms involved in disease-associated protein aggregate entry into recipient 
neurons depending on the nature of the protein aggregate, activation of signals and the fate of 
the internalised material (Mercer and Helenius, 2009).  
Endocytosis can occur by multiple mechanisms that are generally classified into two broad 
categories, including pinocytosis which involves the uptake of fluid and solutes, and 
phagocytosis which involves the uptake of large particles (see Conner and Schmid, 2003). 
Phagocytosis is used to internalise large particles like bacteria and viruses, but only a few cell 
types have the ability to use this mechanism. Pinocytosis is characterised by a range of 
unrelated and highly regulated mechanisms including clathrin-mediated endocytosis, 
cavelolar-mediated endocytosis, clathrin and cavelolar-independent endocytosis, lipid raft 
mediated endocytosis and macropinocytosis (Mercer and Helenius, 2009).  
1.11.1 Clathrin-mediated endocytosis 
Clathrin mediated endocytosis previously known as receptor mediated endocytosis involves 
concentrating transmembrane receptors and their bound soluble ligands into coated pits 
formed by the arrangement of cytosolic clathrin proteins embedded in the plasma membrane, 
which eventually invaginate and pinch off to form endocytic vesicles which are transported 
into the cell (Brodsky et al., 2001; Schmid, 1997).  
1.11.2 Caveolae -mediated endocytosis 
Similarly, caveolae-mediated endocytosis involves caveolin which is a dimeric protein found 
on the surface of most cells and represents a cholesterol-rich microdomain on the plasma 
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membrane, which facilitates the import of molecules (including pathogens) and transports 
them to specific locations within the cell. Caveolin binds cholesterol and inserts into the inner 
leaflet of the plasma membrane where it self-associates, forming the caveolin coat on the 
surface of the membrane invagination, in which many signalling molecules and membrane 
transporting molecules are concentrated (Anderson, 1998).  
1.11.3 Clathrin and caveolin dependant -mediated endocytosis 
Clathrin and cavelolar-independent endocytosis occurs in neurons and neuroendocrine cells 
which may constitute a specialised high capacity endocytic pathway for fluids and lipids, 
including recovering secreted membrane proteins, however, this remains poorly understood 
(Artalejo et al., 2002; Kirkham and Parton, 2005). Lipid-raft mediated endocytosis involves 
lipid rafts which are microdomains embedded in the plasma membrane characterised by a 
unique lipid environment enriched in cholesterol and sphingolipids, which concentrate 
receptors and therefore regulate the induction of signalling pathways (Marmor and Julius, 
2001).  
1.11.4 Macropinocytosis  
Macropinocytosis, also known as a form of fluid-phase endocytosis, is a unique and transient 
actin dependent process that leads to the non-selective internalisation of extracellular fluid, 
membrane and other particles (Watts and Marsh, 1992). 
Fluid-phase and receptor-mediated endocytosis have been implicated in the cellular uptake of 
protein aggregates associated with neurodegenerative diseases. Extracellular α-synuclein 
fibrils and oligomers are thought to enter into neuronal cells via receptor mediated 
endocytosis (Lee et al., 2008), with more recent evidence that α-synuclein fibrils bind 
heparan sulfate proteoglycans (HSPGs) to mediate their entry into in cultured cells and 
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primary neurons (Holmes et al., 2013). Similarly, tau aggregates bind HSPGs to trigger their 
cellular uptake via macropinocytosis, although how this relates to activation of 
macropinocytosis and to entry of other neurodegenerative disease aggregates is unclear 
(Holmes et al., 2013). However, monomeric α-synuclein and mutant huntingtin aggregates 
have been observed to directly translocate and penetrate the plasma membrane, respectively, 
without passage though endocytic compartments (Lee et al., 2008; Ren et al., 2009).  
Several studies now suggest that macropinocytosis may be involved in the uptake of protein 
aggregates associated with various neurodegenerative diseases (Grad et al., 2014; Holmes et 
al., 2013; Münch et al., 2011; Sundaramoorthy et al., 2013). Interestingly, endocytic uptake 
of the pathogenic prion protein can be mediated by lipid-raft dependant macropinocytosis 
(Wadia et al., 2008). Collectively these data show that, despite their size, aggregates from a 
range of neurodegenerative diseases can be efficiently taken up by cells and most importantly 
this can occur in neurons. Given the similar structure and large size of these aggregates it is 
likely that similar mechanisms are used by various subsets of neurons to engulf such large 
aggregates. 
1.12 Hijacking macropinocytosis for SOD1 aggregate entry into cells 
Fluid phase endocytosis has been gaining importance in SOD1-ALS pathogenesis, where 
large SOD1 aggregates have been shown to enter into cells through macropinocytosis (Grad 
et al., 2014; Münch et al., 2011; Sundaramoorthy et al., 2013; Zeineddine and Yerbury, 
2015). Supporting this, the large size of the protein aggregates argues against neuronal entry 
by caveolae (generally used for particle sizes from 50 - 100 nm) (Richter et al., 2008) or 
clathrin-coated pits (for particle sizes < 200 nm) (Traub, 2009) and the fact that neurons are 
incapable of phagocytosis. 
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Specifically, macropinocytosis is a signal-dependent process generally triggered by growth 
factors but can be triggered by a variety of other particles such as bacteria, apoptotic bodies, 
necrotic cells and viruses (Mercer and Helenius, 2012). The activation of macropinocytosis is 
a result of a number of cell‐specific downstream signalling events including activating 
receptor tyrosine kinases that in turn trigger a signalling cascade that induces changes in the 
dynamics of actin filaments and trigger plasma membrane ruffling (or membrane extensions 
and blebbing). Membrane ruffles can take the form of planar lamellipodia, circular ruffles or 
blebs, dependant on the nature of the cell type and ligand (reviewed in Mercer and Helenius, 
2009). These ruffles can then fold back onto themselves to fuse with the plasma membrane 
creating large, fluid filled randomly sized vacuoles (0.5-10 µM) termed macropinosomes that 
lack supporting coating molecules (Meier et al., 2002).  
Various factors and signalling pathways are required for macropinocytosis, including the Ras 
superfamily GTPases which activate the RAC1, Rab5, Arf6, and the phosphatidylinositol‐3-
kinase (PI(3)K) signalling pathways (Bar-Sagi et al., 1987). Kinases, including p21-activated 
kinase 1 (Pak1) activated by RAC1, regulate cytoskeleton dynamics and motility, and are 
required throughout the whole process of macropinocytosis (Dharmawardhane et al., 2000). 
In addition, other factors including Na+/H+ exchangers that maintain pH required for GTPase 
activity are vital for macropinocytosis (West et al., 1989). Following these signalling events, 
macropinosome closure occurs, which involves fusion of membrane folds (Swanson, 2008) 
regulated by kinases, myosins and GTPases (Sun et al., 2003). Once macropinosomes are 
formed they are trafficked into the cytoplasm of the cell, however some macropinosomes are 
recycled to the cell surface, where their contents are released into the extracellular space 
(Hewlett et al., 1994), although the fate of macropinosomes is not completely understood, the 
trafficking process depends on the cell type and mode of induction (Mercer and Helenius, 
2009).  
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Studies on the propagation of SOD1 aggregation by Münch et. al were the first to show that 
mutant SOD1 ALS protein aggregates enter into N2A cells via endocytic vesicles mediated 
by ATP and lipid raft dependent macropinocytosis (Münch et al., 2011), through the use of a 
large panel of inhibitors of a range of cellular functions to systematically rule out specific 
pathways of endocytosis including as caveolin and clatherin dependent endocytosis. 
Specifically, inhibitors of Na+/H+ exchangers (EIPA), kinases (rottlerin), phosphoinositide 
3-kinase and a cholesterol depleting agent were able to strongly diminish the uptake of 
aggregates composed of mutant SOD1 protein into neuronal cells (Münch et al., 2011). 
Furthermore, these mutant SOD1 aggregates were capable of transiently co-localising with 
fluorescent dextran, a marker of fluid phase uptake and therefore together suggests that 
mutant SOD1 aggregates selectively use macropinocytosis to enter the cells. Interestingly, it 
was proposed that once internalised, these mutant SOD1 aggregates can rapidly exit the 
macropinocytic compartment to enter into the cytosol, where these aggregates seed the 
aggregation of their soluble counterparts in a prion-like fashion (Münch et al., 2011). 
In addition, a recent study demonstrated that that uptake of both extracellular WT and mutant 
SOD1 soluble forms into NSC-34 cells can be inhibited by the small molecule EIPA which is 
sometimes considered a specific inhibitor of macropinocytosis (Sundaramoorthy et al., 2013). 
EIPA (ethylisopropylamiloride) is an analogue of amiloride that is an inhibitor of Na
+
/H
+
 
exchangers and is thought to be specific to macropinocytosis due to the susceptibility of 
GTPases such as RAC1 to pH changes (Koivusalo et al., 2010). Further, the protein kinase C 
inhibitor, rottlerin, was also able to inhibit SOD1 uptake consistent with macropinocytosis 
facilitating the uptake of WT and mutant SOD1 (Sundaramoorthy et al., 2013). Following the 
internalisation of the aggregated WT and mutant SOD1 via macropinocytosis, these 
aggregates were observed to form SOD1 containing foci or inclusions which inhibited 
transport from the endoplasmic reticulum to the Golgi apparatus. This resulted in the 
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induction of neurodegenerative pathways reminiscent of ALS pathology, including 
endoplasmic reticulum stress and fragmentation of the Golgi resulting and subsequent 
neuronal cell death (Sundaramoorthy et al., 2013). This further supports the role of misfolded 
WT SOD1 in ALS and therefore the idea that similar mechanisms of neurodegeneration 
spread may be occurring in familial and sporadic ALS. 
Viruses, including vaccinia virus (Huang et al., 2008) and the Adenovirus 3 (Meier et al., 
2002), are known to hijack macropinocytosis pathways to enter cells and likely rupture the 
unsupported and unstructured vacuole to gain entry to the cytosol, including the Japanese 
encephalitis virus that infects neurons (Kalia et al., 2013). The African swine fever virus also 
uses macropinocytosis to internalise into host cells (Sanchez et al., 2012). Interestingly, this 
virus is able to directly stimulate macropinocytosis through induction of cytoplasmic 
membrane perturbation in the form of blebbing and ruffles, fluid (measured using dextran) 
uptake, actin reorganisation, activity of Na+/H+ exchangers and signalling events required 
for macropinocytosis including Pak1 kinases and the Rho-GTPase RAC1 activation. Similar 
to previous studies, EIPA significantly reduced virus entry and infection (Sanchez et al., 
2012). 
Although there is now growing evidence that fluid phase endocytosis and in particular 
macropinocytosis may play a role in SOD1- mediated ALS, the mechanisms by which SOD1 
aggregates utilise macropinocytosis to gain entry into cells and potentially nucleate the 
aggregation of endogenous soluble proteins and if the form of pinocytosis is constitutive or 
stimulated is currently unknown (Figure 1.4). 
1.13 Overview 
It is becoming increasingly evident that the propagation of protein aggregation is a key event 
in the progressive nature of several neurodegenerative diseases such as ALS, Alzheimer’s 
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disease, Parkinson’s disease and Huntington’s disease. This may be explained by the 
nucleation of aggregation in nearby or connected neurons. In the cases where protein 
aggregates are intracellular, in order for this propagation to occur aggregates must be able to 
gain access to the cytosol of naïve neurons. It is; however, clear that SOD1 protein 
aggregates are able to spread to naïve cells in culture gaining access to the cytosol in an 
unknown manner linked with fluid phase endocytosis. Evidence is accumulating that 
implicates neuronal macropinocytosis in the uptake of protein aggregates. Although this 
process is very complex and may involve other processes and factors, the literature published 
to date on the role of macropinocytosis in ALS allows for further detailed investigations into 
the role of SOD1 and macropinocytosis in the propagation of aggregation in neuronal cells in 
a prion-like manner. Furthermore, the involvement of fluid phase endocytosis in the prion-
like propagation of disease proteins in Parkinson’s, Alzheimer’s and Huntingtons disease 
implicates a unifying mechanism of pathogenesis in these proteinopathies. Overall, it appears 
that misfolded disease proteins associated with neurodegenerative disorders exhibit similar 
patterns of disease propagation to prion protein, and interestingly may use similar 
mechanisms of uptake to that of viruses. It is there vital then to understand this mechanism to 
identify targets that will halt passage of the “infectious” particle in a strategy analogous to 
drugs blocking viral entry. 
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Figure 1.4 Proposed mechanism for aggregate uptake via  macropinocytosis.  Aggregates may 
interact with cell surface receptors (such as HSG) (1) and promote the clustering and activation of signalling 
receptors such as receptor tyrosine kinases. This may result in the activation of signalling pathways such as 
those regulated by RAC1 (2), PAK1 and PKC and subsequent mobilisation of actin and formation of 
ruffles/blebs (3). Upon macropinosome closure (4) the structure is internalised (5). Given the unstructured 
nature of the macropinosomes it is likely that rigid aggregate structures may cause rupture (6) and allow access 
of the aggregates to the cytosol where nucleation of aggregation can proceed (7). 
 
 
1.14 Summary 
ALS is a deadly adult-onset neurodegenerative disease affecting thousands of people 
globally. With no effective or promising therapies available at present, the need to understand 
and decipher the mechanisms involved in disease progression is important. This knowledge 
may help slow or halt the propagation of disease in ALS, and eventualy manage quality of 
life and survival rates.  
 
40 
 
 
Emerging evidence implicates the prion-like activity of SOD1 and processes such as 
macropinocytosis as important players in the propagation of disease in ALS. The uptake of 
aggregates via macropinocytosis may have broader implications as a common mechanism 
facilitating spread of protein misfolding in neurodegenerative diseases of aging. Although it 
has been well established previously that common proteinopathies cannot spread between 
humans, reports from post-mortem studies now revealed that some patients who developed 
iatrogenic Creutzfeldt-Jakob disease (CJD) as a result of treatment with human cadaveric 
pituitary-derived growth hormone contaminated with prions exhibited parenchymal and 
vascular amyloid-beta deposition. Given that none of these patients had pathogenic mutations 
or other high risk alleles associated with easrly onset of Alzheimer’s disease, these findings 
are consistent with iatrogenic transmission of amyloid-beta pathology in addition to CJD 
(Jaunmuktane et al., 2015).  
The major difference between PrP and SOD1 is that the pathological PrP is highly stable and 
protease resistant, compared to misfolded SOD1 which becomes protease sensitive (Grad et 
al., 2011), and thus less likely to be able to transmit from one person to another. However, the 
ability of misfolded SOD1 to transmit from cell to cell and region to region posssibly via 
macropinocytosis is thought to be critical for disease progression. However, further detailed 
research is required to understand how SOD1 aggregates are internalised into neuronal cells 
via macropinocytosis. Further understanding is also required around how these aggregates 
can gain access to the cytosol. It is likely that elucidating these mechanisms will provide 
rational therapeutic targets that could stop the spread of pathology and halt ALS and 
potentially other progressive neurodegenerative diseases in their tracks. 
The overarching aim of this project is to investigate the roles of WT and mutant SOD1 in the 
macropinocytosis dependent propagation in ALS, through the use of the motor neuron‐like 
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cell line, NSC‐34, Human primary neurons and Human iPSC derived motor neuron cultures. 
Specifically, this project aims to: 
1. Investigate the mechanism of uptake of SOD1 into neuronal cells, in particular to 
determine the mechanisms and processes involved in, and leading up to the uptake of 
SOD1 proteins in their soluble and aggregated form; 
2. Examine the mechanisms of SOD1 aggregate release, uptake and propagation in 
NSC‐34 motor neurons. 
3. Determine whether exogenous recombinant SOD1 protein aggregates can induce 
and/or contribute to TDP-43 pathology, specifically its mislocalisation and 
aggregation and; 
4. Determine if SOD1 aggregates can enter human neurons via the same mechanism of 
action using both iPSC derived motor neurons and primary neurons.  
 
These aims will be addressed in Chapters 2‐5, respectively. 
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Chapter 2  
SOD1 PROTEIN AGGREGATES 
STIMULATE 
MACROPINOCYTOSIS IN 
NEURON-LIKE CELLS TO 
FACILITATE THEIR 
PROPAGATION 
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2.1 Background 
The hallmark of Amyotrophic Lateral Sclerosis (ALS) is the selective death of upper and 
lower motor neurons in the motor cortex, brainstem and spinal cord, leading to loss of 
voluntary muscle control, muscle atrophy and invariably death. The specific causes of most 
cases of ALS are undefined, although approximately 10% are inherited. The best-studied 
familial ALS (fALS) cases are from families possessing mutations in the gene encoding 
copper/zinc superoxide dismutase (Cu/Zn SOD, SOD1) (Rosen et al., 1993). There is, 
however, a rapidly growing list of other genes in which mutations have been implicated in 
fALS. These include ALS2, SETX, FUS, VAPB, ANG, TARDBP, OPTN, VCP, UBQLN2, 
PFN1, SQSTM1, and a hexanucleotide repeat in a non-coding region of C9ORF72 (Renton et 
al., 2014). Current clinical practices are such that by the time that a diagnosis is confirmed 
disease progression is well under way and as many as 50% of motor units may already have 
been affected (Aggarwal and Nicholson, 2002). There is now very strong evidence in humans 
that neurodegeneration in ALS begins focally and then spreads amongst adjacent motor 
neurons and neighbouring cells or through axonal pathways to other cells throughout the 
three dimensional anatomy of the central nervous system (CNS) (Brettschneider et al., 2014; 
Ravits and La Spada, 2009; Shaw, 2002). More detailed knowledge of the action of this 
spreading is crucial, as is identifying a means of early detection of the disease if we are to 
therapeutically slow disease progression. 
In common with other neurodegenerative diseases, such as Alzheimer’s Disease (AD) and 
Parkinson’s Disease (PD) (Chiti and Dobson, 2006; Knowles et al., 2014), there is growing 
evidence that disruptions to proteostasis, protein misfolding and aggregation are the 
underlying mechanisms driving neurodegeneration in ALS (Pasinelli and Brown, 2006). Of 
particular interest is the fact that, although nucleation of protein aggregation appears to be a 
stochastic process (Abdolvahabi et al., 2016; Hortschansky et al., 2005), suggesting that 
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protein aggregation should cause a random pattern of cell death, cell death in ALS occurs in 
an ordered and progressive manner. One way to explain this ordered progression is the prion-
like propagation of protein misfolding and aggregation between adjacent cells. In addition, 
recent work has indicated that secondary processes, notably nucleation (Cohen et al., 2013; 
Knowles et al., 2009; Knowles et al., 2011), takes place on the surface of aggregates, and 
along with other diffusional or active transport of protein aggregates between cells can give 
rise to cell-to-cell propagation of the type that is often defined as prion-like behaviour. 
Clues to understanding the entry of aggregates into cells comes from studies that show uptake 
of aggregates of SOD1 can be blocked with EIPA, wortmannin, IPA-3 (Munch et al., 2011) 
and rottlerin (Grad et al., 2014; Sundaramoorthy et al., 2013), which inhibit Na
+
/H
+
 
exchangers, phosphoinositide 3-kinases (PI3K), P21 protein (Cdc42/Rac)-activated kinase 1 
(PAK-1) and protein kinase C (PKC), respectively (suppressing signalling events that 
promote actin rearrangement and pinosome closure), findings to date that suggest the 
involvement of fluid phase pinocytosis, possibly macropinocytosis, in the aggregate uptake 
process.  
Macropinocytosis is a form of non-selective endocytosis used by cells to engulf large 
amounts of solute macromolecules (fluid phase) or particles too large for other forms of 
endocytosis. Macropinocytosis is typically defined as a transient, externally induced, actin-
dependent endocytic process associated with vigorous perturbations, such as ruffles and 
blebs, in the plasma membrane (Swanson and Watts, 1995). The activation of this process 
results in a transient increase in receptor-independent fluid phase endocytosis in large 
vesicles or vacuoles (0.5-10 µm) termed macropinosomes (Mercer and Helenius, 2009; 
Swanson and Watts, 1995). Macropinosomes do not have a coat to guide their formation and 
are heterogeneous in size and shape. Macropinocytosis provides non-phagocytic cells with 
the ability to take up large particles, but the process must be triggered by an external 
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stimulus. Bacteria, viruses, apoptotic bodies and necrotic cells have all been shown to induce 
the ruffling behaviour typical of macropinocytosis resulting in their uptake along with fluid 
(Swanson and Watts, 1995). 
There is emerging evidence that prions and prion-like proteins may also enter cells via 
macropinocytosis allowing the propagation of their aggregation (Grad et al., 2014; Holmes et 
al., 2013; Munch et al., 2011; Sundaramoorthy et al., 2013; Wadia et al., 2008). However, the 
small molecule inhibitors utilized to define macropinocytosis, such as EIPA, are not specific 
to a single cellular event and depending on the cell type can prevent various forms of 
endocytosis (Ivanov, 2008). However, whether SOD1 aggregates stimulate macropinocytosis 
in neuronal cells has not been reported. 
2.1.1 Aims 
Recent evidence suggests a role for SOD1 in ALS disease progression through a prion-like 
propagation of protein misfolding and aggregation between neighbouring cells (Münch et al., 
2011; Zeineddine and Yerbury, 2015). Given the potential role for SOD1 in mediating 
disease progression in ALS, this work initially aimed to further investigate the mechanism of 
uptake of SOD1 into neuronal cells. In particular, the current study aimed to investigate the 
mechanism(s) involved in the uptake of SOD1 in both its soluble and aggregated form. 
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2.2 Methods 
2.2.1 Reagents and Antibodies  
DMEM/F-12 medium, DMEM/F-12 without phenol red, 0.05% trypsin-EDTA, GlutaMAX, 
SuperSignal West Pico Chemiluminescent Substrate, SYTOX Red dead cell stain, FM® 1-
43FX, fixable analog of FM® 1-43 membrane stain, 10 kDa 647-dextran, Image-iT ™ LIVE 
Red caspase detection kit and Lab-Tek chambered coverglass 8 well with cover were 
purchased from ThermoFisher Scientific (Waltham, USA). Any kD Mini-PROTEAN TGX 
Precast Protein Gels and Precision Plus Protein dual color protein standard were from Bio-
Rad (California, USA). Foetal Bovine Serum (heat-inactivated prior to addition in media; 
FBS) was from Bovogen Biologicals (East Keilor, Australia). Amersham Hyperfilm was 
obtained from GE Healthcare (Little Chalfont, Buckinghamshire, UK). RedDot 2 was from 
Biotium (Hayward, CA). Sterile cell culture plates were form Greiner Bio-One 
(Frickenhausen, Germany). Casein (heat denatured before use; HDC), dimethyl sulfoxide 
(DMSO), bovine serum albumin (BSA), β-mercaptoethanol, Brilliant blue R concentrate, 
paraformaldehyde (PFA), biotinamidohexanoic acid 3-sulfo-N-hydroxysuccinimide ester 
sodium salt, Bicinchoninic Acid Kit, Glutaraldehyde solution (50% in H2O), Propidium 
iodide, Osmium tetroxide solution (4 WT. % in H2O) and dithiothreitol (DTT) were from 
Sigma-Aldrich (St. Louis, MO). Ethylenediaminetetraacetic acid (EDTA) was from Amresco 
(Solon, USA). Uranyl acetate and 19 mm glass coverslips were from ProSciTech (Kirwan, 
Australia). Protease inhibitor cocktail tablets (complete, Mini, EDTA-free) was from Roche 
Diagnostics (Penzberg, Germany). RAC1 G-LISA Activation Assay Kit (Colorimetric Based) 
was purchased from Cytoskeleton (Denver, CO). All other reagents including salts, powders 
and chemicals were from Amresco, Sigma-Aldrich or Astral Scientific (Gymea, Australia). 
All reagents used were endotoxin free. Antibodies (Abs) and inhibitor compounds and their 
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respective manufacturing companies used in this current study are listed in Table 2.1 and 
Table 2.2 respectively.  
Table 2.1 Antibodies used in this study to investigate the effect of SOD1 proteins on TDP-43 
pathology 
Host species 
(clonality)
1
 
Anti-body target 
(Immunogen)
2
 
Conjugate Manufacturer 
(product number)
3
 
Mouse (mAb) Beta Actin [AC-15] - Abcam (ab8226) 
Rabbit (pAb) Vimentin - Abcam (ab137321) 
Sheep (pAB) SOD1 - ThermoFisher Scientific 
(PAI-30817) 
Mouse (mAb)  RAC1 - Cytoskeleton 
(ARC03) 
Goat (pAB) Mouse IgG Alexa Fluor 488 ThermoFisher Scientific 
A-(11001) 
Goat (pAB) Rabbit IgG Alexa Fluor 488 ThermoFisher Scientific 
( A-11008) 
Donkey (pAb) Sheep IgG Alexa Fluor 488 Abcam (150177) 
Goat (pAb) Mouse IgG Alexa Fluor 633 ThermoFisher Scientific 
( A-21052) 
Donkey (pAb) Sheep IgG HRP Abcam (97125) 
Goat (pAb) Mouse IgG HRP Merck Millipore (12-349) 
1
 pAb, polyclonal anti-body, mAb, monoclonal anti-body; 3 Abcam, Cambridge, USA; ThermoFisher Scientific 
(Waltham,MA, USA); BD Biosciences San Jose, CA, USA; Merck Millipore, Billerica, Massachusetts, USA; Cytoskeleton 
(Denver, CO,USA) 
 
Table 2.2 Pharmacological inhibitors used in this study to investigate the mechanisms of SOD1 
uptake 
Compound Manufacturer 
(product number)
1
 
5-N-ethyl-N-isopropyl-amiloride (EIPA) Sigma (A3085) 
Chlorpromazine hydrochloride (Chlorp 
HCL)- 
Sigma (C8138) 
Genistein (Gen) Sigma (G6649) 
Rottlerin (Rot)- Sigma (R5648) 
 RAC1 inhibitor W56 Tocris Bioscience (2221) 
1
Sigma, (St. Louis, MO, USA), Tocris Bioscience (Avonmouth, Bristol,UK) 
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2.2.2 Cell Lines  
The mouse neuroblastoma x spinal cord hybrid cell line (NSC-34 cells) (Cashman et al., 
1992) were routinely cultured in DMEM/F12 supplemented with 10% (v/v) FBS and 2 mM 
GlutaMAX. Cells were maintained in an incubator at 37°C under a humidified atmosphere 
containing 5% (v/v) CO2. 
2.2.3 Aggregation and biotinylation of WT and mutant G93A SOD1 proteins  
WT and G93A SOD1 were expressed and purified from E.coli as previously outlined 
(Lindberg et al., 2002; Roberts et al., 2013). SOD1 aggregation was performed in vivo as 
previously described (Roberts et al., 2013). Briefly, solutions of purified WT or G93A mutant 
SOD1 protein (1 mg/ml) in PBS were co-incubated with 20 mM dithiothreitol (DTT) and 5 
mM ethylenediaminetetraacetic acid (EDTA) for 72 h at 37 °C with shaking using a orbital 
shaker (universal IKA
®
 MS 3, 230 V) (Sigma, St. Louis, MO). The aggregated SOD1 was 
then labelled with biotin amidohexanoic acid 3-sulfo-N-hydroxysuccinimide ester sodium 
salt (40 mg/ml) in DMSO for 2 h at RT. The unconjugated biotin was then separated from the 
aggregates by centrifugation (21 000 x g for 30 min) and washed three times with PBS (300 x 
g for 5 min). The purified aggregates free of unconjugated biotin were then resuspended in 
PBS (1 mg/ml). A bicinchoninic acid (BCA) protein assay was performed to determine the 
amount of protein in solution.  
2.2.4 SOD1 protein Immunoblotting  
Purified SOD1 proteins in their soluble and aggregate form (1 μg protein/lane) were 
separated under reducing conditions (5% β-mercaptoethanol) using Any kD Mini-PROTEAN 
TGX Stain-Free™ Precast Gels (Bio-Rad, Hercules, CA). Proteins were then transferred onto 
nitrocellulose membranes using the Trans-Blot Turbo Transfer System (Bio-Rad). 
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Membranes were blocked with heat denatured casein (HDC) in for 1 h at 37°C. To confirm 
immunoreactivity of SOD1 and confirm the aggregation and biotinylation of the SOD1 
proteins, sheep anti-SOD1 pAb (1:500) and streptavidin−peroxidase (1:400) (Sigma, St. 
Louis, MO) diluted in HDC/PBS was incubated with membranes for 1 h at 37°C, to detect 
SOD1 soluble and biotinylated-aggregated protein respectively. The following day, the 
membrane containing soluble proteins was washed three times over 15 min with PBS 
containing 0.1% Triton X-100. The membrane was then incubated with peroxidase-
conjugated to anti-sheep IgG Ab (1:1000) for 1 h at 37°C. Membranes were washed three 
times over 30 min with PBS containing 0.1% Triton X-100 and membranes were visualised 
using chemiluminescent substrate and Amersham Hyperfilm ECL (GE Healthcare). The 
processing of films was achieved using GBX Developer and Replenisher and GBX Fixer and 
Replenisher (Kodak Australiasia, Collingwood, Victoria Australia). Images of the films were 
collected using a GS-800 Calibrated Densitometer (Bio-Rad). 
2.2.5 Transmission electron microscopy of SOD1 aggregates 
Negative staining transmission electron microscopy (TEM) was performed using substrate 
carbon-coated nickel grids (Proscitech Kirwan, Australia). Initially, 2 µl aliquots of SOD1 
WT and G93A proteins (1 mg/ml) were loaded onto carbon-coated nickel grids (Proscitech 
Kirwan, Australia) for 1 min at RT. Grids were washed 3 times with filtered Milli-Q water. 
Grids were then negatively stained using 2% (w/v) uranyl acetate (ProsciTech Kirwan, 
Australia) diluted in Milli-Q water for 2 min at RT. Grids were then dried using filter paper 
blotting and then left at RT for 5 min, until processing. Protein structure and morphology was 
then analysed using a JEOL 2011 TEM (Tokyo, Japan) operated at 200kV. Images were 
taken using a Gatan Microscopy Suite (Version 2.30.542.0) (California, USA). 
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2.2.6 Internalisation of SOD1 by flow cytometry 
NSC-34 cells were incubated with 20 μg/ml of aggregated SOD1 or PBS (no protein; 
negative control) for 60 min at 4°C. Cells were then washed twice in PBS, harvested using 5 
mM EDTA (5 min, 37°C) and then washed again using centrifugation (300 x g for 5 min). 
Cells were fixed with 4% PFA in PBS for 20 min at RT, and then washed again using 
centrifugation (300 x g for 5 min). Cells were washed once with ice-cold PBS and then 
incubated with Triton X-100 for 30 min at 4°C. Cells were washed again in ice cold PBS 
(300 x g for 5 min) and incubated with blocking solution (5% FCS, 1% BSA and 0.3% Triton 
X-100) for 20 min at RT. Cells were incubated with anti- SOD1 IgG Ab (1:500; diluted in 
4% BSA and 0.1% Triton X-100) for 30 min at 4°C. Cells were washed again in ice cold PBS 
(300 x g for 5 min) and incubated with anti-sheep IgG conjugated to Alexa Fluor 488 (1:500 
diluted in 1% BSA and 0.1% Triton X-100) for 30 min at 4°C protected from light. Cellular 
events were collected using a LSR II flow cytometer (BD Biosciences) (Excitation 488 nm, 
emission collected with 515/20 band-pass filter). The live cells were analysed using gating 
methods with forward and side scatter parameters. Mean fluorescence intensity (MFI) was 
then determined using FlowJo software (Tree Star, Ashland, OR).  
2.2.7 Detection of internalised SOD1 aggregates by immunoblotting 
In separate experiments, NSC-34 cells were treated with biotin conjugated-SOD1 aggregates 
as previously outlined above. Post incubation, cells were washed (300 x g for 5 min) twice 
with PBS and harvested using 0.05% trypsin-EDTA (5 min, 37°C) and then washed again 
using centrifugation (300 x g for 5 min). Cells were lysed (1.5 x 10
6
 - 1.5 x 10
8
 cells/ml) over 
15 min at 4°C in ice-cold lysis buffer (10 mM Tris, 150 mM NaCl, 5 mM EDTA, 1% Triton 
X-100 and protease inhibitor cocktail, pH 7.0). Cell debris was then cleared (21,000 × g at 
4°C for 30 min) and supernatants (75 μg protein/lane) were collected and separated under 
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reducing conditions (5% β-mercaptoethanol) using Any kD Mini-PROTEAN TGX Stain-
Free Gels (Bio-Rad, Hercules, CA). Proteins were then transferred to nitrocellulose 
membranes using a Trans-Blot Turbo Transfer System (Bio-Rad). The membrane was 
blocked with heat denatured casein (HDC) in for 1 h at 37°C. The nitrocellulose membrane 
was then incubated with mouse anti-actin mAb (1:5000), diluted in HDC/PBS for 1 h at 
37°C. The membrane was washed three times over 15 min with PBS containing 0.1% Triton- 
X-100. The membrane was then incubated with peroxidase-conjugated anti-streptavidin 
(1:400) (Sigma, St. Louis, MO) and goat anti-mouse IgG Ab-HRP diluted in HDC/PBS for 1 
h at 37°C for aggregates and actin respectively, and then washed as above. Internalised SOD1 
aggregates were visualised using chemiluminescent substrate and Amersham Hyperfilm ECL 
(GE Healthcare). Images of films were collected using a GS-800 Calibrated Densitometer 
(Bio-Rad). Actin was used as a loading control.  
2.2.8 Rapid detection of aggregated SOD1 by flow cytometry 
NSC-34 cells were incubated with 20 μg/ml of soluble and aggregated SOD1, GST or PBS 
(no protein, control) for 30 min at 37°C/5% CO2. Cells were then washed twice in ice-cold 
PBS, harvested using 5 mM EDTA (5 min, 37°C) and then washed again using centrifugation 
(300 x g for 5 min). Cells were fixed with 4% PFA for 20 min at RT, and then washed again 
(300 x g for 5 min) with ice-cold PBS. Cells were then incubated with Triton X-100 for 30 
min at 4°C. Cells were washed again in ice cold PBS (300 x g for 5 min) and incubated with 
blocking solution (5% FCS, 1% BSA and 0.3% Triton X-100) for 20 min at 4°C. Cells were 
then incubated anti-SOD1 IgG Ab (1:500 diluted in 4% BSA and 0.1% Triton X-100) for 30 
min at 4°C. Cells were washed again in ice cold PBS (300 x g for 5 min) and incubated with 
anti-sheep IgG conjugated to Alexa Fluor 488 (1:500 diluted in 1% BSA and 0.1% Triton X-
100) for 30 min at 4°C protected from light. Cellular events were collected using a LSR II 
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flow cytometer (BD Biosciences) (Excitation 488 nm, emission collected with 515/20 band-
pass filter). The live cells were analysed using gating methods with forward and side scatter 
parameters. Mean fluorescence intensity (MFI) of these cells was then determined using 
FlowJo software (Tree Star, Ashland, OR). 
2.2.9 Rapid detection of aggregated SOD1 by confocal microscopy 
NSC-34 cells (2–3 x 10
4
 cells/0.2 ml/chamber) were cultured in chamber slides at 37°C/5% 
CO2 overnight. Cells were incubated with 20 μg/ml of aggregated SOD1 or PBS (no protein 
control) for 30 min at 4°C to slow endocytosis. Cells were fixed with 4% PFA in PBS for 20 
min at RT and washed twice with ice cold PBS over 5 min. Cells were then incubated with 
Triton X-100 for 30 min at 4°C. Cells incubated with blocking solution (5% FCS, 1% BSA 
and 0.3% Triton X-100) for 20 min at RT. Cells were incubated with anti- SOD1 IgG Ab 
(1:500 diluted in 4% BSA and 0.1% Triton X-100) for 30 min at 4°C. Cells were washed 
again in ice cold PBS and incubated with anti-sheep IgG conjugated to Alexa Fluor 488 
(1:500 diluted in 1% BSA and 0.1% Triton X-100) for 30 min at 4°C protected from light. An 
inverted microscope (DM IBRE) and a Leica TCS SP confocal imaging system were used to 
visualise and image cells (excitation 488, emission collected at 520-545). Fluorescence, 
bright field (differential interference contrast; DIC) and merged images were captured using 
Leica confocal software.  
2.2.10 Permeabilisation of NSC-34 cells 
NSC-34 cells were incubated in chamber slides with 20 μg/ml of aggregated-biotin 
conjugated SOD1 for 60 min at 4°C. Cells were fixed with 4% PFA in PBS for 20 min at RT 
and washed twice with ice cold PBS over 5 min. Cells were then incubated with Triton X-100 
(permeabilised) or PBS (not permeabilised) for 30 min at 4°C. Cells were incubated with 
blocking solution (5% FCS and 1% BSA ) for 20 min at RT. Cells were incubated in 1 µg/ml 
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Alexa Fluor 488 streptavidin (diluted in 1% BSA and 0.1% Triton X-100) for 1 hr at RT 
protected from light. An inverted microscope (DM IBRE) and a Leica TCS SP confocal 
imaging system were used to visualise and image cells (excitation 488, emission collected at 
520-545). Fluorescence, bright field (differential interference contrast; DIC) and merged 
images were captured using Leica confocal software.  
2.2.11 Treatment with trypsin  
NSC-34 cells (2–3 x 10
4
 cells/0.2 mL/chamber) were cultured in chamber slides at 37°C/5% 
CO2 overnight. Cells were incubated with 20 μg/ml labelled aggregated SOD1 for 1 h at 
37°C/5% CO2. Cells were incubated with 0.25% trypsin or PBS (control) for 5 min at 
37°C/5% CO2. Cells were washed (300 x g for 5 min) and the resulting suspended cells were 
re-cultured in complete DMEM culture medium for a total of 6 h at 37°C/5% CO2 to allow 
cells to recover. Cells were then immediately fixed with 4% PFA in PBS for 20 min at RT 
and washed twice with PBS over 5 min. Cells incubated with 0.5% Triton X-100 for 30 min 
at 4°C. Cells were then incubated with blocking solution (5% FCS, 1% BSA and 0.3% Triton 
X-100) for 20 min at RT. Cells were then incubated with Alexa Fluor 488 streptavidin 
(1:1000 diluted in 1% BSA and 0.1% Triton X-100) for 1 h at RT. Sytox Red (5 µM) was 
used as a counter stain, and incubated with cells for 10 at RT. An inverted microscope (DM 
IBRE) and a Leica TCS SP confocal imaging system were used to visualise and image cells 
(excitation 488, emission collected at 520-545 and excitation 633, emission collected at 635-
650). Fluorescence, bright field (differential interference contrast; DIC) and merged images 
were captures using Leica confocal software. Mean fluorescence intensities (MFI) per cell of 
SOD1 aggregate uptake were quantified from confocal images using ImageJ software 
(Version 1.48) (National Institutes of health, Bethesda, MD). 
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2.2.12 Pre-treatment of NSC-34 cells with trypsin 
NSC-34 cells were harvested using either 5 mM EDTA (control) or 0.25% trypsin-EDTA (10 
min, 37°C) and then washed again using centrifugation (300 x g for 5 min). Cells were then 
incubated with 20 μg/ml of aggregated SOD1 or PBS (no protein, control) for 30 min at 
37°C/5% CO2. Cells were then washed twice in ice-cold PBS (300 x g for 5 min), and fixed 
with 4% PFA for 20 min at RT, then washed again with ice-cold PBS using centrifugation 
(300 x g for 5 min). Cells were then incubated with Triton X-100 for 30 min at 4°C. Cells 
were washed again in ice cold PBS (300 x g for 5 min), incubated in solution (5% FCS, 1% 
BSA and 0.3% Triton X-100) for blocking for 20 min at RT. Cells were incubated with anti- 
SOD1 IgG Ab (1:500 diluted in 4% BSA and 0.1% Triton X-100) for 30 min at 4°C. Cells 
were washed again in ice cold PBS (300 x g for 5 min) and incubated with anti-sheep IgG 
conjugated to Alexa Fluor 488 (1:500 diluted in 1% BSA and 0.1% Triton X-100 ) for 30 min 
at 4°C protected from light. Cellular events were collected using a LSR II flow cytometer as 
described above.  
2.2.13 Inhibition of SOD1 uptake - confocal microscopy 
Internalisation of aggregated SOD1 was measured in the presence or absence of a range of 
compounds that inhibit various internalisation mechanisms. NSC-34 cells (4 x 10
4
 cells/.35 
ml/well) were incubated in 24-well culture plates fitted with sterile 19 mm glass coverslips 
(1.5 ml/ well) and incubated at 37°C/5% CO2 overnight to allow time to adhere. Cells were 
pre-treated with various endocytic inhibitors including 100 µM 5-N-ethyl-N-isopropyl-
amiloride (EIPA), 5 µM chlorpromazine hydrochloride (Chlorp HCl), 10 µM genistein (Gen) 
or 3 µM rottlerin (Rot) diluted in 1% BSA/PBS or PBS (no inhibitor, diluted in 0.1% DMSO 
or 20% acetonitrile in water) for 30 min at 37°C/5% CO2. Cells were then co-incubated with 
by 20 μg/ml soluble or aggregated SOD1 for an additional 30 min at 37°C/5% CO2. Cells 
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were immediately fixed with 4% PFA in PBS for 20 min at RT and washed twice with PBS 
over 5 min. Cells were incubated with Triton X-100 for 30 min at 4°C. Cells were then 
incubated with blocking solution (5% FCS, 1% BSA and 0.3% Triton X-100) for 20 min at 
RT. Cells were incubated with anti-SOD1 IgG Ab (1:500 diluted in 4% BSA and 0.1% Triton 
X-100) for overnight at 4°C. Cells were subsequently washed again in PBS and incubated 
with anti-sheep IgG conjugated to Alexa Fluor 488 (1:500 diluted in 1% BSA and 0.1% 
Triton X-100) for soluble proteins and with Alexa Fluor 488 streptavidin (1:1000 diluted in 
1% BSA and 0.1% Triton X-100) for 1 h at RT. Sytox Red (5 nM) was used as a counter 
stain, and incubated with cells for 10 min at RT. An inverted microscope (DM IBRE) and a 
Leica TCS SP confocal imaging system were used to visualise and image cells (excitation 
488, emission collected at 520-545). Fluorescence, bright field (differential interference 
contrast; DIC) and merged images were captured using Leica confocal software.  
2.2.14 Inhibition of SOD1 uptake - flow cytometry 
Cells were harvested using 5 mM EDTA (5 min, 37°C) and then washed again using 
centrifugation (300 x g for 5 min). Cells were pre-treated with various endocytic inhibitors 
including 100 µM EIPA, 5 µM Chlorp HCl, 10 µM Gen, 3 µM Rot or RAC1 inhibitor W56 
(200 µM) diluted in 1% BSA/PBS or PBS (no inhibitor, diluted in 0.1% DMSO or 20% 
acetonitrile in water) for 30 min at 37°C/5% CO2. Cells were then washed twice in PBS (300 
x g for 5 min) and then co-incubated with by 20 μg/ml soluble or aggregated WTSOD1 for an 
additional 30 min at 37°C/5% CO2. Cells were then washed twice in PBS (300 x g for 5 min) 
and immediately fixed with 4% PFA in PBS for 20 min at RT. Cells were then washed twice 
in PBS (300 x g for 5 min) and then incubated with Triton X-100 for 30 min at 4°C. Cells 
were washed twice in PBS (300 x g for 5 min) and incubated with blocking solution (5% 
FCS, 1% BSA and 0.3% Triton X-100) for 20 min at RT. Cells were then washed twice in 
PBS (300 x g for 5 min) and incubated with anti-SOD1 IgG Ab (1:500 diluted in 4% BSA 
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and 0.1% Triton X-100) for 30 min at 4°C for 1 h at RT. Cells were washed again (300 x g 
for 5 min) in PBS and incubated with anti-sheep IgG conjugated to Alexa Fluor 488 (1:500 
diluted in 1% BSA and 0.1% Triton X-100 ) for soluble proteins and with Alexa Fluor 488 
streptavidin (1:1000 diluted in 1% BSA and 0.1% Triton X-100) for 1 h at RT. Cells were 
then washed twice in PBS (300 x g for 5 min). Cellular events were collected using a LSR II 
flow cytometer (excitation 488 nm, emission collected at 515/20 nm) and the MFI of relative 
SOD1 uptake into NSC-34 cells was determined using FlowJo software. Results are the 
average of at least five independent experiments.  
2.2.15 Field emission scanning electron microscopy (FESEM)  
Detached NSC-34 cells (7x10
4
 cells/ml/well) were incubated in 24-well culture plates fitted 
with sterile 19 mm glass coverslips (1.5 ml/well) and incubated at 37°C/5% CO2 overnight to 
allow time to adhere. Cells were then serum starved in DMEM F12 phenol red free culture 
medium for 24 h at 37°C/5% CO2. Cells were then washed once with PBS and incubated with 
20 µg/ml soluble or aggregated proteins in PBS or PBS containing 200 nM phorbol 12-
myristate 13-acetate (PMA) for 2 h at 37°C/5% CO2. Post incubation, cells were washed 
three times in PBS then fixed in 2.5% glutaraldehyde/4% PFA in 0.1 M phosphate buffer for 
3 h at 4°C. Cells were then washed three times in phosphate buffer and postfixed in 2% 
OsO4/water at RT for 1 h. After washing with water, the cells were dehydrated using a 
gradient of ethanol at 30%, 50%, 70%, 80%, 90% and 100% (30 min per incubation) at RT. 
The cells were then critical point dried for 2 h using a LEICA CPD030 (Vienna, Austria) and 
coated with graphite-gold in a sputter coater. Cellular structures were visualised with a JEOL 
6490LV SEM (Tokyo, Japan) microscope operated at 10 kV at a 10 mm working distance 
and a spot size setting of 35.  
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2.2.16 Membrane activity quantification 
NSC-34 cells (2–3 x 10
4
 cells/0.2 ml/chamber) were cultured in 8-well chamber slides in 
DMEM/F12 media supplemented with 10% FCS and were incubated overnight at 
37°C/5%CO2. Cells were incubated with 20 µg/ml of SOD1 proteins, PBS alone, or PMA 
(200 nM) in PBS for 1 h at 37°C/5% CO2. Cells were then washed twice in PBS and 
incubated with 10 µM of FM 1-43FX membrane stain diluted in PBS for 7 min at 37°C/5% 
CO2. Excess dye was removed by several washes in PBS and cells were returned to the 
incubator (37°C/5% CO2) for 4 min. This procedure was repeated to give a total of 8 min of 
incubation in PBS. Post incubation, ice-cold PBS was added to stop endocytosis and prepare 
cells for fixation in 4% PFA in PBS for 20 min at 4°C. Post fixation, cells were washed twice 
in PBS and incubated with 1x Red Dot 2 for 10 min at RT.  
2.2.17 Fluid phase uptake - confocal microscopy 
Pinocytosis involves uptake of solutes from the extracellular medium. One well established 
solute is dextran. To quantify the amount of fluid phase solute uptake NSC-34 cells (2–3 x 
10
4
 cells/0.2 ml/chamber) were incubated in chamber slides with 20 µg/ml of SOD1 proteins 
in PBS alone or PMA (200 nM) for 30 min at 37°C/5%CO2. Prior to harvesting or fixation, 
cells were then co-incubated for 15 min with 0.5 mg/ml 10 kDa dextran conjugated to Alexa 
Fluor 647 at 37°C/5% CO2. The cells were then placed on ice to stop dextran uptake and cells 
were washed three times with ice cold PBS and once with low pH buffer (0.1 M sodium 
acetate, 0.05 M NaCl, pH 5.5) for 10 min. The cells were then incubated with anti-SOD1 IgG 
Ab (1:500 diluted in 4% BSA and 0.1% Triton X-100) overnight at 4°C. Cells were washed 
again in PBS and incubated with anti-sheep IgG conjugated to Alexa Fluor 488 (1:500 diluted 
in 1% BSA and 0.1% Triton X-100) for soluble proteins and Alexa Fluor 488 streptavidin 
(1:1000 diluted in 1% BSA and 0.1% Triton X-100) for 1 h at RT. An inverted microscope 
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(DM IBRE) and a Leica TCS SP confocal imaging system were used to visualise and image 
cells (excitation 488, emission collected at 495-515 and 650-668). Fluorescence, bright field 
(differential interference contrast; DIC) and merged images were captured using Leica 
confocal software.  
2.2.18 Fluid phase uptake - flow cytometry 
NSC-34 cells (5 x 10
4
 cells/0.5 ml/well) were incubated with 20 µg/ml of SOD1 proteins in 
PBS alone or PMA (200 nM) for 30 min at 37°C/5% CO2. Cells were co-incubated with 0.5 
mg/ml 10 kDa dextran conjugated to Alexa Fluor 647 for 15 min at 37°C/5% CO2. The cells 
were then placed on ice to supress dextran uptake and cells were washed three times with ice 
cold PBS (300 x g for 5 min) and once with low pH buffer (300 x g for 5 min) (0.1 M sodium 
acetate, 0.05 M NaCl, pH 5.5) for 10 min. The cells were then incubated with anti-SOD1 IgG 
Ab (1:500 diluted in 4% BSA and 0.1% Triton X-100) for 1 h at RT. Cells were washed 
again (300 x g for 5 min) in PBS and incubated with anti-sheep IgG conjugated to Alexa 
Fluor 488 (1:500 diluted in 1% BSA and 0.1% Triton X-100) for soluble proteins and Alexa 
Fluor 488 streptavidin (1:1000 diluted in 1% BSA and 0.1% Triton X-100) for 1 h at RT. 
Cellular events were collected using a LSR II flow cytometer as described above. 
2.2.19 Inhibition of PMA induced dextran uptake  
NSC-34 cells (5 x 10
4
 cells/0.5 ml/well) were serum starved for 24 h. Cells were pre-treated 
with various endocytic inhibitors including 100 µM EIPA, 5 µM chlorpromazine 
hydrochloride (Chlorp HCL), 10 µM Gen and 3 µM Rot diluted in 1% BSA/PBS or PBS 
(0.1% DMSO) for 30 min at 37°C/5% CO2. Cells were co-incubated with 200 nM PMA for 
an additional 30 min at 37°C/5% CO2. Cells were co-incubated with 0.5 mg/ml 10 kDa 
dextran conjugated to Alexa Fluor 647 for 15 min at 37°C/5% CO2. The cells were then 
placed on ice to supress dextran uptake and cells were washed three times with ice cold PBS 
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(300 x g for 5 min) and once with low pH buffer (300 x g for 5 min) (0.1 M sodium acetate, 
0.05 M NaCl, pH 5.5) for 10 min. Cellular events were collected using a LSR II flow 
cytometer (BD Biosciences) as outlined above. 
2.2.20 RAC1 activation ELISA assay 
NSC-34 cells were incubated in sterile 12-well culture plates (2 ml/well) and incubated at 
37°C/5% CO2 overnight. Cells were then serum starved in phenol red free culture medium for 
24 h at 37°C/5% CO2. Cells were then washed once with ice cold PBS and incubated with 20 
µg/ml of soluble and aggregated SOD1 proteins for 30 min at 37°C/5% CO2. Cells were 
washed twice with ice-cold PBS and harvested by treatment with 0.05% trypsin for 10 min at 
37°C. Cells were washed again (300 x g for 5 min) in PBS. RAC1 activation was measured 
using a G-LISA activation kit (Kit #BK128 Cytoskeleton, Inc. Denver, USA) as per the 
manufacturer’s recommendations. Absorbance values of wells were recorded with a 
SpectraMax Plus 384 Microplate Reader and SoftMax Pro software (Molecular Devices, 
Silicon Valley, CA) (490nm). 
2.2.21 RAC1 inhibition and membrane activity 
NSC-34 cells (2–3 x 10
4
 cells/0.2 ml/chamber) were cultured in 8-well chamber slides in 
complete culture medium and were incubated overnight at 37°C/5% CO2. Cells were pre-
incubated with RAC1 inhibitor W56 or PBS (in 20% acetonitrile in water) diluted in 1% 
BSA/PBS for 1 h at 37°C/5% CO2. Cells were then co-incubated with PMA (200 nM) in PBS 
for an additional 30 min at 37°C/5% CO2. Cells were then washed twice in PBS and 
incubated with 10 µM of FM 1-43FX membrane stain diluted in PBS for 7 min at 37°C/5% 
CO2. Excess dye was removed by several washes in PBS and cells were returned to the 
incubator (37°C/5% CO2) for 4 min. This procedure was repeated to give a total of 8 min of 
incubation in PBS. Post incubation, ice-cold PBS was added to stop endocytosis and prepare 
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cells for fixation in 4% PFA in PBS for 20 min at 4°C. Post fixation, cells were washed twice 
in PBS and incubated with 1x Red Dot 2 for 10 min at RT for imaging with confocal 
microscopy.  
2.2.22 Etoposide Assay 
To confirm cell blebbing is not apoptosis related, a Caspase Detection kit was used according 
to manufacturer’s instructions. Detached NSC-34 cells (10x10
4
 cells/ml/well) were incubated 
in 12-well culture plates fitted with sterile 19 mm glass coverslips (1 ml/well) and incubated 
at 37°C/5%CO2 overnight to allow time to adhere. Cells were incubated with either 20 μg/ml 
soluble and labelled aggregated SOD1 or 100 µM Etoposide for 2 h at 37°C/5% CO2. Cells 
were incubated with 1X FLICA reagent for 60 min at 37°C/5% CO2, protected from light. 
Cells were washed gently with cell-culture medium (DMEM F12 phenol red free). Cells were 
then incubated with SYTOX Green stain (5 µM) for 8 min at 37°C/5% CO2. The cells were 
then washed with 2 ml of 1X wash buffer and coverslips were mounted on slides using one 
drop of apoptosis fixative solution in 1X wash buffer according to manufacturer’s 
instructions. An inverted microscope (DM IBRE) and a Leica TCS SP confocal imaging 
system were used to visualise and image cells (excitation 488, emission collected at 495-515 
and 650-668). Fluorescence, bright field (differential interference contrast; DIC) and merged 
images were captures using Leica confocal software. 
2.2.23 Presentation of data and statistical analyses 
Data is presented as the mean ± SD. ANOVA paired with Tukey’s HSD multiple comparison 
post-test tests were used to analyse and compare differences between multiple treatments. 
Unpaired student’s t-tests were performed for single treatment comparisons. Prism 5 for 
Windows (Version 5.01) (GraphPad Software, San Diego, CA) was used to generate these 
statistical analyses. Differences were defined as significant for P < 0.05.  
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2.3 Results  
2.3.1 SOD1 aggregates associate with the cellular surface and internalise into neuronal 
cells via membrane proteins 
2.3.1.1 Aggregating WT and G93A SOD1 proteins  
Given the identification of SOD1-positive lewy-body like hylaline inclusions and skein like 
inclusions in surviving motor neurons derived from spinal cords of SOD1-related fALS 
patients (Piao et al., 2003) it is now generally accepted that pathogenic mutations in SOD1 
increases the propensity of SOD1 to aggregate (Bruijn et al., 1998), and that SOD1 
misfolding and aggregation contribute to the underlying cause for pathology in SOD1 fALS 
cases (Furukawa and O’Halloran, 2005). To investigate the effects of properly folded soluble 
SOD1 and aggregated proteins on motor-neuron like cell lines, recombinantly produced, 
properly folded (soluble SOD1) and dimeric human WT and G93A SOD1 was purified and 
subsequently aggregated in vivo to form fibrillar structures, as previously described (Yerbury 
et al., 2013). To investigate the morphology of these aggregates, negative staining TEM was 
performed. Representative TEM images of endpoint aggregates for both the WT and G93A 
SOD1 proteins displayed short fibril-like structures, similar to those seen in human fALS 
cases (Figure 2.1) 
 
 
 
Figure 2.1 SOD1 proteins aggregate in to fibril -like structures . Representative TEM image of 
endpoint aggregates. WT and G93A (1 mg/ml) protein samples (2 µl) were loaded onto carbon-coated nickel 
grids for 1 min at RT and negatively stained using 2% uranyl acetate for 2 min at RT. Bars represent 20 nm. 
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2.3.1.2 Applying exogenous recombinant SOD1 aggregates to the extracellular environment 
of NSC-34 mouse motor neuron like cells  
Our group and others have previously shown that aggregated human SOD1 can be taken up 
by neuronal cells (Grad et al., 2014; Münch et al., 2011; Sundaramoorthy et al., 2013). To 
confirm these results and further investigate entry, preformed SOD1 aggregates were added 
to the media of NSC-34 cells (Figure 2.2). Following incubation of the cells with the SOD1 
aggregates for 60 min, the aggregates could be detected in association with the cells by flow 
cytometry Figure 2.2A). Next, to further investigate whether the SOD1 aggregates had 
entered into NSC-34 cells, cells were incubated with SOD1 aggregates for 60 min and lysed. 
Immunoblotting of cell lysates resulted in bands corresponding to the size of SOD1, 
including SDS resistant high molecular weight (HMW) species (Figure 2.2B).  
 
 
 
 
 
 
 
 
Figure 2.2 SOD1 protein aggregates are internalised into NSC -34 cells . (A) NSC-34 cells were 
incubated with 20 μg/ml of SOD1 aggregates (blue line) or PBS alone (no protein, gray line) for 60 min at 4°C. 
Cells were harvested, labelled with anti-sheep IgG conjugated to Alexa Fluor 488. (B) (Right panel) Western 
blot of cell lysates detecting human SOD1 (and actin as a loading control). Lysates from NSC-34 cells were 
treated with SOD1 aggregates or PBS (control) for 60 min at 4°C and were separated by SDS-PAGE under non-
reducing conditions, transferred to nitrocellulose membrane and probed with streptavidin-peroxidase and mouse 
anti-actin mAb. Arrows indicate approximate size of each band. Results are representative of at least 2 
independent experiments. 
2.3.1.3 Uptake into NSC-34 cells is specific for SOD1 and occurs rapidly  
To further characterise the entry of SOD1 aggregates into NSC-34 cells, putative uptake of 
SOD1 was investigated (Figure 2.3). NSC-34 cells were incubated with soluble SOD1 or 
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aggregates for 30 min and immediately examined by flow cytometry (Figure 2.3A). 
Incubation with the soluble (properly folded) WT SOD1 and non-aggregated ALS associated 
mutant G93A SOD1 resulted in a significant increase in fluorescence compared to control 
cells in the absence of protein. Similarly, aggregated WT SOD1 also associated with cells 
when compared to the cells incubated in the absence of protein. In contrast, there was no 
statistically significant increase in immunofluorescence after incubation with an unrelated 
control protein GST suggesting that the uptake of both soluble and aggregated forms of 
SOD1 is relatively specific. Next, to examine whether these aggregates enter cells efficiently 
and rapidly, cells were incubated with SOD1 aggregates at 4ºC for 30 min. SOD1 aggregates 
were found associated with the surface of NSC-34 cells after the 30 min incubation (Figure 
2.3B), suggesting that interaction occurs relatively rapidly, given that endocytosis is slowed 
and or inhibited by ice cold temperatures. To show that the observed SOD1 aggregates 
associated with the cell surface are taken up by NSC-34 cells, cells were incubated with the 
aggregates and treated with Triton X-100 detergent which non-selectively permeabilises 
membranes. Similar to the flow cytometry observations described above, SOD1 aggregates 
were no longer detected on the cell surface at 60 min (Figure 2.3C nevertheless they were 
detected following permeabilisation of cells with Triton X-100, consistent with their 
internalisation (Figure 2.3D).  
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Figure 2.3 SOD1 protein aggregate are internalised rapidly into NSC -34 cells.  (A) NSC-34 
cells treated with 20 μg/ml of soluble and aggregated WT SOD1, GST or PBS (no protein, control) for 30 min at 
37°C, fixed with 4% PFA, permeabilised and labelled with Alexa Fluor 488 streptavidin. Uptake of proteins was 
determined by flow cytometry and results shown as means ± SE, n = 3, 
***
P < 0.001 compared to corresponding 
control. (B) NSC-34 cells treated with 20 μg/ml of aggregated SOD1 for 30 min at 4°C, fixed with 4% PFA, and 
labelled with Alexa Fluor 488 streptavidin. Slides were analysed by confocal microscopy. Bars represent 20 µm. 
(C-D) NSC-34 cells treated with 20 μg/ml of aggregated SOD1 for 60 min at 4°C, fixed with 4% PFA, 
permeabilised (or not) and labelled with Alexa Fluor 488 streptavidin. Slides were analysed by confocal 
microscopy. Outline of cells from transmission images are indicated with white dashed lines. Bars represent 20 
µm. Results are representative of at least 3 independent experiments. 
2.3.1.4 SOD1 protein aggregates are not solely bound to the cells surface 
Next, the possibility that WT and G93A SOD1 aggregates were bound primarily to the cell 
surface was investigated. Previous work has used trypsin digestion to remove surface-bound 
proteins (Wu et al., 2013). Incubation with 0.25% trypsin post treatment with SOD1 
aggregates induced no significant differences in SOD1 signal, with similar levels of WT and 
G93A SOD1 aggregate uptake in the presence or absence of trypsin, indicating that signal 
observed in the flow cytometry experiments was not solely due to SOD1 aggregates 
associated with the cell membrane, rather SOD1 aggregates were inside cells (Figure 2.4A 
and B).  
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Figure 2.4 SOD1 aggregates are detected inside in NSC-34 cells.  Adherent NSC-34 cells were 
incubated with 20 μg/ml of aggregated SOD1 or PBS (no protein, control) for 1 h at 37°C. Cells were then 
incubated with 0.25% trypsin or PBS (control) for 5 min at 37°C. Suspended cells were re-plated for 6 h at 37°C 
before fixation and immunocytochemistry. Biotinylated aggregates were detected with streptavidin-Alexa488. 
Sytox Red (5 µM) was used as a counter stain (10 min at RT). Outline of cells from transmission images are 
indicated with white dashed lines. Bars represent 20 µm. Mean fluorescence intensities (MFI) of SOD1 
aggregate uptake were quantified from these images using ImageJ software (Version 1.48) (National Institutes 
of health, Bethesda, MD). Results shown as mean cellular fluorescence intensity means ± SD, n > 3, 
***
P <0.001 
compared to corresponding control (no protein treatment). 
 
2.3.1.5 Digestion of membrane proteins by trypsin inhibits SOD1 uptake 
Since SOD1 aggregate uptake had been observed and quantified, the possible role of 
membrane proteins in the uptake into NSC-34 cells was next investigated. To investigate 
whether an association between SOD1 aggregate uptake and membrane proteins exists, cells 
were pre-treated with trypsin prior to the addition of SOD1 aggregates (Figure 2.5). In the 
absence of a pre-incubation step with trypsin, a significantly higher fluorescence intensity 
was measured for both WT and G93A protein aggregate treatments, compared to cells pre-
incubated with trypsin. This indicates that digestion of plasma membrane associated proteins 
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result in significant inhibition of aggregate association with cells, suggesting that the uptake 
of SOD1 aggregates is dependent upon cell surface proteins. 
 
 
 
 
 
 
 
Figure 2.5 SOD1 protein aggregates associate with NSC-34 cells via  membrane proteins.  
Internalisation of aggregated WT and G93A SOD1 (20 µg/ml) proteins for 30 min at 37oC, in the absence 
(control) or presence of a pre-incubation step with 0.05% trypsin for 10 min at 37°C. MFI of 10 kDa dextran 
conjugated to Alexa Fluor 647 uptake was measured using flow cytometry. Results shown as geometric means ± 
SD, n = 6. Results shown as mean cellular fluorescence intensity means ± SD, n > 30, 
*
P < 0.05 compared to 
corresponding control (no protein treatment).  
2.3.2 SOD1 aggregates are internalised via macropinocytosis pathways in NSC-34 cells 
2.3.2.1 Pharmacological inhibitors of Macropinocytosis reduce SOD1 aggregate uptake in 
NSC-34 cells 
Previous studies have shown that small molecules that inhibit actin rearrangement, Na
+
/H
+
 
exchangers, Pak-1, PI3K, and PKC suppress aggregate uptake (Grad et al., 2014; Munch et 
al., 2011; Sundaramoorthy et al., 2013), consistent with macropinocytosis. However, it 
remains to be shown whether SOD1 triggers macropinocytosis through an interaction with 
cells or whether aggregates are taken up by a constitutive process. To investigate the 
involvement of macropinocytosis-like pathways in the uptake of SOD1 aggregates into NSC-
34 cells, cells were firstly incubated in the absence or presence of EIPA (an inhibitor of the 
Na
+
/H
+
 exchanger and subsequent endocytosis) and rottlerin (an inhibitor of PKC), as 
reported previously (Grad et al., 2014; Munch et al., 2011; Sundaramoorthy et al., 2013), and 
assessed by confocal microscopy and the mean fluorescence intensity for SOD1 uptake 
determined by flow cytometry (Figure 2.6).  
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Similar to previous experiments (Grad et al., 2014; Münch et al., 2011; Sundaramoorthy et 
al., 2013), incubation with rottlerin and EIPA resulted in a significant reduction in the uptake 
of SOD1 aggregates by (37±5% and 76±4%, Figure 2.6B) and (49±1% and 44±1%, Figure 
2.6D for the WT and G93A aggregate treated cells respectively, compared to cells incubated 
in the absence of inhibitors. However, inhibitors of clathrin (chlorpromazine) or caveolin 
(genistein) dependent endocytosis had no significant effect on the uptake process. Therefore, 
similar results were found regardless of whether or not the aggregates were WT or mutant 
G93A SOD1. When soluble (non-aggregated) WT SOD1 (Figure 2.6C) was applied to cells 
(Figure 2.6A) pre-incubated with EIPA, a significant reduction in SOD1 uptake was also 
observed (48±8%). Similarly, pre-incubation with rottlerin suppressed WT SOD1 uptake by 
(50±9%), however, this was not statistically significant. Although rotterlin (44±6%), EIPA 
(50±9%) as well as genistein (43±6%) had some effect on reducing the uptake of G93A 
SOD1 proteins into cells, pre-incubation with chlorpromazine hydrochloride was able to 
significantly suppress uptake by (65±0.5%). Likewise, immunocytochemical analyses 
confirmed these flow cytometry results, whereby lower signals of immunofluorescence are 
indicative of reduced uptake of SOD1 proteins.  
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Figure 2.6 Small molecule inhibitors block SOD1 uptake . NSC-34 cells treated with 20 μg/ml of 
(A-C) soluble or (B-D) aggregated SOD1 proteins (20 µg/ml) for 30 min at 37
o
C, in the absence (control) or 
presence of a pre-incubation step with either rottlerin (3 µM) a PAK-1 and PKC inhibitor, EIPA (100 µM) a 
Na+/H+ exchange inhibitor, genistein (10 µM) a caveolin mediated uptake inhibitor or chlorpromazine 
hydrochloride (Chlorp HCL) (5 mM) a clathrin mediated endocytosis inhibitor, fixed with 4% PFA, 
permeabilised and labelled with either (A-C) anti-human SOD1 Ab (soluble) or (B-D) Alexa Fluor 488 
streptavidin. Slides were analysed by confocal microscopy. Outline of cells are indicated with white dashed 
lines. Bars represent 20 µm. Results are representative of at least n = 3. Uptake of proteins under the same 
conditions were determined by flow cytometry and results shown as mean fluorescence intensity ± SD, n = 6, 
***
P < 0.001 or 
*
P < 0.05 compared to corresponding control.  
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2.3.3 SOD1 aggregates trigger cell surface ruffling and activate RAC1 in NSC-34 cells 
allowing the exploitation of macropinocytosis as a route of entry into cells 
2.3.3.1 SOD1 aggregates induce cell surface ruffles and blebs in the membrane to enter into 
NSC-34 cells 
Actin cytoskeleton restructuring and the formation of ruffles and blebs in the cellular surface 
are required for macropinocytosis and are generally formed upon an external stimuli such as 
growth factors but can be triggered by a variety of other particles such as bacteria, apoptotic 
bodies, necrotic cells and viruses (Swanson and Watts, 1995; Mercer and Helenius, 2012). 
Since macropinocytosis has been implicated in SOD1 uptake (Münch et al., 2011; 
Sundaramoorthy et al., 2013), the possible role of SOD1 aggregates in stimulating cellular 
ruffles and blebs was investigated. To test whether there were any perturbations to the cell 
surface membrane caused by incubation with SOD1, cells were treated with either PMA 
(positive control) or SOD1 (aggregated and non-aggregated), for 2 h and then the detailed 
morphology of cells was examined by field emission scanning electron microscopy (FESEM) 
(Figure 2.7). In the absence of protein treatment, little to no membrane perturbations were 
observed (Figure 2.7A), however, incubation with 200 nM PMA resulted in an obvious 
increase in membrane perturbations, including ruffles and blebs (Figure 2.7B), consistent 
with an activation of macropinocytosis. Incubation with soluble WT (Figure 2.7C) and G93A 
SOD1 (Figure 2.7D) did not induce such membrane perturbations. In contrast, incubation 
with aggregated WT (Figure 2.7E) and G93A SOD1 (Figure 2.7F) induced pronounced 
membrane ruffling and blebbing consistent with stimulated macropinocytosis. Subsequent 
quantifiable investigations into membrane perturbations induced by SOD1 were therefore 
carried out. 
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Figure 2.7 Aggregated SOD1 induces ruffles in the plasma membrane of NSC -34 cells.  
NSC-34 cells were serum starved for 24 h and were incubated with (A) PBS (control, no protein), (B) PBS 
containing 200 nm PMA or 20 μg/ml of (C-D) soluble (non-aggregated) and (E-F) aggregated SOD1, for 2 h, 
fixed with 2.5% glutaraldehyde/4% PFA in 0.1 M phosphate buffer for 3 h, postfixed in 2% OsO4/ water, 
dehydrated using a gradient of ethanol (30-100%, 30 min per treatment), critical point dried for 2 h and coated 
with graphite-gold. Increases in membrane perturbations can be observed, such as ruffles and blebs. Slides were 
analysed by field emission scanning electron microscopy. Bars represent 1 µm. Results are representative of n = 
2. 
2.3.3.2 SOD1 protein aggregates induce significant membrane perturbations in the cellular 
surface of NSC-34 cells 
To visualise and quantify the extent of observed SOD1 aggregate-induced membrane 
perturbation to the cellular surface of NSC-34 cells, cells were treated with either PMA or 
SOD1 (aggregated and non-aggregated), prior to incubation with the membrane dye FM 1-
43FX (Figure 2.8). FM1-43FX has been used in previously for studies of membrane 
perturbation during growth cone ruffling (Kolpak et al., 2009). Fluorescence images of NSC-
34 cells were then acquired (Figure 2.8A) and quantified (Figure 2.8B). In cells treated with 
PMA, a significant increase in membrane dye fluorescence was observed (57±2) compared to 
cells incubated in the absence of protein (30± 0.7). Similarly, incubation with WT (63±1) and 
G93A (69±3) soluble SOD1 also resulted in a significant increase in fluorescence. 
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Nevertheless, there was a three-fold higher mean fluorescence intensity for membrane 
fluorescence in cells incubated with WT (97±6) and G93A (93±3) SOD1 aggregates, 
consistent with an increase in membrane perturbation.  
 
 
 
 
 
 
 
 
 
Figure 2.8 SOD1 aggregates induce membrane perturbations in the cell surface of NSC -34 
cells (A) NSC-34 cells were incubated with PBS alone, 200 nM PMA or 20 μg/ml of aggregated SOD1for 60 
min at 37°C, incubated with the membrane dye FM1-43FX and fixed with 4% PFA. Outline of cells are 
indicated with white dashed lines. Bars represent 20 µm. (B) Mean fluorescence intensities (MFI) of membrane 
dye per cell were quantified from these images using ImageJ software (Version 1.48) (National Institutes of 
health, Bethesda, MD). A minimum of 200 cells were scored per treatment. Results shown as mean cellular 
fluorescence intensity means ± SD, n = 3, 
***
P <0.001 compared to corresponding control (no protein 
treatment); 
†††
P < 0.001 compared to corresponding soluble protein.  
2.3.3.3 SOD1 aggregates interact with the cell surface to trigger fluid phase uptake 
Macropinocytosis is a form of fluid phase endocytosis that engulfs solutes at whatever 
concentrations they are found in the extracellular medium, rather than concentrating ligands 
at the cell surface. Thus, activation of macropinocytosis is well known to induce a transient 
increase in dextran, a fluid phase marker (Kerr and Teasdale, 2009). To investigate whether 
the interaction of SOD1 aggregates with cells triggers an increase in fluid phase uptake, 
NSC-34 cells were incubated in the presence of both SOD1 and 10 kDa dextran conjugated to 
Alexa Fluor 647 and assessed by both confocal microscopy (Figure 2.9A) and flow cytometry 
(Figure 2.9B). Firstly, cells incubated in the presence of both WT and G93A SOD1 
aggregates displayed an increase in fluid uptake compared to the untreated cells, with little to 
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no difference observed for the cells treated with soluble SOD1. Next, cells were then 
analysed by flow cytometry. Again, incubation with both WT (16±0.1%) and G93A 
(18±0.3%) SOD1 aggregates triggered a significant increase in dextran uptake compared to 
that in the absence of treatment (9±0.2%) or following incubation with WT (13±0.2%) and 
G93A (13±0.1%) soluble SOD1. Whilst there was a small increase in dextran uptake in cells 
treated with the soluble SOD1 compared to those not treated, it was concluded that this was 
thus not attributable to stimulated macropinocytosis as it occurred in the absence of 
membrane ruffling (see above).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 SOD1 aggregates trigger fluid phase uptake using fluorescently labelled 
dextran. NSC-34 cells were incubated with PBS alone (control) or 20 μg/ml of soluble and aggregated SOD1 
for 30 min at 37°C, co-incubated with dextran Alexa-647 for 15 min, fixed with 4% PFA, permeabilised and 
labelled with either anti-human SOD1 Ab (non-aggregated/ soluble) or Alexa Fluor 488 streptavidin. Slides 
were analysed by (A) confocal microscopy. Outline of cells are indicated with white dashed lines. Bars 
represent 10 µm. Results are representative of at least n = 3. (B) Cells were firstly gated on forward (FSC) and 
side (SSC) scatter to exclude dead cells and the mean fluorescence intensities (MFI) of dextran Alexa-647 in 
NSC-34 cells was determined by flow cytometry. Results shown as means ± SD, n = 6; 
***
P < 0.001 compared 
to corresponding control;
 †††
P < 0.001 or 
†
P < 0.05 compared to corresponding soluble treatment. 
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2.3.3.4 Pharmacological Inhibitors of Macropinocytosis also inhibit dextran uptake into 
NSC-34 cells 
To confirm that inhibitors of macropinocytosis can suppress dextran uptake into NSC-34 
cells, cells were pre-incubated in the absence (PMA) or presence of pharmacological 
inhibitors of macropinocytosis or in the absence of PMA and inhibitors (mock) (Figure 2.10). 
As above (Figure 2.6) EIPA and rottlerin inhibited fluid phase uptake (quantified as uptake of 
10 kDa dextran conjugated to Alexa647) stimulated by PMA treatment of NSC-34 cells, but 
genistein and chlorpromazine did not, demonstrating the specificity of the inhibitors to PKC-
dependent fluid phase uptake. 
 
 
 
 
 
 
 
Figure 2.10 PMA induced dextran uptake is suppressed by inhibitors of macropinocytosis.  
The induction of fluid phase uptake was measured using fluorescently labelled dextran. NSC-34 cells were 
serum starved for 24 h and co-incubated with 200 nM PMA for 30 min, in the absence (PMA) or presence of a 
pre-incubation step with either rottlerin (3 µM), EIPA (100 µM), genistein (10 µM) or in the absence of PMA 
and inhibitors (mock) for 30 min, and co-incubated with dextran Alexa-647 for 15 min. Induced fluid uptake 
was determined by flow cytometry and results shown as mean cellular fluorescence intensity means. Cells were 
firstly gated on forward (FSC) and side (SSC) scatter to exclude dead cells and the mean fluorescence intensities 
(MFI) of dextran Alexa-647 in NSC-34 cells was determined by flow cytometry. Results shown as means ± SD, 
n = 6; 
***
P < 0.001 compared to corresponding PMA treatment.  
2.3.4 RAC1-GTPase activation is required for SOD1 aggregate uptake into NSC-34 cells 
2.3.4.1 SOD1 aggregates trigger RAC1 activation to enter into NSC-34 cells 
To further characterise the role of SOD1 protein aggregates in stimulating macropinocytosis, 
additional events downstream of macropinocytosis activation were investigated. This 
included activation of the Rho GTPase RAC1, which is involved in triggering membrane 
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ruffling on the cell surface (Ridley et al., 1992). To investigate the activation status of RAC1 
during entry of SOD1 aggregates into NSC-34 cells, cells were incubated with SOD1 and 
RAC1 activation was probed for using a G-LISA based assay (Figure 2.11). Incubation of 
cells with soluble SOD1 and aggregated WT SOD1 had no significant effect on RAC1 
activation. While incubation with G93A SOD1 aggregates resulted in an almost one and a 
half–fold significant increase in the amount of activated RAC1 ( RAC1-GTP) in NSC-34 
cells.  
 
 
 
 
 
 
 
 
 
 
Figure 2.11 RAC1 has an important role in SOD1 aggregate entry into NSC -34 cells.  NSC-
34 cells were serum starved 24 h, incubated with PBS alone (mock) or 20 μg/ml of soluble and aggregated 
SOD1 for 30 min at 37°C and lysed. RAC1 activation was measured using a RAC1 activation G-LISA kit 
activation assay that probes for RAC1-GDP. Absorbance values of anti- RAC1 HRP at 490 nm were determined 
by spectrometry and results are shown as mean absorbances (490 nm) ± SD of 6 experiments, 
**
P < 0.01 
compared to corresponding mock.  
2.3.4.2 Addition of RAC1 inhibitor reduces SOD1 uptake. 
To further examine the role of RAC1 in the uptake of SOD1 aggregates, the effect of the 
RAC1 inhibitor W56 on SOD1 aggregate uptake was investigated (Figure 2.12). Significant 
WT (19±0.4%) and G93A (21±0.4%) SOD1 aggregate uptake was observed in cells 
incubated in the absence of W56. However, pre-treatment with W56 significantly suppressed 
the uptake of WT (12±0.1%) and G93A (17±0.2%) SOD1 aggregates into NSC-34 cells. 
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Figure 2.12 RAC1 inhibitor W56 suppresses the uptake of SOD1 aggregates.  NSC-34 cells 
treated with 20 μg/ml of aggregated SOD1 proteins (20 µg/ml) for 30 min, in the absence (control) or presence 
of a pre-incubation step with RAC1 inhibitor W56 (200 µM) for 1 hr, fixed with 4% PFA, permeabilised and 
labelled with either anti-human SOD1 Ab (non-aggregated/ soluble) or Alexa Fluor 488 streptavidin. (A) Slides 
were analysed by confocal microscopy. Outline of cells are indicated with white dashed lines. Bars represent 10 
µm. (B) Mean fluorescence intensities (MFI) per cell of a minimum of 100 cells were quantified from these 
images using ImageJ software (Version 1.48) (National Institutes of health, Bethesda, MD). Results shown as 
mean cellular fluorescence intensity means ± SD, n = 3, 
***
P <0.001 compared to corresponding control 
(absence of RAC1 inhibitor). 
2.3.4.3 RAC1 inhibitor W56 suppresses the formation of Ruffles in the cell surface in NSC-34 
cells 
Lastly, the effect of the W56 on ruffle formation in NSC-34 was investigated. Cells were 
incubated with PMA in the presence or absence of pre-treatment with W56 and then 
examined for membrane perturbations using membrane dye FM1-43FX (Figure 2.13). PMA 
induced ruffle formation (112±1%) was significantly inhibited upon incubation with W56 
(72±2%). Collectively, these results confirm that RAC1 activation is upstream of membrane 
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ruffling, which in turn is required for macropinosome formation and entry of SOD1 
aggregates into NSC-34 cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13 RAC1 activation is upstream of membrane ruffling.  (A) NSC-34 cells treated with 
200 nM PMA for 30 min, in the absence (PMA) or presence of a pre-incubation step with RAC1 inhibitor W56 
(200 µM) or absence of PMA and inhibitor (control) for 1 hr, incubated with the membrane dye FM1-43FX for 
7 min and fixed with 4% PFA. 1X RedDot2 was used as a counter stain (10 min, RT). Outline of cells are 
indicated with white dashed lines. Bars represent 10 µm. (B) Mean fluorescence intensities (MFI) of membrane 
dye per cell were quantified from these images using ImageJ software (Version 1.48) (National Institutes of 
health, Bethesda, MD). A minimum of 200 cells were scored per treatment. Results shown as mean cellular 
fluorescence intensity means ± SD, n = 6, 
***
P < 0.001 compared to corresponding control (no protein 
treatment); 
†††
P < 0.001 compared to corresponding soluble protein. 
2.3.5 SOD1 induced macropinocytosis activation is not associated with cell death under 
experimental conditions, in NSC-34 cells  
Membrane perturbations in the form of ruffling and blebbing are required for entry of 
particles and macromolecules to enter cells via macropinocytosis. However, protrusions of 
the plasma membrane in the form of blebs can also be found in association with cell injury, 
including apoptosis (Trump et al., 1997). To exclude the possibility that cells were blebbing 
due to apoptosis, cells were firstly incubated in the absence or presence of SOD1 proteins or 
the positive control etoposide (Schonn et al., 2010), and then the cells were examined for 
levels of activated caspase-3 over the 2 h time period of the experiment (Figure 2.14 ).  
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Incubation with SOD1 proteins; WT (25±1%) and G93A (20±2%) soluble (non-aggregated) 
and WT (9±0.3%) and G93A (10±1%) aggregates did not induce caspase 3 activation in cells 
above basal (22±0.5%) levels (PBS treated) in the timeframe of this experiment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14 Addition of SOD1 does not induce rapid apoptosis.  (A) NSC-34 cells were incubated 
with PBS alone (mock), 100µM etoposide or 20 μg/ml of aggregated SOD1 for 2 h at 37°C, followed by 
incubation with FLICA reagent and fixed with apoptosis fixative solution. The levels of activated caspase-3 
were tested using Image-IT kit. Outline of cells are indicated with white dashed lines. Bars represent 20 µm. (B) 
Mean fluorescence intensities (MFI) of FLICA reagent per cell were quantified from these images using ImageJ 
software (Version 1.48) (National Institutes of health, Bethesda, MD). Results shown as mean cellular 
fluorescence intensity means ± SD, n = 3, 
***
P <0.001 compared to corresponding control (no protein 
treatment).  
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2.4 Discussion 
The current study confirms a role for stimulated macropinocytosis in the uptake of SOD1 
aggregates into NSC-34 cells. The morphology of SOD1 aggregates were assessed in the 
current study and these short fibrillar aggregates were found to associate with NSC-34 cells 
via membrane proteins and efficiently internalise into cells. In addition, the addition of 
pharmacological inhibitors of macropinocytosis including EIPA, rottlerin and W56 disrupted 
the uptake of SOD1 aggregates into cells. Furthermore, this study demonstrated for the first 
time that aggregates of SOD1 trigger activation of the Rho GTPase RAC1, leading to the 
formation of membrane ruffles on the cell surface and fluid phase uptake that defines 
macropinocytosis. Collectively, this suggests that SOD1 aggregates are capable of 
stimulating macropinocytosis to facilitate their entry into NSC-34 cells. This process would 
facilitate further seeding of SOD1 aggregates similar to what is suggested to occur during 
progression of disease in SOD1 ALS.  
It has been suggested that extracellular misfolded or aggregated SOD1 plays an active role in 
the spread of pathology among motor neurons (Grad et al., 2014; Münch et al., 2011), 
contributing to disease progression via interactions with both the cell surface and 
internalisation into cells in both fALS and sALS (Sundaramoorthy et al., 2013). In the current 
study, exogenously applied WT and mutant G93A SOD1 fibril-like aggregates were taken up 
efficiently by naïve motor neuron-like cells. Similarly, the uptake of extracellular WT SOD1 
aggregates, recombinantly produced or derived from conditioned media has previously been 
observed (Grad et al., 2014; Sundaramoorthy et al., 2013). The morphology of human 
recombinant SOD1 proteins were amlyloid-like in structure, consistent with another study 
which suggest SOD1 positive inclusions derived from fALS patients do not stain with 
amyloid dyes (Kerman et al., 2010). Furthermore, the work presented here demonstrated that 
uptake of SOD1 was selective and rapid. Incubation with the soluble (properly folded) WT 
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SOD1 and non-aggregated ALS associated mutant G93A SOD1 resulted in their uptake into 
cells, to a similar extent to that of WT SOD1 aggregates. In contrast, there was no statistically 
significant increase in immunofluorescence after incubation with an unrelated control protein 
GST, suggesting that the uptake of both soluble and aggregated forms of SOD1 is relatively 
specific. Other studies have also utilised recombinant soluble SOD1 proteins and similarly 
demonstrated the uptake of soluble WT and mutant SOD1 (Sundaramoorthy et al., 2013). 
This may reflect the proposed role of non-classically secreted SOD1 in signal transduction 
(Damiano et al., 2013; Turner et al., 2005). 
In the current study, SOD1 aggregates were shown to associate with the neuronal cell surface 
after 30 min incubation and after 60 min are no longer detected on the surface but instead are 
only detected following permeabilisation of cells with Triton X-100, suggesting these entered 
into cells with remarkable efficiency, consistent with reports from previous studies (Münch et 
al., 2011). Furthermore, this current study suggests that uptake of aggregates is dependent 
upon cell surface membrane proteins, since trypsinisation of potential endocytosis receptor 
proteins prior to treatment with aggregates significantly inhibited aggregate association with 
cells. This is consistent with another study which shows treatment of the cell surface with 
trypsin, inhibited the uptake of α-synuclein (Sung et al., 2001).  
A role for macropinocytosis in the uptake of extracellular native and aggregated WT and 
mutant SOD1 into neuronal cells has been previously suggested (Grad et al., 2014; Münch et 
al., 2011; Sundaramoorthy et al., 2013). In these studies, the addition of small molecules that 
inhibit actin rearrangement, Na
+
/H
+
 exchangers, Pak-1, PI3K, and PKC was reported to 
impair the uptake of SOD1 aggregates (Grad et al., 2014; Munch et al., 2011; 
Sundaramoorthy et al., 2013), consistent with macropinocytosis. In the current study, EIPA 
(an inhibitor of the Na
+
/H
+
 exchanger and subsequent endocytosis) and rottlerin (an inhibitor 
of PKC), as reported previously (Grad et al., 2014; Munch et al., 2011; Sundaramoorthy et 
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al., 2013), were used to confirm the involvement of macropinocytosis-like pathways in the 
uptake of SOD1 aggregates into NSC-34 cells. EIPA and rottlerin inhibited the uptake of 
SOD1 aggregates, however, inhibitors of clathrin (chlorpromazine) or caveolin (genistein) 
dependent endocytosis had no significant effect on this process. Furthermore, this process 
differs from that responsible for the uptake of soluble SOD1 proteins, which occurs 
presumably via a constitutive form of pinocytosis in the case of the WTSOD1 and potentially 
via a range of mechanisms in the case of soluble G93A SOD1. Thus, these results suggest a 
primary role for macropinocytosis in the uptake of SOD1 aggregates  
While previous work demonstrated a role for macropinocytosis in the uptake of SOD1 
aggregates into neuronal cells, it had been unclear whether macropinocytosis is triggered 
through an interaction of SOD1 with cells or whether aggregates are taken up by some other 
constitutive process. SOD1 aggregate-mediated activation of macropinocytosis and 
subsequent internalisation into NSC-34 cells was confirmed in the current study. Triggering 
the activation of macropinocytosis leads to the entry of large amounts of solute 
macromolecules or particles too large for other forms of endocytosis across the plasma 
membrane (Swanson and Watts, 1995). Activation of macropinocytosis has been reported to 
induce a number of downstream signaling events including the activation of a Rho GTPase, 
RAC1 (Ridley et al., 1992), which contributes to the modulation of ruffle formation, 
macropinosome closure and membrane trafficking (Lanzetti et al., 2004).  
Activated RAC1, has been identified as an important and central player in triggering 
membrane ruffles and blebbing in the form of lamellipodia, circular-shaped membrane 
extensions (ruffles) and large plasma membrane extrusions (blebs) (Mercer and Helenius, 
2009), associated with virus entry into cells and has been found to do so by activating 
downstream effectors of actin polymerisation (Sanchez et al., 2012). While the precise role of 
PKC in virus entry is still unclear, its activation with PMA (as used in this current study) can 
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induce ruffling and fluid uptake in the absence of ligands that bind the cell surface (Swanson, 
1989). The activation of RAC1 and subsequent membrane ruffling was supported in the 
current study. Similarly, intracellular mutant SOD1 has been found to interact with and 
activate RAC1 (Harraz et al., 2008). Of note, inhibition of RAC1, supressed the uptake of 
SOD1 aggregates, thus implicating these membrane perturbations in SOD1 entry. As 
expected, incubation with SOD1 aggregates induced increased membrane perturbations, 
including ruffles (retracting) and blebs, consistent with the formation of large vacuoles 
(macropinosomes) at the plasma membrane, thus further supporting uptake of SOD1 
aggregates occurs as part of the activation of macropinocytosis process. Of note, the current 
study confirmed that activation of RAC1 activation is upstream of membrane ruffling.  
Macropinocytosis is a form of fluid phase endocytosis that engulfs fluids and solutes at 
whatever concentrations they are found in the extracellular medium, rather than concentrating 
ligands at the cell surface. The data presented here shows that the activation of 
macropinocytosis mediated by SOD1 aggregates induced fluid uptake, coinciding with the 
formation of membrane ruffling, attributable to stimulated macropinocytosis. EIPA and 
rottlerin inhibited fluid phase uptake (quantified as 10 kDa dextran conjugated to Alexa Fluor 
647uptake) stimulated by phorbol 12-myristate 13-acetate (PMA) treatment of NSC-34 cells, 
but genistein and chlorpromazine did not, demonstrating the specificity of the inhibitors to 
PKC-dependent fluid phase uptake.  
In addition to SOD1 aggregates, various viruses, such as the vaccinia virus, adenovirus 3, 
herpes simplex virus 1 and HIV, utilize macropinocytosis to gain entry to cells. This 
phenomenon is likely to be due to the fact that macropinosomes are not restricted in size, 
enabling even large virions to be internalised, and that many cell types, not just professional 
phagocytes (such as macrophages), have the ability to activate the macropinocytosis 
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pathways (Swanson and Watts, 1995). Indeed, macropinocytosis can be activated in neurons 
by interactions with large viral particles (Kalia et al., 2013).  
While it was not confirmed in this study whether addition of recombinant SOD1 induced 
stress, previous studies have found that addition of extracellular recombinant mutant and/or 
aggregated SOD1 to naïve neuronal cells induce ER stress (Sundaramoorthy et al., 2013). In 
the current study, NSC-34 cell death was not observed following incubation with SOD1 
aggregates in the short timeframe of the experiment, as apoptosis is likely to occur at a much 
longer incubation period (least 10 hours). Collectively, this suggests that SOD1 aggregates 
are capable of mediating macropinocytosis, independent of cell death. 
In conclusion, the current study represents the first findings of SOD1 aggregate mediated 
activation of macropinocytosis pathways, similar to those utilized by virions, in neuronal 
cells, in the specific context of ALS. While, this was not demonstrated in vivo, it is likely that 
the activation of macropinocytosis occurs potentially alongside other pathways. Indeed, 
future studies investigating whether macropinocytosis occurs in vivo is warranted. 
Collectively, this suggests that extracellular SOD1 aggregates together with the activation of 
macropinocytosis are key components of ALS progression. Thus, future investigations into 
the role of SOD1-induced activation of macropinocytosis during disease progression in 
SOD1-ALS in vivo are warranted. 
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Chapter 3  
SOD1 AGGREGATES 
PROPAGATE IN A PRION-LIKE 
MANNER 
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3.1 Background 
Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing neurodegenerative 
disorder, affecting both upper and lower motor neurons. ALS is characterised by a focal onset 
of motor neuron degeneration, followed by outward neurospatial spreading of disease 
pathology, to neighbouring neurons and to distant regions via axonal pathways (Braak et al., 
2013). One potential explanation for the progressive spread of pathology is the prion-like 
propagation of protein misfolding. Evidence is mounting that ALS associated proteins, such 
as SOD1, may play an active role in the systematic spread of disease pathology (Ayers et al., 
2016; Grad et al., 2014; Münch et al., 2011; Zeineddine and Yerbury, 2015). 
For propagation of aggregation to occur, the newly formed intracellular aggregates must 
initially be released into the extracellular space. The secretion or release of SOD1 by 
neuronal cells has been suggested to occur via both active mechanisms such as the secretion 
of proteins from cells via exosomes and passive mechanisms such as cell death, as previously 
demonstrated in vivo (Gomes et al., 2007; Grad et al., 2014; Urushitani et al., 2006). Both 
human wild type (WT) and mutant SOD1 proteins have been observed in association with 
vesicles, particularly exosomes (Gomes et al., 2007; Grad et al., 2014; Silverman et al., 2016) 
or released as free aggregates as a result of cell death (Grad et al., 2014). SOD1 has also been 
detected in the cerebrospinal fluid of ALS patients with and without SOD1 mutations and in 
animals, implying its release via non-classical mechanisms (Jacobsson et al., 2001; Winer et 
al., 2013; Zetterstrom et al., 2011). Given that SOD1lacks an ER signal peptide, this suggests 
that the secretion of pathogenic SOD1 from affected cells may occur via similar mechanisms 
in vivo and in vitro; however the exact triggers and mechanisms of secretion in vivo are yet to 
be established. 
 
 
85 
 
Soluble and aggregated SOD1 have previously been shown to be taken up by neuroblastoma 
cells (mouse NSC-34 and human SHSY5Y) via macropinocytosis (Grad et al., 2014; 
Sundaramoorthy et al., 2013) (reviewed in Chapter 1). Once SOD1 internalises into cells, it 
accumulates in cytosolic inclusions (Sundaramoorthy et al., 2013). In addition, the uptake of 
extracellular misfolded WT or mutant SOD1 inhibits protein transport between the ER-Golgi 
apparatus, leading to Golgi fragmentation, induction of ER stress and apoptotic cell death, 
(Sundaramoorthy et al., 2013), similar to ER-stress related neurodegenerative pathways 
observed in ALS pathology (Atkin et al., 2008; Saxena et al., 2009). 
For intracellular spread of pathological proteins to occur, after exogenous misfolded SOD1 is 
internalised into neighbouring naïve cells, the SOD1 misfolding competent seeds need to 
escape the vesicular lumen and gain access to the cytosol to further nucleate the aggregation 
of soluble endogenous SOD1. Examples of protein aggregates escaping membrane vesicles is 
that amyloid fibrils have previously been shown to induce membrane damage, thus causing 
the rupture of membrane vesicles leading to cellular toxicity (Milanesi et al., 2012). In 
addition, particles such as virions, including those of the vaccinia virus, Japanese encephalitis 
and adenovirus species (Mercer and Helenius, 2012), have been shown to hijack 
macropinocytosis pathways to enter the cytoplasm of cells, including neurons (Kalia et al., 
2013). A lack of physical structure of the macropinosome is thought to leave it vulnerable to 
a loss of integrity and may explain why particles (e.g. bacteria and virions) can efficiently 
escape macropinosomes and reach the cytosol (Conner and Schmid, 2003). 
Previous work has shown that exogenously applied mutant SOD1 aggregates induce a self‐
perpetuating seeding of aggregation of native SOD1 (Grad et al., 2014; Munch et al., 2011). 
Importantly, recent work shows that injection of spinal cord homogenates from symptomatic 
G93A SOD1 mice into the sciatic nerve of mice expressing G85R SOD1-YFP has been 
shown to kindle protein aggregation and subsequently induce an ALS-like phenotype (Ayers 
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et al., 2014). In addition, using human embryonic kidney HEK‐293 or human WT SOD1‐
expressing murine primary spinal cord cultures, it has been reported that uptake and self-
perpetuating propagation of SOD1 misfolding is dependent upon the passage of misfolded 
SOD1 (either WT or mutant) from cell-to-cell, a process that can be neutralised by antibodies 
reactive with misfolded SOD1 epitopes (Grad et al., 2014). However, the precise mechanism 
by which SOD1 aggregates reached the cytosol to seed endogenous SOD1 was not 
determined in these studies. Presumably, the newly formed aggregates must then be secreted 
or released into the extracellular space to reinitiate the propagation cycle. 
 
3.1.1 Aims 
SOD1 aggregates have been shown to be released, associated with cell death, and internalised 
by naïve cells to seed the aggregation of native soluble proteins (Grad et al., 2014; Münch et 
al., 2011). Thus, this study aimed to investigate the mechanisms of SOD1 aggregate uptake in 
to naïve cells, and more importantly identify and quantify seeding activity between donor and 
recipient cells expressing SOD1 using a novel technique for quantifying inclusions; flow 
cytometric characterisation of inclusions and trafficking (FloIT).  
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3.2 Methods 
3.2.1 Reagents and antibodies  
DMEM/F-12 medium, DMEM/F-12 without phenol red, 0.05% trypsin-EDTA, GlutaMAX, 
SuperSignal West Pico Chemiluminescent Substrate, FM
®
 1-43FX, fixable analog of FM
® 
1-
43 membrane stain, LysoTracker Red DND-99, Lipofectamine 2000, Lipofectamine 3000, 
SuperSignal West Pico Chemiluminescent Substrate, Subcellular Protein Fractionation Kit 
for Cultured Cells, CellTrace CFSE Cell Proliferation Kit, restriction endonucleases BamHI 
and HindIII, Ez- link- NHS- Biotin and SYTOX Red dead cell stain were purchased from 
ThermoFisher Scientific. Cell culture 8‐chamber μ‐slides were purchased from Ibidi, 
(Planegg‐Martinsried, Germany). Any kD Mini-PROTEAN TGX Precast Protein Gels and 
Precision Plus Protein dual color protein standard were from Bio-Rad (California, USA). 
Foetal Bovine Serum (heat-inactivated prior to addition in media; FBS) was from Bovogen 
Biologicals (East Keilor, Australia). Amersham Hyperfilm and cellulose acetate membrane 
(0.2 µm) was obtained from GE Healthcare (Little Chalfont, Buckinghamshire, UK). RedDot 
2 was from Biotium (Hayward, CA). Sterile cell culture plates were form Greiner Bio-One 
(Frickenhausen, Germany). Casein (heat denatured before use; HDC), dimethyl sulfoxide 
(DMSO), bovine serum albumin (BSA), β-mercaptoethanol, Brilliant blue R concentrate, 
paraformaldehyde (PFA), biotinamidohexanoic acid 3-sulfo-N-hydroxysuccinimide ester 
sodium salt, Bicinchoninic Acid Kit, Propidium iodide, Osmium tetroxide solution (4 WT. % 
in H2O), ethidium bromide, Deoxyribonuclease I from bovine pancreas and dithiothreitol 
(DTT) were from Sigma-Aldrich (St. Louis, MO). Ethylenediaminetetraacetic acid (EDTA) 
was from Amresco (Solon, USA). Digitonin, High Purity was from Calbiochem was from 
San Diego, CA, USA. Glass coverslips (19 mm) were from ProSciTech (Kirwan, Australia). 
Protease inhibitor cocktail tablets (complete, Mini, EDTA-free) was from Roche Diagnostics 
(Penzberg, Germany). All other reagents including salts, powders and chemicals were from 
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Amresco, Sigma-Aldrich or Astral Scientific (Gymea, Australia). All reagents used were 
endotoxin free. Antibodies (Abs) and inhibitor compounds and their respective 
manufacturing companies used in this current study are listed in Table 3.1. 
Table 3.1 Antibodies used in this study to investigate the effect of SOD1 proteins on TDP-43 
pathology 
Host species 
(clonality)
1
 
Anti-body target 
(Immunogen)
2
 
Conjugate Manufacturer 
(product number)
3
 
Mouse (mAb) Beta Actin [AC-15] - Abcam (ab8226) 
Rabbit (pAb) Vimentin - Abcam (ab137321) 
Rabbit (pAb) EEA1 - Abcam (ab2900) 
Mouse (mAb) LAMP1 [H4A3] - Abcam (25630) 
Mouse (mAb) beta III Tubulin [2G10] - Abcam (78078) 
Rabbit (pAb) Green fluorescent 
protein 
- Abcam (ab6556) 
Mouse (mAb) BiP/GRP78 - BD Biosciences (610978) 
Sheep (pAb) SOD1 - ThermoFisher Scientific 
(PAI-30817) 
Goat (pAb) Transferrin - Sigma‐Aldrich 
(T2027) 
Mouse (pAb) GST - Sigma‐Aldrich 
(ge27-4577-01) 
Mouse (mAb) Galectin 3 - Abcam (A3A12) 
Goat (pAB) Mouse IgG Alexa Fluor 488 ThermoFisher Scientific 
A-(11001) 
Goat (pAb) Rabbit IgG Alexa Fluor 488 ThermoFisher Scientific 
( A-11008) 
Donkey (pAb) Sheep IgG Alexa Fluor 488 Abcam (150177) 
Goat (pAb) Mouse IgG Alexa Fluor 633 ThermoFisher Scientific 
( A-21052) 
Donkey (pAb) Sheep IgG HRP Abcam (97125) 
Goat (pAb) Mouse IgG HRP Merck Millipore (12-349) 
1
 pAb, polyclonal anti-body, mAb, monoclonal anti-body; 3 Abcam, Cambridge, USA; ThermoFisher Scientific 
(Waltham,MA, USA); BD Biosciences San Jose, CA, USA; Merck Millipore, Billerica, Massachusetts, USA; Cytoskeleton 
(Denver, CO,USA) ; Sigma‐Aldrich (St. Louis, MO) 
 
 
3.2.2 Cell Lines  
The mouse neuroblastoma x spinal cord hybrid cell line (NSC-34 cells) (Cashman et al., 
1992) were routinely cultured in DMEM/F12 supplemented with 10% (v/v) FBS and 2 mM 
GlutaMAX. Cells were maintained in an incubator at 37°C under a humidified atmosphere 
containing 5% (v/v) CO2.  
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3.2.3 Cell Transfections 
3.2.3.1 Plasmid purification  
pEGFP-N1 expression vectors containing SOD1
WT
, SOD1
G93A
 and SOD1
A4V
 cDNAs were 
provided by Bradley Turner (University of Melbourne, Melbourne, Australia) (Turner et al., 
2005a). pFUW expression vectors containing SOD1
G127X
 cDNAs were kindly provided by 
Edward Pokrishevsky (University of British Columbia, Vancouver, Canada) (Grad et al., 
2011). SOD1-tomato red (TdTomato) constructs were created by replacing the EGFP 
sequences with tdTomato from pcDNA3.1(+)Luc2tdT by GenScript (Piscataway, NJ). 
pCAG-RFP expression vectors containing TDP-43
WT
 cDNA was obtained from Addgene, 
provided by Zuoshang Xu (University of Massachusetts Medical School, Worcester, 
Massachusetts, USA)(Yang et al., 2010). Chemically competent DH5α Escherichia coli cells 
were provided by Jason McArthur (University of Wollongong, Wollongong, Australia). Cells 
were transformed with the TDP-43 and SOD1 containing plasmids as per manufacturer’s 
instructions, using the heat shock (42 ºC) method. Transformed cells were then transferred 
onto lysogeny broth (10% w/v tryptone, 10% w/v NaCl, and 5% w/v yeast; LB) agar plates 
with 50 µg/ml kanamycin sulphate and incubated overnight at 37°C. Single-transformed 
bacterial colonies were selected and inoculated into sterile LB media containing 50 µg/ml 
kanamycin sulphate to prepare starter cultures. Plasmid DNA was then extracted from 
bacterial cells using the CompactPrep Plasmic Maxi Kit (Qiageb, Hilden, Germany), as per 
manufacturer’s instructions.  
The purity (260/280 ratio) and concentration of extracted DNA was measured using the 
NanoDrop 2000c dual-mode UV-Vis Spectrophotometer (ThermoFisher Scientific, Waltham, 
USA). To further confirm the purity of the extracted DNA samples, a restriction digestion 
was carried out at 37ºC for 1 h using enzymes HindIII and BamHI that correspond to specific 
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restriction sites in the plasmids. Digested DNA samples were separated on a 1% agarose gel 
in tris-acetate-EDTA (TAE) buffer (1 mM ethylenediaminetetraacetic acid (EDTA) disodium 
salt, 40 mM Tris and 20 mM acetic acid). The resulting gel was then stained with ethidium 
bromide overnight and visualised using the GS-800 Calibrated Densitometer (Bio-Rad).  
3.2.3.2 Transfecting cells with Lipofectamine 2000 
NSC-34 cells were maintained in DMEM/F12 medium supplemented with 10% FBS and 2 
mM GlutaMAX (complete culture medium) at 37°C under a humidified atmosphere 
containing 5% (v/v) CO2 unless otherwise stated. To transfect, cells previously seeded at (6 x 
10
5 
cells/mL) were incubated in DMEM/F-12, in the absence of serum, containing 2 μg 
plasmid DNA and Lipofectamine 2000 for 5 h. Cells were then washed once with serum free 
DMEM/F12 media and replenished with complete culture medium for the duration of the 
experiment.  
3.2.3.3 Transfecting cells with Lipofectamine 3000 
NSC-34 cells were seeded in 8-well chamber slides at a density of 3-4 x 10
5
 cells/ 200 µL/ 
chamber and were incubated overnight. Cells were then incubated in complete DMEM/F-12 
culture medium containing 2 μg plasmid DNA, P3000 reagent and Lipofectamine 3000 
(diluted in serum free DMEM/F-12 medium) for either 24 h, 48 h, or 72 h. For co-
transfection assays, 1 μg of each plasmid was used for a total of 2 μg of DNA. 
3.2.3.4 Collection and separation of transfected cells and conditioned media 
To confirm transfection and determine sufficient transfection efficiency, cells were visualised 
by fluorescence microscopy using an Eclipse TE2000 inverted microscope (Nikon, Tokyo, 
Japan). Following transfection (2, 24, 48, or 72 h), conditioned media were collected from 
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respective treatments. Cells were harvested using 0.05% trypsin (5 min, 37°C) and 
conditioned media were processed and analysed as described below. 
3.2.4 Aggregation and biotinylation of WT and mutant G93A SOD1  
WT and G93A (mutant SOD1) SOD1 were expressed and purified from E.coli as previously 
outlined (Lindberg et al., 2002; Roberts et al., 2013). SOD1 aggregation was performed in 
vivo as previously described (Roberts et al., 2013). Briefly, solutions of purified WT or 
mutant SOD1 (1 mg/ml) in PBS were incubated with 20 mM dithiothreitol (DTT) and 5 mM 
EDTA (Sigma, St. Louis, MO) for 72 h at 37 °C with shaking using a digital shaker 
(universal IKA
®
 MS 3, 230 V). The aggregated SOD1 was then labelled with 
biotinamidohexanoic acid 3-sulfo-N-hydroxysuccinimide ester sodium salt (40 mg/ml) in 
DMSO for 2 h at RT. The unconjugated biotin was then separated from the aggregates by 
centrifugation (21 000 x g for 30 min) and washed three times with PBS (300 x g for 5 min). 
The purified aggregates free of unconjugated biotin were then resuspended in PBS (1 mg/ml). 
A bicinchoninic acid (BCA) protein assay was performed to determine the amount of protein 
remaining after labelling.  
3.2.5 Aggregated SOD1 association with acidic compartments by confocal microscopy 
NSC-34 cells (2–3 x 10
4
 cells/200 µL/chamber) were cultured in chamber slides at 37°C 
overnight. Cells were pre-treated with Lysotracker Red (75 nM) for 2 h at 37°C as per the 
manufacturer’s instructions. Cells were then washed and incubated with 20 μg/ml of 
aggregated WT and mutant SOD1 for either 10 min, 30 min or 60 min at 37°C. Cells were 
fixed at respective time points with 4% PFA in PBS for 20 min at RT and washed twice with 
PBS over 5 min. Cells were then incubated with Triton X-100 for 30 min at 4°C. Cells were 
incubated with blocking solution (5% FCS, 1% BSA and 0.3% Triton X-100) for 20 min at 
RT. Cells were incubated with anti- SOD1 IgG (1:500 diluted in 4% BSA and 0.1% Triton X-
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100) overnight at 4°C. Cells were subsequently washed again in PBS and incubated with anti-
sheep IgG conjugated to Alexa Fluor 488 (1:500 diluted in 1% BSA and 0.1% Triton X-100) 
protected from light for 1 h at RT. An inverted microscope (DM IBRE) and a Leica TCS SP 
confocal imaging system were used to visualise and image cells (excitation 488, emission 
collected at 520-540). Fluorescence, bright field (differential interference contrast; DIC) and 
merged images were captures using Leica confocal software.  
3.2.6 Subcellular Fractionation assay of NSC-34 cells 
NSC-34 cells were incubated with WT or mutant G93A SOD1 proteins in aggregated form 
(20 µg/mL) in PBS for 2 h at 37°C/5% CO2. Post incubation, the cells were washed three 
times with PBS (300 x g for 5 min) harvested using 0.5% trypsin and 5 mM EDTA and 
washed (500 x g for 5 minutes). The cells were washed three times with ice cold PBS (500 x 
g for 3 minutes) for fractionation using a Subcellular Protein Fractionation Kit for Cultured 
Cells as per manufacturer’s instructions (Thermo Fisher Scientific). Initially, NSC-34 cells 
(10 x 10
6
 cells/mL) were incubated with cytoplasmic extraction buffer (CEB) containing 
protease inhibitors for 10 min rotating at 4°C. The supernatant (cytoplasmic fraction) was 
collected (500 × g for 5 minutes). The cell pellet was then incubated with membrane 
extraction buffer (MEB) containing protease inhibitors for 10 min rotating at 4°C. Post 
incubation, the supernatant (extracted membrane fraction) was collected (3000 × g for 5 
minutes). Ice cold nuclear extraction buffer (NEB) containing protease inhibitors was added 
to the cell pellet for 30 min rotating at 4°C. The supernatant (extracted soluble nuclear 
fraction) was collected (5000 × g for 5 minutes). Chromatin-bound extraction buffer (NEB, 
100 mM CaCl2 and 300 units of Micrococcal Nuclease) was added to the pellet for 15 mins at 
RT. The supernatant (chromatin-bound nuclear extract) was collected (16,000 x g for 5 mins). 
Lastly, Pellet Extraction Buffer (PEB) containing protease inhibitors was added to the cell 
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pellet for 10 mins at RT. The supernatant (the cytoskeletal extract) was collected (16,000 x g 
for 5 mins).  
Protein concentration was determined using the BCA method. Fractions (20 μg protein/lane) 
were separated under reducing conditions (5% β-mercaptoethanol) using Any kD Mini-
PROTEAN TGX Stain-Free™ Precast Gels. Proteins were then transferred to nitrocellulose 
membranes using a Trans-Blot Turbo Transfer System (Bio-Rad). Total protein per lane was 
then imaged and measured with a Bio-Rad Criterion Stain Free Imager and Image Lab 
software. Membranes were blocked with heat denatured casein (HDC) in for 1 h at 37°C. To 
test the efficiency of the separation, rabbit anti-EEA1 pAb (1:500), rabbit anti-Vimentin pAb 
(1:500) and mouse anti-actin mAb (1:5000), diluted in HDC/PBS for 1 h at 37°C were used 
to probe the CE, ME, NE and PE fractions. Membranes were visualised using 
chemiluminescent substrate and Amersham Hyperfilm ECL (GE Healthcare). Images of films 
were collected using a GS-800 Calibrated Densitometer (Bio-Rad). The processing of films 
was achieved using GBX Developer and Replenisher and GBX Fixer and Replenisher 
(Kodak Australiasia, Collingwood, Victoria Australia). Images of the films were collected 
using a GS-800 Calibrated Densitometer (Bio-Rad). 
3.2.7 Selective Permeabilisation of NSC-34 cells  
NSC-34 cells were incubated in chamber slides with 20 μg/ml of soluble and biotin-
conjugated aggregated WT and G93A SOD1 protein for either 60 or 120 min at 37°C. Cells 
were immediately fixed with 4% PFA in PBS for 20 min at RT and washed twice with PBS 
over 5 min. Cells were incubated with either Triton X-100 (0.5%) or digitonin (10 µM) for 30 
min and 10 min at 4°C respectively. Cells were then incubated with blocking solution (5% 
FCS, 1% BSA and 0.3% Triton X-100) for 20 min at RT. Cells were incubated with anti-
SOD1 IgG (1:500 diluted in 4% BSA and 0.1% Triton X-100) overnight at 4°C. Cells were 
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washed again in PBS and incubated with Alexa Fluor 488 streptavidin (1:1000 diluted in 1% 
BSA and 0.1% Triton X-100) for 1 h at RT. Cells were incubated with Sytox Red (5 nM) for 
10 min at RT. An inverted microscope (DM IBRE) and a Leica TCS SP confocal imaging 
system were used to visualise and image cells (excitation 488, emission collected at 510-
550). Fluorescence and merged images were captured using Leica confocal software.  
3.2.7.1 Controls for selective permeabilisation 
NSC-34 cells incubated in chamber slides for 24 h in complete culture media were fixed with 
4% PFA in PBS at RT for 20 min at RT, and washed twice with PBS over 5 min. Cells were 
incubated with either Triton X-100 (0.5%) or digitonin (10 µM) for 30 min and 10 min at 4°C 
respectively. Cells were then incubated with blocking solution (5% FCS, 1% BSA and 0.3% 
Triton X-100) for 20 min at RT. Next, cells were incubated with mouse anti-LAMP1 (mAb) 
(0.3 µg/ 100µL), mouse anti-BiP/GRP78 (mAb) (0.5 µg/ 100µL), mouse anti-β-tubulin 
(mAb) (0.2 µg/ 100µL) and rabbit anti-EEA1 (pAb) (0.5 µg/ 100µL) overnight at 4°C. Cells 
were subsequently washed again in PBS and incubated with goat Alexa Fluor 488‐conjugated 
goat anti‐rabbit IgG Ab (0.3 μg/ 100 μL) and Alexa Fluor 488‐conjugated goat anti‐mouse 
IgG Ab (0.3 μg/ 100 μL) in PBS containing 1% BSA and 0.1% Triton X-100 protected from 
light for 1 h at RT. Cells were incubated with RedDot2 (1:200) for 10 min at RT. Imaging 
was performed as outlined above.  
3.2.8 Membrane damage (haemolytic) assay  
Fresh Human venous blood was kindly provided by Wollongong Hospital Pathology Unit; 
NSW, Wollongong, Australia (The University of Wollongong Human Ethics Approval 
H202/080). Firstly, human blood was incubated with 5 mM EDTA and protease inhibitor 
cocktail, pH 7.0 for 1 h at 4ºC. The next day, the blood samples were gently mixed by 
inversion and were washed three times in PBS (300 x g for 5 min) and harvested (1 x10
6
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cells/mL/tube) by resuspension in phosphate/sodium acetate buffer (10 mM CH3CO2Na, 
10mM Na2HPO4, 137 mM NaCl, 2.7 mM and 2 mM) pH 7.2. Clarified blood cells were 
incubated with 20 μg/ml of WT and G93A SOD1 soluble and aggregated protein or 0.1% 
Triton-x100 was used for total cell lysis for 2 h at 37°C. Following incubation, blood cells 
were washed twice in phosphate/sodium acetate buffer (300 x g for 5 min). Total 
Haemoglobin levels of the supernatant were determined via optical density (absorbance) 
measurements, a measure of lysed erythrocytes using a SpectraMax Plus 384 Microplate 
Reader and SoftMax Pro software (Molecular Devices, Silicon Valley, CA) (540 nm). 
3.2.9 Preparation of Giant Unilamellar Vesicles  
The rapid evaporation method was used to prepare giant unilamellar vesicles for confocal 
microscopy as described in (Milanesi et al., 2012). Briefly, soy L-α-phosphatidylcholine 
(Avanti Polar Lipids Inc) was dissolved in CHCl3:MeOH (2:1) to give a phospholipid 
concentration of 5 mM. Liposome buffer (50 mM HEPES, 107 mM NaCl, 1 mM EDTA, 0.1 
M sucrose, pH 7.4, 2.5 mL) was then added to the lipid/solvent solution in a 50 mL round 
bottom flask and the two phases mixed by vigorous pipetting. The organic solvent was 
removed by rotary evaporator under reduced pressure (final pressure 44 mbar) for 5 min at 
37°C. The resulting liposome suspension was stored overnight at 4°C prior to confocal 
microscopy studies. The next day, liposomes were incubated with 20 μg/ml of aggregated 
SOD1 proteins for 2 h 37°C.  
3.2.10 Galectin -3 as a marker of cell rupture 
NSC-34 cells were incubated in chamber slides with 20 μg/ml of soluble and biotin-
conjugated aggregated WT and G93A SOD1 protein for 2 h at 37°C. Cells were immediately 
fixed with 4% PFA in PBS for 20 min at RT and washed twice with PBS over 5 min. Cells 
were incubated with either Triton X-100 (0.5%, control) or digitonin (10 µM) for 30 min and 
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10 min at 4°C respectively. Cells were then incubated with blocking solution (5% FCS, 1% 
BSA and 0.3% Triton X-100) for 20 min at RT. Cells were incubated with anti-Galectin 3 
IgG (0.5 µg/100 µL) overnight at 4°C. Cells were subsequently washed again in PBS and 
incubated with goat Alexa Fluor 488‐conjugated goat anti‐mouse IgG (0.3 μg/ 100 μL) in 
PBS containing 1% BSA and 0.1% Triton X-100 protected from light for 1 h at RT. Cells 
were incubated with RedDot2 (1x) for 10 min at RT. Imaging was performed as outlined 
above. 
3.2.11 Release of SOD1 aggregates and filter trap assay  
Following transfection (at 72 h), conditioned media from SOD1 transfected cells were 
collected and pre-incubated with 1 unit DNaseI per μg of transfected DNA for 10 min at RT 
and centrifuged for 30 min at 21,000 x g at 4°C into soluble and pelletable fractions. 
Pelletable fractions were incubated with an equal volume of phosphate‐buffered saline (PBS) 
containing 1% SDS at RT for 15 min. Samples were analaysed using using filter trap analysis 
and SDS-PAGE. For filter trap analysis, pellatable fractions were added to the microfiltration 
apparatus and then SDS resistant protein were collected and separated onto a cellulose acetate 
membrane with 0.2 μm pores (GE Healthcare) using a Bio‐Dot SF Microfiltration System 
(Bio‐Rad) under vacuum pressure. The membrane was washed with PBS containing 1% SDS 
three times over 5 min, followed by PBS. In addition, pelletable fractions were separated 
under reducing conditions (5% β-mercaptoethanol) using Any kD Mini-PROTEAN TGX 
Stain-Free™ Precast Gels. Proteins were then transferred to nitrocellulose membranes using a 
Trans-Blot Turbo Transfer System (all Bio-Rad). The presence of EGFP-SOD1 aggregates 
were then detected by immunoblotting. The membranes were blocked with heat denatured 
casein (HDC) for 1 h at 37°C. The membranes were then incubated with at 4°C overnight 
with an anti‐EGFP pAb (1:1000‐1:10000). The following day, the membrane was washed 
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three times over 15 min with PBS containing 0.1% Triton X‐100. The membrane was then 
incubated at room temperature for 1 h with peroxidise‐conjugated anti‐rabbit (1:1000) IgG 
Ab and then washed as above. Released SOD1 protein aggregates were visualised using 
chemiluminescent substrate and Amersham Hyperfilm ECL (GE Healthcare). Images of films 
were collected using a GS-800 Calibrated Densitometer (Bio-Rad. Relative EGFP and EGFP-
SOD1 aggregates were quantified from these images using ImageJ software (Version 1.48) 
(National Institutes of Health, Bethesda, MD). 
3.2.12 Released protein uptake assay by immunoblotting and confocal microscopy 
Conditioned media from transfected cells were collected 72 h post-transfection and pre-
incubated with 1 unit DNaseI per μg of transfected DNA for 10 min at RT and centrifuged for 
30 min at 21,000 x g at 4°C into soluble and pelletable fractions. Pelletable fractions were 
washed and resuspended in complete culture media (500 μL) and added to adherent naïve 
NSC-34 cells plated in 12‐well plates at (1.5 × 106 cells/ 0.4 mL/ well) 24 h prior to treatment 
with conditioned media for 2 h at 37°C/5% CO2. Imaging was performed as outlined above 
(see section 3.2.5). NSC-34 cells were washed in three times in PBS and harvested using 
trypsin (0.5%) and washed (500 x g for 5 minutes). Cells were then lysed over 15 min at 4°C 
in ice-cold lysis buffer (10 mM Tris, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100 and 
protease inhibitor cocktail, pH 7.0). Cell debris was then cleared (21,000 × g at 4°C for 30 
min) and large SDS resistant protein aggregates in the supernatants (100 μg protein/slot) were 
trapped onto a cellulose acetate membrane with 0.2 μm pores (GE Healthcare) using a Bio‐
Dot SF Microfiltration System (Bio‐Rad) under vacuum pressure. The membrane was 
washed with PBS containing 1% SDS three times over 5 min, followed by PBS. The presence 
of EGFP-SOD1 aggregates were then detected by immunoblotting as above. Internalised 
SOD1 protein aggregates in the supernatants were visualised using chemiluminescent 
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substrate and Amersham Hyperfilm ECL (GE Healthcare). Images of films were collected 
using a GS-800 Calibrated Densitometer (Bio-Rad).  
3.2.13 Cell death assay  
Following transfection (24 , 48 , and 72 h in total), NSC-34 cells expressing EGFP(control), 
SOD1
WT
 and SOD1
G93A 
-EGFP were washed twice in incomplete culture media (lacking 
FCS) and then harvested using 5 mM EDTA (5 min, 37°C) and then washed again using 
centrifugation (300 x g for 5 min). Cells (1 x10
5
 cells/mL/tube) were resuspended in PBS and 
incubated with SYTOX Red dead cell stain (5 µM) immediately before analysis by flow 
cytometry. Cellular events were collected using a LSR II flow cytometer (excitation 488 nm, 
emission collected at 515/20 nm band pass filter; excitation 488nm, emission collected at 
575/20 nm band pass filter) for EGFP and PI respectively. The percentage of dead cells was 
expressed as cells positive for PI as a proportion of total EGFP-positive cells and was 
determined FlowJo software. Results are the average of at least three independent 
experiments.  
3.2.14 UV ablation assay by confocal microscopy 
Adherent NSC‐34 cells in 8‐chamber well slides were transiently transfected with TDP-43WT 
and TDP
G294A‐EGFP using Lipofectamine 3000 (see above). Following transient transfection 
of NSC-34 cells (48 h), a fluorescent cell with aggregates was identified and assessed as 
suitable for ablation. UV laser mediated cell selective destruction was performed on the 
nucleus of the cell for 20s using Leica Confocal Software. Live cell imaging was performed 
at 15 min time intervals and then fluorescent and bright‐field images were captured for 24 h 
using a DM IBRE inverted microscope and TCS SP confocal imaging system (Leica, 
Germany) (excitation 488 nm, emission collected at 510‐540 nm).  
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3.2.15 FloIT assay by flow cytometry 
Adherent NSC‐34 cells in 24‐well plates (6 × 105 cells/ 0.5 mL/well) were transiently 
transfected separately (co-culture) or co-transfected with SOD1
WT
 and SOD1
G93A
 fused to 
either EGFP or tdTomato using Lipofectamine 3000 (see section 3.2.3.3). For the co-culture 
assay, following transient transfection (24 h), cells expressing SOD1
WT
-tdTomato were 
washed three times in incomplete culture media, and cells expressing SOD1
G93A
-EGFP were 
harvested using 0.5% trypsin and 5 mM EDTA and washed (500 x g for 5 minutes). The cells 
were then resuspended in complete culture media (500 µl) and were co-plated with adherent 
cells (at a ratio 1:1) expressing SOD1
WT
-tdTomato for a total of 72 h (post co-culture). As an 
additional control, cells expressing SOD1
WT
-tdTomato and SOD1
G93A
-EGFP were cultured 
separately, and then mixed immediately before flow analysis (corresponding to the respective 
timepoint). For the co-transfection assay, NSC-34 cells were co-transfected with SOD1
WT
-
tdTomato and SOD1
G93A
-EGFP (6 h prior to co-culturing) for a total of 72 h (corresponding 
to the time point of the co-culture experiment). For the seeding assays, cells expressing 
SOD1
WT
-tdTomato were cultured in the presence of 20 μg/ml of with human recombinant 
mutant SOD1 (G93A) aggregates at the indicated time points. Following co-transfection, co-
culturing or addition of recombinant SOD1 aggregates (at 24h, 48 h and 72h in total), cells 
were harvested using 5 mM EDTA (5 min, 37°C) and then washed again using centrifugation 
(300 x g for 5 min). Cells were then washed twice in PBS (300 x g for 5 min) and 
resuspended in PBS (0.5 mL/tube). An aliquot of cells were (2 x 10
5
cells/0.15mL) collected 
then analysed for transfection efficiency (excitation 488 nm, emission collected with 525/50 
nm band pass filters; excitation 561 nm and emission collected with 586/15 nm band pass 
filters for EGFP and tdTomato respectively) determined by flow cytometry. The remaining 
cells (2 x 10
5
cells/0.35mL) were washed as above and lysed prior to analysis in lysis buffer 
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(0.5% Triton X-100 and Complete protease inhibitor in PBS). Cell lysates were then 
incubated with RedDot2 (1:1000) at RT for 2 min.  
All events were collected using a LSRFortessa X‐20 Cell Analyzer (BD Biosciences) 
(excitation 488 nm, emission collected with 525/50 band-pass filter and excitation 561, 
emission collected with 586/15 nm band-pass filter for EGFP and RedDot2, respectively; 
excitation 561 nm and emission collected with 586/15 nm band pass filters for tdTomato). All 
parameters were set to log
10
 during acquisition from cell lysates. The forward scatter 
threshold was set to the minimum value (200 AU) to minimize the exclusion of small protein 
inclusions. Nuclei were identified and enumerated based on RedDot2 fluorescence and 
forward scatter and then excluded from further analysis. The percentage of EGFP
+
/tdTomato
+
 
particles was determined using quadrant markers in FlowJo software. The remaining particles 
were analysed for the presence of inclusions based on GFP/ tdTomato fluorescence, forward 
scatter and comparison lysates prepared from cells expressing only the corresponding 
fluorescent protein. 
The number of inclusions in the population can be normalised to the number of nuclei, and 
reported as inclusions/1000 transfected cells (iFloIT) according to the equation: 
𝑖𝐹𝑙𝑜𝐼𝑇 =  100 (
𝑛𝑖
𝛾. 𝑛𝑛𝑢𝑐
) 
where ni represents the number of inclusions acquired, nnuc is the number of nuclei acquired, 
and γ is the transfection efficiency.  
Analysis of all events were performed using FlowJo software (Tree Star, Ashland, OR). A 
summary of the methods carried out for analysis of SOD1 propagation in NSC-34 cells is 
summarised (Figure 3.1) and described below. 
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Figure 3.1 Summary of methods to investigate the prion-like propagation of SOD1 in 
NSC‐34 motor neurons  Following transfection (72 h), conditioned media from NSC‐34 cells were 
collected and centrifuged (21,000 x g for 30 min) to remove cell debris, and analysed using filter trap. Naïve 
NSC- 34 cells were incubated with fractionated conditioned media for 2 h and then lysates were analysed by 
filter trap analysis. In other experiments, SOD1 aggregate formation (in the absence or presence of recombinant 
human mutant SOD1 aggregates) was visualised by confocal microscopy. Transiently transfected NSC-34 cells 
were either co-cultured or co-transfected with SOD1-EGFP or SOD1 tdTomato for 72 h and assessed by flow 
cytometry to identify transfer events. 
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3.3 Results 
3.3.1 Transient expression of mutant SOD1 can induce cell death in NSC-34 motor 
neurons over time 
SOD1 proteins have been shown to have spontaneous fibrilisation activity in vivo (Chia et al., 
2010; Furukawa et al., 2008). Therefore, the presence of inclusion bodies containing SOD1 
aggregates indicative of spontaneous aggregation was investigated. To investigate the number 
of SOD1 positive inclusions in NSC-34 motor neurons, cells were transfected with SOD1
WT
 
tdTomato and SOD1
G93A
 GFP for 48 and 72 h and the number of inclusions were quantified 
using flow cytometric characterisation of inclusions and trafficking (FloIT) technique (Figure 
3.2A). Initially, the lysates of NSC-34 cells containing large particles were gated (nuclei and 
inclusions). After nucleus removal, particles were analysed for green or red fluorescence to 
identify inclusions positive for EGFP or tdTomato (Figure 3.2B). A significantly greater 
number of inclusion bodies were identified in cells expressing mutant SOD1
G93A
 and 
SOD1
WT 
compared to cells expressing EGFP or tdTomato alone (Figure 3.2C). Furthermore, 
a significantly greater number of inclusions were measured between cells expressing mutant 
SOD1
G93A
 and SOD1
WT
. However, there was no statistical difference in the number of 
inclusions between tdTomato and EGFP controls. 
Next, the relationship between timing of SOD1 aggregate formation and cell death was 
investigated. NSC-34 motor neurons were transfected with SOD1
WT
 and SOD1
G93A
-EGFP for 
48 and 72h, treated with SYTOX red dead cell stain and assessed by flow cytometry (Figure 
3.2D). Cell death is expressed as the total of dying and dead cells (red dot exclusion) that are 
positive for EGFP. A significantly greater amount of cell death was observed for the cells 
expressing SOD1
WT
-EGFP at 48 h relative to cells expressing EGFP alone although this 
increase was only ~1% of GFP positive cells. At 72 h however, the percentage of cell death 
 
103 
 
between these treatments was similar. A significantly higher percentage of total cell death 
was however observed for cells expressing SOD1
G93A
-EGFP relative to cells transiently 
expressing EGFP alone, and this increased two-fold at 72 h. Furthermore, cell death was 
significantly higher from 48-72 h in cells expressing SOD1
G93A
-EGFP compared to cells 
transfected with SOD1
WT
-EGFP, consistent with reports of mutant SOD1 induced toxicity to 
cells (Brotherton et al., 2013). These findings suggest a relationship between SOD1-inclusion 
body formation and cell death in NSC-34 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Spontaneous aggregation of SOD1 and cell death of EGFP -positive cells after 
72 h post transfection was examined by flow cytometry.  Following transfection, using 
Lipofectamine 3000, NSC‐34 transiently transfected with SOD1WT tdTomato, SOD1G93A‐EGFP, tdTomato or 
EGFP were cultured separately for 48 and 72 h. (A) Cell lysates were firstly gated on forward scatter (FSC) and 
RedDot2 fluorescence to identify nuclei and then (B) the number of EGFP and tdTomato positive- inclusions 
were identified from the non-nuclei gated population determined by flow cytometry. (C) Results shown as mean 
number of inclusions per 100 transfected cells ± SEM, n = 3; 
***
P < 0.001 and 
*
P < 0.05 compared to controls 
(fluorescent tags); 
†††
P < 0.001 compared to corresponding SOD1
WT 
tdTomato. (D) Following transfection at 48 
h, and 72 h, using lipofectamine 2000 adherent NSC-34 cells in complete DMEM medium expressing EGFP 
(control), SOD1
WT
 and SOD1
G93A 
EGFP were harvested and incubated with propidium iodide (1 mg/mL). Cells 
were gated on forward and side scatter to exclude doublets and cell debris and then the percentage of cells 
positive for EGFP and SYTOX Red dead cell stain were determined by flow cytometry. Results shown as total 
percentage of cell death in EGFP expressing cells ± SD, n = 3;
 ***
P < 0.001 or 
*
P <0.05 compared to 
corresponding EGFP control; 
†††
P < 0.001 and 
†
P < 0.05 compared to corresponding SOD1
WT-
EGFP. 
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3.3.2 Intracellular SOD1 aggregates are released from NSC-34 motor neurons 
Intracellular SOD1 protein aggregates have been previously been reported to be secreted via 
active mechanisms and released by passive means (Gomes et al., 2007; Grad et al., 2014). 
Filter trap analysis and immunoblotting is a conventional method to study protein aggregates 
(Juenemann et al., 2015), including SOD1 aggregate detection in conditioned media (Grad et 
al., 2014), thus this technique was used to observe and quantify the profile of secreted WT 
and a series of mutant SOD1 proteins in conditioned media (Figure 3.3). To determine 
whether a range of SOD1 aggregates can be released from NSC-34 motor neurons, cells were 
transfected with EGFP or WT and mutant SOD1- EGFP variants including SOD1
WT
 and 
mutant SOD1 variants including SOD1
G93A, 
SOD1
A4V 
and SOD1
G127X
 for 72 h. Total 
conditioned media was then collected from these cells and separated by centrifugation.  
Pelletable fractions were examined by immunoblotting, and the relative amount of SOD1-
EGFP quantified (Figure 3.3A). Little to no EGFP was detected in the fraction derived from 
conditioned medium of cells transfected with EGFP. In comparison, filter trap analysis 
identified small but significant amounts of SDS‐resistant material that was anti‐EGFP 
reactive and larger than the 0.2 μm pore size of the membrane in conditioned media from 
cells expressing SOD1
WT
. A significantly greater amount of SDS‐resistant material positive 
for EGFP was identified in conditioned medium from NSC‐34 cells expressing SOD1G93A, 
SOD1
A4V
 and SOD1
G127X
 –EGFP (Figure 3.3A).  
To further characterise these SOD1 aggregates released from NSC‐34 cells, the conditioned 
medium was analysed by SDS PAGE separation and immunoblotting (Figure 3.3B). Again, 
no EGFP was identified in the fraction obtained from conditioned medium of cells 
transfected with EGFP. In comparison, anti-EGFP bands with an approximate molecular size 
of 35 kDa and 50 kDa consistent with the molecular weight of SOD1-EGFP monomer and 
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dimer respectively (Turner et al., 2005), were identified in conditioned media from cells 
expressing SOD1
WT
, expressing SOD1
G93A
, SOD1
A4V
 and SOD1
G127X
 –EGFP. In addition, 
high molecular weight, SDS-resistant oligomeric species were detected in these respective 
fractions, ranging in molecular size from 150 kDa to above 250 kDa. This is consistent with 
above filter trap analysis data. 
 
 
 
 
 
 
 
 
Figure 3.3 Wild type and mutant SOD1 proteins can be detected in conditioned media of 
NSC-34 motor neurons  (A) Following transfection (at 72 h) using lipofectamine 2000, conditioned media 
were collected and incubated 250 units of DNase for 10 min at RT, fractionated into pelletable fractions by 
centrifugation and incubated with 1% SDS in PBS. SDS resistant proteins were separated onto cellulose acetate 
membrane (0.2µM) in a filter trap apparatus, and then incubated with anti‐EGFP Ab. Results shown as mean 
band density relative to EGFP ± SD, n = 6;
 ***
P < 0.001,
 **
P < 0.01 or 
*
P <0.05 compared to corresponding 
EGFP control. (B) Conditioned media were fractionated into pelletable and soluble fractions by centrifugation. 
Pelletable fractions were then separated by SDS‐PAGE under reducing conditions and transferred to a 
nitrocellulose membrane. The membrane was then incubated with anti‐EGFP Ab. The black arrow indicates 
SOD1–EGFP monomer whereas the red arrow indicates SOD1–EGFP dimer. The area indicated by an asterisk 
represents SDS-resistant oligomeric SOD1 species. The slot-blot presented is representative of bands cut 
horizontally, and displaying n = 1.  
3.3.3 Released SOD1 aggregates are capable of entering into Naïve NSC-34 motor 
neurons 
Next, to investigate whether released SOD1 aggregates are capable of entering into naïve 
NSC-34 motor neurons, naïve cells were incubated with pelleted fractions derived from 
conditioned medium of NSC-34 cells transfected with SOD1
WT
 and mutant SOD1 variants 
including SOD1
G93A, 
SOD1
A4V 
and SOD1
G127X
 for 2 h (Figure 3.4). Following incubation, 
conditioned media was then collected from these cells and separated by centrifugation 
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(Figure 3.4A). Cells were incubated in conditioned media and visualised by microscopy to 
identify SOD1-EGFP inclusions inside the cells (Figure 3.4B), and then whole lysates were 
probed with anti-EGFP pAb. SOD1 or EGFP in pelletable fractions derived from conditioned 
media was then examined by immunoblotting with an anti‐EGFP pAb (Figure 3.4C). 
Similar to above data, no SDS-resistant material was identified in the fraction derived from 
conditioned medium of cells transfected with EGFP. However, a substantial amount of SDS‐
resistant material, larger than the 0.2 μm pore size that was anti‐EGFP reactive in conditioned 
media from cells expressing SOD1
WT
and SOD1
G93A
, SOD1
A4V
 and SOD1
G127X
 –EGFP. 
Similarly, large SDS resistant material was present in the respective fractions obtained from 
whole lysates of cells expressing WT and mutant variants of SOD1, however these were 
present at a much lower intensity. Prior to lysis, cells were assessed by microscopy, cells 
incubated with conditioned media from cells expressing SOD1-EGFP displayed discrete and 
diffuse fluorescence, characteristic of SOD1 inclusions. 
 
 
 
 
 
 
 
 
Figure 3.4 Wild type and mutant SOD1 proteins can be detected in conditioned media of 
NSC-34 motor neurons transiently transfected with SOD1 and these can transmit to naïve  
NSC-34 cells  (A) After identifying the presence of aggregates using filter trap analysis (72 h) (B) conditioned 
media was collected and treated with 250 units of Dnase for 10 min at RT, centrifuged and pelletable fraction 
added onto adherent naïve NSC-34 cells for 2 h and were visualised by confocal microscopy to observe for 
internalised extracellular SOD1 protein aggregates. Bars represent 10 μm and results are representative of n=2 
(C) Cells were lysed and a pelletable fractions were obtained by centrifugation. Pelletable fractions were then 
separated onto cellulose acetate membrane (0.2µM) in a filter trap apparatus, and then incubated with anti‐
EGFP Ab. 
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3.3.4 SOD1 aggregates can transfer from cell to cell  
Given the ability for naïve cells to take up aggregates from conditioned media, the ability of 
aggregate transfer from cell-to-cell was next examined. Prior to analysis, fluorescence 
compensation was performed to account for spectral overlap into the GFP channel (Figure 
3.5A). Cells were either transfected with GFP or tdTomato separately and then cell 
populations mixed, any acceptor cells with both red and green after the incubation period was 
deemed a SOD1 transfer event. Next, transfer events were quantified as the percentage of 
transfected acceptor cells positive for both EGFP/tdTomato using the gating strategy outlined 
in Figure 3.5B. Two cell populations transiently expressing SOD1
WT
 tdTomato or SOD1
G93A‐
EGFP proteins were co-cultured at a ratio of 1:1 and analysed using flow cytometry (Figure 
3.5C). Control cells were also transfected separately, however they were mixed immediately 
prior to flow cytometry analysis. Similar to previous cell to cell in culture findings (Grad et 
al., 2014), approximately 2.7 ± 1% at 24 h, 1.2 ± 0.1% at 48 h and 5.2 ± 0.6% at 72 h 
acceptor NSC-34 cells were found to contain significantly greater amount of both SOD1
WT
 
tdTomato and SOD1
G93A‐EGFP from donor cells, and were scored as EGFP/tdTomato red 
double-positive, compared to the controls. These results therefore indicate that that either or 
both SOD1
WT
 tdTomato and SOD1
G93A‐EGFP can release from NSC-34 donor cells into the 
conditioned media, into which they are then taken up by other neighbouring transiently 
transfected NSC-34 acceptor cells. This therefore demonstrated cell to cell transfer of SOD1 
between donor and acceptor cells. 
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Figure 3.5 SOD1WT tdTomato and SOD1G93A ‐EGFP proteins can transfer between co-
cultured NSC-34 motor neurons.  Following transfection, using Lipofectamine 3000, NSC‐34 transiently 
transfected with SOD1
WT
 tdTomato, SOD1
G93A‐EGFP, tdTomato or EGFP were either co-cultured or cultured 
separately for 24, 48 and 72 h. NSC-34 cells cultured separately were mixed prior to analysis (control) (A) 
SOD1
WT
 tdTomato compensation to account for spectral overlap into the GFP channel (B) Results shown as dot 
plots of one representative set of data demonstrating the quadrant markers (C) mean percentage of cells ± SEM, 
n = 3; ∗∗∗P < 0.001 or 
*
P < 0.05 compared to control (mixed population of cells).  
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3.3.5 SOD1 aggregates escape the endocytic pathway by damaging or rupturing the 
membrane of vesicles to gain access to the cytosol in NSC-34 motor neurons.  
3.3.5.1SOD1 aggregates escape the endolysosomal system and enter into cytosol 
 
The data presented in Chapter 2 demonstrated that SOD1 aggregates are indeed able to enter 
NSC-34 cells via stimulated macropinocytosis. However, the mechanism by which 
exogenously applied SOD1 aggregates induce the formation of cytoplasmic inclusions 
containing intracellular SOD1 has not yet been established. Given that this likely involves the 
escape of SOD1 from membrane bound endolysosomes, the ability of SOD1 aggregates to 
escape from endolysosomal compartments following its uptake was first investigated (Figure 
3.6). NSC-34 cells were incubated with SOD1 aggregates at 37°C and imaged following 
incubation at incremental time intervals as indicated. Cells were then probed for SOD1 
aggregates (using biotin-SA), and for lysosomes using Lysotracker red and images were 
captured with confocal microscopy. Exogenously added WT SOD1 aggregates entirely co-
localised with Lysotracker dye, until 30 minutes, after which low levels of SOD1 could be 
observed outside the acidic endo-lysosomal system (Figure 3.6A) as indicated by the arrows. 
Similarly, G93A SOD1 aggregates were predominately observed in association with the 
lysotracker at 10 min and 30 min, however at 60 min aggregates were detected outside the 
acidic vesicles (Figure 3.6B) as indicated by the arrows. 
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Figure 3.6 Internalised SOD1 aggregates entering via  the endocytic pathway escape from 
the endosomes to the cytosol . Representative confocal images of NSC-34 cells pre-treated with 
Lysotracker Red for 2 h followed by treatment with 20 μg/ml of aggregated (A) WT SOD1 or (B) G93A SOD1 
for either 10 min, 30 min or 60 min at 37°C, fixed with 4% PFA, permeabilised and labelled with an anti-human 
SOD1 pAB and anti-sheep IgG conjugated to Alexa Fluor 488. Slides were analysed by confocal microscopy. 
Representative confocal images are shown. Outline of cells are indicated with white dashed lines. Bars represent 
10 µm. Results are representative of at least n = 3.  
These data suggest that SOD1 aggregates can escape the endolysosomal system (Figure 3.6). 
However, to confirm whether SOD1 aggregates had entered the cytosol, NSC-34 cells were 
incubated with WT and G93A SOD1 aggregates and their location within the cell was then 
investigated by immunoblotting of cytosolic, membrane (ER/Golgi), nuclear and cytoskeletal 
supernatant fractions (Figure 3.7). In the WT SOD1 treated fractions (Figure 3.7A), WT 
SOD1 aggregates predominantly fractionated with the cytoskeleton (PE) fraction presenting 
as a high molecular weight smear ranging from 50 to over 160 kDa in size. An additional 
band in the cytoplasmic (CE) fraction was detected, with an approximate size of 16 kDa, 
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corresponding to human SOD1 monomer likely separated from larger aggregates. Similarly, 
treatment with G93A SOD1 aggregates (Figure 3.7B) resulted in the detection of high 
molecular weight smear ranging from approximately 60 to over 150 kDa in size in the 
cytoskeleton (PE) fraction. In addition, minor smearing of high molecular weight bands was 
observed in the cytoplasmic (CE) fraction ranging from approximately 50-160 kDa in size 
and a band at 16 kDa; the predicted size of human SOD1 monomer. Non-specific Ab binding 
was also observed, predominantly in the G93A blot. To further confirm the efficiency of the 
fractionation, the fractions were immunoblotted using an anti-actin, anti-EEA1 and anti-
vimentin Ab (Figure 3.7C). Confirming the success of the fractionation vimentin (54 kDa) 
was predominantly found in the PE fraction and EEA1 (180 kDa) was primarily detected in 
the ME fraction. Actin was found in all fractions. Furthermore, proteins remaining in the 
endolysosomal system would be present in the membrane extract (ME) fraction, and 
therefore absence of these proteins in the ME fraction support above findings. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Internalised aggregates are detected in the cytoplasm of  NSC-34 cells. 
Cytoplasmic extract (CE), membrane extract (ER/Golgi) (ME), nuclear extract (NE) and pellet extract 
(cytoskeleton) (PE) fractions by centrifugation from NSC-34 cells treated with either (A) WT or (B) G93A 
SOD1 aggregates (20 μg/mL) or (C) PBS alone and were separated by SDS PAGE under reducing conditions, 
transferred to nitrocellulose membrane and incubated with streptavidin-HRP, anti-actin, anti-EEA1 or anti-
vimentin Abs (as indicated). Results show one experiment and are representative of two experiments.  
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To further investigate the presence of SOD1 aggregate uptake into membrane bound vesicles 
and their subsequent escape to the cytosol, a selective permeabilisation assay was performed 
(Figure 3.8). Selective permeabilisation involves the use of Triton X-100 detergent, which 
disrupts all cellular membranes, or the glycoside digitonin which selectively permeabilises 
the plasma membrane leaving only intracellular, nuclear, ER and Golgi membranes intact 
(Figure 3.8A) (Nizard et al., 2007). Firstly, the assay conditions were optimised to confirm 
adequate and selective permeabilisation of NSC-34 cells. Cells were incubated with either 
Triton X-100 (0.5%) or digitonin (10 µM) for 30 min and 10 min at 4°C respectively, and 
immunolabelled with Abs specific for lysosomal associated membrane protein 1, LAMP1; 
Binding immunoglobulin protein, BiP; Early endosome antigen 1, EEA1; and cytosolic 
protein, β-Tubulin and analysed by confocal microscopy (Figure 3.8B). LAMP1, BIP and 
EEA1 were detected upon treatment with Triton-X 100 only, and no protein signal was 
observed upon treatment with digitonin, consistent with their location in membrane enclosed 
vesicles. However, β-Tubulin was detected after treatment with both Triton-X100 and 
digitonin consistent with its presence in the cytoplasm. This indicated that the Triton-
X100/digitonin method under these conditions, and in NSC-34 cells, provides satisfactory 
selective permeabilisation. 
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Figure 3.8 Digitonin selectively permeabilises the plasma membrane of NSC-34 cells. 
Adherent NSC-34 cells were incubated in complete culture media for 24 h. min at 37°C, fixed with 4% 
paraformaldehyde, permeabilised with either triton-x 100 or digitonin. Cells were labelled with anti-LAMP1 
mAb, anti-BiP/GRP78 mAb, anti-β-tubulin mAb and anti-EEA1 pAb followed by Alexa Fluor 488‐conjugated 
anti- rabbit and mouse Ab and analysed by confocal microscopy. RedDot2 (1X) was used as a counter stain (10 
min at RT). Representative confocal images are shown. Outline of cells are indicated with white dashed lines. 
Bars represent 10 µm. Results are representative of at least n = 2.  
Next, to confirm that aggregates were present outside any membrane enclosed compartments, 
cells were incubated with aggregated or soluble SOD1 and treated either with Triton X-100 
or digitonin, immunolabelled with a specific Ab and analysed by confocal microscopy 
(Figure 3.9). At the 60 min time-point, SOD1 aggregates were detected only after Triton X-
100 permeabilisation in NSC-34 cells treated with WT (Figure 3.9A) and mutant G93A 
SOD1 aggregates (Figure 3.9B), with no detectable fluorescence signal in cells treated with 
digitonin.  
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Figure 3.9 Internalised SOD1 aggregates are not detected in the cytoplasm of  NSC-34 cells 
at 60 min Adherent NSC-34 cells were incubated with 20 μg/ml of aggregated (A) WT or (B) 
G93A SOD1 for 60 min at 37°C, fixed with 4% paraformaldehyde, permeabilised with either triton-x 100 or 
digitonin and labelled with Alexa Fluor 488 streptavidin for biotinylated aggregates. Sytox Red (5 µM) was 
used as a counter stain (10 min at RT). Slides were analysed by confocal microscopy. Representative confocal 
images are shown. Outline of cells are indicated with white dashed lines. Bars represent 10 µm. Results are 
representative of at least n = 3.  
While it had been observed that SOD1 aggregates appear to escape the endolysosomal system 
after 60 min incubation, the above data suggest that aggregates remain within membrane 
bounded compartments at 60 min of incubation (Figure 3.9). Thus, the release of SOD1 
aggregates from membrane bound vesicles was further investigated after the 60 min time-
point in NSC-34 cells (Figure 3.10). Cells were incubated with SOD1 aggregates for an 
extended period of 120 min and then treated with either Triton-X 100 or digitonin as above. 
Interestingly, both WT (Figure 3.10A) and G93A (Figure 3.10B) SOD1 aggregates were now 
detected after permeabilization by digitonin, suggesting that SOD1 aggregates are present in 
the cytosol at 120 min. To demonstrate the specificity of the assay, NSC-34 cells were 
incubated with the control protein RAP-GST for 120 min (Figure 3.10C). After 120 min 
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RAP-GST was detected after Triton-X 100 permeabilisation but not after digitonin 
permeablisation, consistent with its maintenance in a membrane bound vesicle.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Internalised SOD1 aggregates are detected in the cytoplasm of  NSC-34 cells at 
120 min Adherent NSC-34 cells were incubated with 20 μg/ml of aggregated SOD1 for 120 min at 37°C, fixed 
with 4% paraformaldehyde, permeabilised with either triton-x 100 or digitonin. Biotinylated aggregates were 
detected with Alexa Fluor 488 streptavidin or anti-RAP Ab. Sytox Red (5 µM) was used as a counter stain (10 
min at RT). Representative confocal images are shown. Outline of cells are indicated with white dashed lines. 
Bars represent 10 µm. Results are representative of at least n = 3.  
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3.3.5.2 SOD1 aggregates induce the rupture of endocytic vesicles in NSC-34 motor neurons 
Exogenous human SOD1 aggregates have been shown to enter into NSC-34 cells via 
stimulated macropinocytosis, thus are transported intracellularly in macropinosomes (Chapter 
1) which are thought to be ‘leaky’ due to their lack of a physical or rigid structure (Conner 
and Schmid, 2003). Since the redistribution of Galectin-3 has been used as a tool to identify 
and measure vesicle rupture in studies of bacteria and viruses (Maier et al., 2012; Ray et al., 
2010), here the redistribution of galectin-3 was used to examine if extracellularly applied 
SOD1 aggregates could rupture vesicles (Figure 3.11). Galectin-3 is a cytosolic protein that 
binds strongly to structures on the luminal side of the endosome, thus upon rupture a 
redistribution of galectin-3 occurs. To examine whether SOD1 aggregates lead to the 
accumulation of galectin-3, cells were incubated with SOD1 aggregates for 2 h and 
specifically permeabilised with digitonin, stained for galectin-3 and then examined by 
confocal microscopy (Figure 3.11A). Galectin-3 staining was quantified from these images 
(Figure 3.11B). Cells permeabilised by digitonin and treated with PBS alone (negative 
control) presented with very little accumulated galectin-3 staining compared to cells 
permeabilised with triton x-100 which presented with significantly higher galectin-3 staining. 
This is consistent with a large fraction of galectin-3 being bound on the inside of endosomal 
compartments (Schneider et al., 2010). Similarly, incubation with WT and G93A SOD1 
aggregates and mutant SOD1 soluble protein induced a significant increase galectin-3 
staining and pronounced intracellular and punctate structures. This is consistent with 
endosome rupture and accumulation of galectin-3. 
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Figure 3.11 SOD1 aggregates and mutant SOD1 soluble proteins induce discrete Galectin -
3 puncta immunofluorescence (A) Adherent NSC-34 cells were incubated with 20 μg/ml of soluble and 
aggregated WT and G93A SOD1 for 2 h at 37°C, fixed with 4% paraformaldehyde, permeabilised with either 
triton-x 100 (control only) or digitonin (all samples). Cells were labelled with anti-Galectin 3 mAb followed by 
Alexa Fluor 488‐conjugated anti- mouse Ab and analysed by confocal microscopy. RedDot2 (1X) was used as a 
counter stain (10 min at RT). Representative confocal images are shown. Outline of cells are indicated with 
white dashed lines. Bars represent 10 µm. (B) Mean fluorescence intensities (MFI) of Galectin-3 per cell were 
quantified from these images using ImageJ software (Version 1.48) (National Institutes of health, Bethesda, 
MD). A minimum of 200 cells were scored per treatment. Results shown as mean cellular fluorescence intensity 
means ± SD, n = 3, 
***
 P <0.001, 
**
P < 0.01 or 
*
P < 0.05 compared to corresponding control (no protein 
treatment).  
 
3.3.5.3 SOD1 aggregates induce significant changes in biological membrane structures 
To further characterise the ability of exogenous human SOD1 aggregates to rupture 
membranes, human red blood cells and liposomes were obtained and examined for 
interactions with SOD1 aggregates (Figure 3.12). First, purified human red blood cells were 
incubated for 2 h in the presence of SOD1 aggregates and then the amount of membrane 
disruption was measured by total amount of free hemoglobin in the supernatants (Figure 
3.12A). Very little hemoglobin was detected in the supernatants of cells treated with PBS 
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only; however, a significantly higher amount of hemoglobin was measured in the 
supernatants of red blood cells treated with Triton-X100. Incubation with soluble mutant 
G93A SOD1 and aggregated SOD1 proteins significantly increased the amount of free 
hemoglobin consistent with an ability to damage biological membranes. Similar to red blood 
cells, SOD1 aggregates altered the morphology liposomes, deforming their structures (Figure 
3.12B). Collectively, this suggests that SOD1 aggregates are capable of inducing damage to 
biological membranes and thus allowing their escape in to the cytosol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Mutant SOD1 and SOD1 protein aggregates damage biological membranes.  (A) 
Clarified human blood cells were incubated with 20 μg/ml of WT and G93A SOD1 soluble and aggregated 
proteins or 0.1% Triton-x100 for 2 h at 37°C. Absorbance of haemoglobin (A540nm) was determined by 
spectrometry and results shown as means A540 nm ± SD, n = 6; 
***
P < 0.001, 
**
P < 0.01 or 
*
P < 0.05 compared 
to corresponding control (PBS). (B) Unilamellar vesicles were formed from L-α-phosphatidylcholine and 
incubated with 20 μg/ml of SOD1 aggregates for 2 h at 37°C as indicated. Slides were analysed by confocal 
microscopy. Bars represent 10µM. Results are representative of one experiment.  
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3.3.6 SOD1
G93A
 –EGFP can induce aggregation of SOD1
WT
 tdTomato protein in co-
cultured NSC-34 motor neurons 
The above data indicates that SOD1 proteins can transfer between co-cultured NSC-34 motor 
neurons and that SOD1 aggregates can escape membrane bound vesicles. Thus, the ability of 
mutant SOD1 aggregates to induce aggregation of WT SOD1 was next characterised in NSC-
34 cells. Given that SOD1
WT
 tdTomato produces cells with very few aggregates it was used 
as a marker for seeding by SOD1
G93A‐EGFP (Figure 3.13). Initially, the lysates of NSC-34 
cells containing large particles were gated (nuclei and inclusions) and after nucleus removal, 
particles were analysed for green or red fluorescence to identify inclusions made by EGFP or 
tdTomato (see Figure 3.2). Using FloIT, the number of SOD1
WT
 inclusions was then 
investigated to identify and measure seeding activity induced by mutant SOD1
G93A‐EGFP. To 
calculate the average number of inclusions per 100 transfected cells in the populations 
analysed, the number of inclusions acquired is simply divided by the transfection efficiency 
(separately determined by flow cytometry) of the sample, which is then multiplied by the 
corresponding number of cell nuclei enumerated. An increase in the amount of SOD1
WT 
tdTomato
 
inclusion formation in the co-cultured treatment was observed from 24 to 72 h. 
However, a statistical significance was only measured at 72 h compared to the corresponding 
control, indicative of mutant SOD1
G93A‐EGFP induced seeding of SOD1WT. However, the 
control treatment which is transfected NSC-34 cells cultured separately and mixed prior to 
analysis; presented with significantly high amounts of inclusions overtime, potentially due to 
differences in toxicity or an effect of seeding reactions. 
 
 
 
 
120 
 
 
 
 
 
 
Figure 3.13 Co-culture with SOD1G93A increases WT SOD1 aggregation.  Following 
transfection, NSC‐34 cells expressing SOD1WT tdTomato or SOD1G93A‐EGFP were subsequently co-cultured, 
co-transfected or cultured separately together for 24, 48 and 72 h. The number of WT SOD1 inclusions obtained 
were enumerated by the FloIT method; means ± SEM, n = 3; 
***
P < 0.001 compared to corresponding treatment 
at 24 h. 
3.3.7 Recombinant mutant SOD1 can seed aggregation and induce inclusion formation 
in NSC-34 cells expressing SOD1
WT
 tdTomato protein 
It has previously been observed that mutant SOD1 aggregates in conditioned media can 
induce the aggregation of soluble intracellular mutant SOD1 (Münch et al., 2011). 
Furthermore, other studies have shown that mutant SOD1 induces the misfolding of human 
SOD1
WT
 when transfected in human mesenchymal and neural cell lines (Grad et al., 2011). In 
addition, the above data indicates that there is a significant increase in the number of 
inclusions identified in transfected NSC-34 motor neurons from co-cultured with cells 
expressing SOD1G93A at 72 h. Thus, the seeding behaviour of protein only aggregates of 
SOD1 was further investigated at 72 h. To assess whether non-vesicular mutant SOD1 
aggregates induce the aggregation of endogenous SOD1 proteins in NSC-34 motor neurons, 
cells were transiently transfected with SOD1
WT
 tdTomato protein and incubated with human 
recombinant G93A mutant SOD1 aggregates for 72 h (Figure 3.14). As previously described 
above, the number of inclusions per transfected cell was determined by flow cytometry using 
the FLoIT technique. Incubation with mutant SOD1 aggregates at 72 h, induced a 
significantly higher number of inclusions (75 ± 3) in comparison to cells incubated in the 
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absence of mutant SOD1 aggregates (32 ± 3). This suggests that mutant SOD1 aggregates 
can induce aggregation of SOD1
WT
 tdTomato in NSC-34 cells. 
 
 
 
 
 
 
 
Figure 3.14 Recombinant human mutant SOD1 aggregates induce the aggregation of 
SOD1WT tdTomato in NSC-34 motor neurons.  Following transfection, using Lipofectamine 3000, 
NSC‐34 cells expressing SOD1WT tdTomato, were incubated with 20 µg/mL of human recombinant protein 
only; G93A mutant SOD1 for 72 h. The number of inclusions obtained were enumerated by FloIT method 
means ± SEM, n = 3; 
***
P < 0.001 compared to corresponding control (absence of mutant SOD1 aggregates). (+) 
refers to the presence of recombinant mutant SOD1 aggregates, (-) refers to the absence of recombinant mutant 
SOD1 aggregates.  
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3.4 Discussion 
The current study demonstrated that WT and mutant G93A SOD1 proteins can form 
spontaneous aggregates in cells and their appearance coincides with an increase in cell death. 
The current study also demonstrated and confirmed that SOD1 aggregates can be released 
from transiently transfected NSC‐34 motor neurons potentially from dying or dead cells. 
Furthermore, extracellular released SOD1 aggregates derived from conditioned media were 
shown associated with naïve cells and their internalisation was confirmed. The transfer of 
SOD1 between NSC-34 cells was also confirmed in this study. Upon endocytosis by NSC-34 
motor neurons, soluble and aggregated SOD1 escapes the endolysosome system to be 
deposited in the cytosol. Lastly, using the novel FLoIT method which is a tool to accurately 
measure and quantify inclusions, demonstrated increased inclusion formation of WT SOD1 
induced by co culture with cells expressing mutant SOD1. Seeding by protein only human 
recombinant exogenous aggregates was also demonstrated, supporting these results. The 
results presented here suggest that SOD1 aggregates rupture macropinosomes and escape into 
the cytosol where they can induce aggregation of SOD1, consistent with reports of exogenous 
mutant SOD1 aggregates identified in the cytosolic compartment of mammalian cells (Münch 
et al., 2011). Collectively, this supports a role for SOD1 in the infectious prion-like spread of 
protein aggregation in neuronal cells.  
Previous studies have suggested that WT and mutant forms of SOD1 can spontaneously form 
aggregates and fibrils given the right conditions in vivo (Chia et al., 2010) and in vivo where 
human WT SOD1 has been shown to spontaneously aggregate in G93A Gurney strains of 
mice (Prudencio et al., 2010). Similar to these observations, spontaneous SOD1 aggregate 
formation in NSC-34 cells was confirmed in the current study. In addition, NSC-34 cells 
expressing mutant SOD1
G93A
 formed significantly greater numbers of inclusions compared to 
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the SOD1
WT 
expressing cells. Inclusion formation has been reported to inversely correlate to 
the number of motor neurons found in ALS spinal cord tissue, suggesting that inclusion 
formation is toxic and leads to cell death (Giordana et al., 2010). Similarly, a previous study 
has reported that cytoplasmic mislocalisation and aggregation of mutant SOD1 induces cell 
death in WT and mutant G93A SOD1 mouse primary neurons and astrocytes (Lee et al., 
2015). Supporting this notion, a significant increase in cell death was observed over the 72 h 
transfection period in NSC-34 cells expressing SOD1
G93A
EGFP. Cell death was also apparent 
for NSC-34 cells expressing SOD1
WT
-EGFP to a lesser extent. Although misfolded wild-type 
and mutant SOD1 have been reported to activate the same neurotoxic mechanism and share 
an aberrant conformation (Bosco et al., 2010), mutants possess a higher inherent propensity 
to aggregate, thus may be more toxic to cells (Prudencio et al., 2009b; Valentine and Hart, 
2003). Recently, a study was able to show that different mutant SOD1 variants have 
differential aggregation propensities in NSC-34 cells (McAlary et al., 2016). This study also 
reported that cellular aggregation correlates with cell loss and that the major predictor for 
cellular aggregation of SOD1 variants is the abundance of destabilized SOD1 states which differs 
between different mutants. However, although a strong correlation exists between cellular 
aggregation and cell loss, translating this to severity of human disease is limited, given that 
one of the variants (SOD1
G37R
) reported in this study is toxic in cells and has a high 
propensity to aggregate, however has a mean disease duration of 17 years (McAlary et al., 
2016).  
While there is now good evidence that both soluble and aggregated SOD1 can be taken up by 
neurons and neuron like cells, there is little work describing the release of SOD1 aggregates. 
Soluble SOD1 secretion into the culture medium has previously been shown using human 
hepatocyte, fibroblast, neuroblastoma, and thymic-derived cell lines (Cimini et al., 2002; 
Mondola et al., 1996). In the current study, the release of WT and mutant SOD1 variants 
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including G93A, A4V and G127X from NSC-34 motor neurons was initially observed 72 h 
following transfection. The release of SOD1 from transiently transfected cells has previously 
been attributed to cell death (Grad et al., 2014). While other studies have reported SOD1 
release is mediated via constitutive mechanisms such as calcium dependant release and 
chromaginin mediated secretion of SOD1 (Santillo et al., 2007; Urushitani et al., 2006), the 
current study suggests that SOD1 release coincides with toxicity, under the conditions used 
for the filter trap assay.  
The work presented here cannot rule out that SOD1
G93A
-EGFP released from cells was 
secreted either via exosomes, microvesicles or neurosecretory vesicles or a combination of 
these. In support of this idea, the active release of SOD1 as part of exosomes and 
microvesicles from NSC-34 and neuroblastoma cells respectively, has been previously 
reported (Gomes et al., 2007; Grad et al., 2014; Mondola et al., 2003). Further supporting this 
notion, ALS pathology spreads from region to region in a spatiotemporal manner (Ravits and 
Spada, 2009) prior to obvious cell death, suggesting an active release process in the early 
stages of the disease. In addition, mutant SOD1 can interact with chromogranins which 
promote their secretion from neurosecretory vesicles (Urushitani et al., 2006). Consistent 
with this, mutant SOD1 has shown to translocate from the cytosol to the ER-Golgi pathway 
(Urushitani et al., 2008), and the secretion of mutant SOD1 from NSC-34 can be reduced 
upon incubation with a secretion inhibitor (Turner et al., 2005). In addition, it is suggested 
that less mutant SOD1 is secreted when compared to WT SOD1, and this impaired secretion 
coincides with intracellular formation of inclusions thus toxicity (Gomes et al., 2007; Turner 
et al., 2005).  
Recent lines of evidence implicate the transmission of extracellular SOD1 in the progression 
of disease in ALS via a prion-like mechanism, involving pathological interactions with the 
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cell surface and internalisation into neuronal and non-neuronal neighbouring cells. A toxic 
role for SOD1 was suggested by a previous study, which found secreted SOD1 from 
astrocytes derived from post-mortem spinal cord tissues from sALS and SOD1-related fALS 
induced motor neurons cell death (Haidet-Phillips et al., 2011). The uptake of SOD1 has 
previously been thought to be mediated by non-specific endocytosis, specifically 
macropinocytosis (see Chapter 1) (Münch et al., 2011; Sundaramoorthy et al., 2013). 
Furthermore, both WT and mutant SOD1 can be detected in the cerebrospinal fluid of fALS 
patients and healthy controls (Zetterstrom et al., 2011). In the current study, both WT and 
mutant SOD1 variants released into conditioned media were found to internalise into naïve 
NSC-34 cells. This transmission was unaffected by DNase digestion of conditioned media, 
ruling out a role for residual plasmid in recipient culture media. The uptake of secreted SOD1 
from conditioned media was also reported in other studies (Grad et al., 2014; Münch et al., 
2011; Sundaramoorthy et al., 2013). While experiments in chapter 2 showed that uptake of 
SOD1 was relatively specific (i.e. GST was not taken up), here we could not rule out a non-
specific uptake of GFP given no measurable amount of EGFP was detected in the conditioned 
media. Moreover, consistent with observations presented here, media-to-cell transfer of 
protein aggregates has been previously reported for α-synuclein (Desplats et al., 2009), 
polyglutamine peptides and Huntingtin protein aggregates associated with Huntington’s 
disease (Ren et al., 2009; Yang et al., 2002).  
Cell-to-cell transmission is a characteristic of mammalian prions. The spreading of pathology 
through neuronal pathways has previously been suggested to involve the cell-to-cell 
transmission of toxic protein species in ALS. Recent work has identified transmission of 
protein misfolding in the case of both WT and mutant SOD1 (Grad et al., 2014; Münch et al., 
2011). However, the exact mechanisms involved in this transfer are not yet understood. In the 
current study, SOD1 released into co-culture conditioned medium from cells expressing 
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SOD1
WT
-EGFP and SOD1
G93A
-EGFP were found to be taken up into acceptor cells. This 
suggests that these proteins were able to transfer from cell-to-cell, consistent with reports 
from others (Grad et al., 2014; Münch et al., 2011). The percentage of co-cultured cells 
containing dual fluorescence, that is containing both WT SOD1-tdTomato and G93A SOD1-
EGFP was around 1-2% for the first 48 h after which the numbers of dual coloured cells 
increased to around 5 % at 72 h. This suggests that at a time point when both aggregation and 
toxicity is increased so too is transfer of protein. This further supports the idea that motor 
neurons may be dying, releasing their content and transferring from cell to cell during disease 
propagation.  
The autophagic-lysosomal pathway has been shown to play major roles in the removal of 
intracellular protein aggregates, however, previous reports suggest that certain infectious 
protein aggregates can escape these intracellular vesicles to enter into the cytosol (Freeman et 
al., 2013; Frost et al., 2009; Ren et al., 2009). Furthermore, propagation of aggregation in 
SOD1-ALS has been suggested to involve the escape of SOD1 aggregates from membrane 
bound endolysosomes (Münch et al., 2011). In the current study, recombinant WT and G93A 
SOD1 aggregates co-localised with acidic compartments until 30 min after which SOD1 
aggregates were detected in the cytosol at 60 min. Thus, this suggests that SOD1 aggregates 
are initially compartmentalised to acidic compartments but rapidly escape these.  
It has been identified previously that aggregates that enter cells somehow escape endocytic 
vesicles to interact with cytosolic protein. As described in Chapter 2 and other studies suggest 
that SOD1 aggregates are entering via macropinocytosis, thus these SOD1 aggregates are 
likely trafficked through large macropinosomes once internalised and the subsequent fate of 
macropinosomes varies depending on the cell type (Meier and Greber, 2003; Swanson and 
Watts, 1995). Macropinosomes are known to be leaky due to their lack of physical structure 
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and the resulting relatively easy loss of integrity of the macropinosome membrane (Conner 
and Schmid, 2003). This fact is often exploited by certain viruses to reach the cytosol (Kalia 
et al., 2013; Mercer and Helenius, 2009; 2012). Thus, it is suggested that the rigid structure of 
the SOD1 aggregates promote their escape from membrane bound vesicles, as a result of the 
destabilisation of the lipid bilayer (Holmes et al., 2013).  
Consistent with the current study, protein aggregates made from other proteins, including α‐
synuclein associated with Parkinson's disease, enters cells via macropinocytosis and then the 
newly formed macropinosomes undergo traditional maturation and fuse with the lysosome 
(Nara et al., 2012). However, α‐synuclein aggregates were then shown to induce the rupture 
of lysosomes following endocytosis into SH-SY5Y cells (Freeman et al., 2013). In addition, 
amyloid plaques, which are associated with Alzheimer’s disease, are shown to contain active 
lysosomal hydrolases, which implies that plaques may originate from lysosomal rupture 
(Nixon et al., 2000). Moreover, protein aggregates are not the only infectious particle that 
enter the cytosol via rupture of endosomes, other infectious particles such as the Adenovirus 
protein type 5 enter the cytosol via this mechanism (McGuire et al., 2011). In the current 
study, SOD1 aggregates and mutant SOD1 G93A soluble protein induced membrane damage 
and rupture in human red blood cells, further supporting the notion that aggregated or 
misfolded SOD1 can interact with and destabilize membranes through exposed hydrophobic 
surfaces, therefore this suggests that the G93A soluble protein may have been in its unfolded 
state. Consistent with this idea, fibrillar β2-microglobulin amyloid fibrils caused pronounced 
distortions to the membrane of liposomes (Milanesi et al., 2012). Further evidence of protein 
aggregate rupture of vesicles is the fact that non-monomeric forms α‐synuclein induced the 
relocalisation of galectin-3 and the rupture of vesicles in the neuronal cell lines N27 and SH-
SY5Y (Freeman et al., 2013). Similarly, in the current study, SOD1 aggregates and mutant 
SOD1 soluble proteins were shown to be able to disrupt the integrity of vesicular membranes 
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resulting in the relocation of galectin-3. Previous studies have shown that ROS generation is 
induced upon vesicular rupture (Freeman et al., 2013; Halle et al., 2008; McGuire et al., 
2011), therefore making cells more susceptible to cell death. While it was not a line of 
investigation in the current study, it will be an interesting future direction to determine 
whether SOD1 induced rupture of lysosomes corresponds with an increase in cellular reactive 
oxygen species (ROS) and cell dysfunction and death in neurons, possibly contributing to 
disease progression. 
Work presented here shows that both WT and G93A SOD1 aggregates were localised to the 
cytoplasmic and cytoskeleton fractions 2 h post-incubation. These results are consistent with 
SOD1 aggregates having a density comparable to cytoskeleton elements and, in addition, is 
consistent with cytosolic exposure of SOD1 aggregates. There was also a very small amount 
of high molecular weight WT SOD1 detected associated with the nuclear fraction, again 
consistent with cytosolic exposure (outside of the endo-lysosome system). However, in 
confocal microscopy experiments, aggregates were not observed within the nucleus 
suggesting aggregated material either bound the external portion of the nuclear membrane or 
pelleted at a similar density to the nuclear fraction. Nevertheless, this is consistent with other 
reports (Münch et al., 2011).  
Selective permeabilisation using digitonin and Triton-X 100 (Nizard et al., 2007) confirmed 
that SOD1 aggregates were present outside any membrane-enclosed compartments. 
Specifically, imaging after plasma membrane permeabilisation with digitonin suggested that 
SOD1 aggregates could only be detected in cells after 120 min incubation with aggregates. 
This work suggests that SOD1 aggregates were within membrane bound organelles at 60 min, 
after which time the membrane of vesicles were ruptured by recombinant SOD1 aggregates. 
In comparison, RAP-GST, which is well-established to be internalised by receptor mediated 
endocytosis because of the recognition of RAP by LRP (Caetano-Pinto et al., 2016), was not 
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detected after digitonin permeabilsation at 120 min, indicating the maintenance of RAP-GST 
in endosomal-lysosomal compartment and suggesting that rupture of intracellular vesicles 
and/or escape of SOD1 is specific to SOD1.  
A role for misfolded or aggregated SOD1 in seeding the aggregation of intracellular native 
SOD1 in a fashion similar to that of prions has been suggested by a number of recent studies 
(Chia et al., 2010; Grad et al., 2014; Münch et al., 2011; Pokrishevsky et al., 2012). It is well 
established that misfolded protein alone is sufficient to induce further misfolding in native 
proteins (Prusiner, 1982), and that newly formed misfolded protein may propagate misfolding 
pathology either through template-directed misfolding or nucleated polymerisation (Horwich 
and Weissman, 1997). In the current study, mutant SOD1 expressed in one population of 
cells was shown to induce the aggregation of intracellular WT SOD1 in another population of 
cells in a mechanism that must involve cell-to-cell transfer. Given that the methods used 
identified both dual coloured NSC-34 cell populations and also measured increases in 
intracellular WT SOD1 associated aggregates, this indicates that the transfer of mutant SOD1 
seeded the aggregation of intracellular WT SOD1 proteins. Furthermore, the addition of 
human recombinant mutant SOD1 G39A protein aggregates to cells expressing SOD1
WT
-
EGFP enhanced the average number of WT SOD1 inclusions measured following incubation 
at 72 h, suggesting that mutant SOD1 aggregates are capable of inducing the misfolding and 
aggregation of human WT SOD1 in NSC-34 cells in a manner similar to prion template 
misfolding. Furthermore, this observation is consistent with another study that observed the 
conversion of native WT SOD1 to misfolded SOD1 in both a cellular context and in a cell-
free system by mutant conformers (Grad et al., 2011). Although the exact mechanisms were 
not investigated in this current study, previous studies suggest that inducing the misfolding of 
human WT SOD1 is limited by the exposure of a single amino acid residue, a tryptophan 
(Trp) at position 32 (Grad et al., 2011). The seeding behaviour observed in the current study 
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is therefore similar to that of prion-activity, and consistent with the hypothesis that the 
propagation of protein aggregates between cells is responsible for the orderly progression of 
disease pathology observed in some neurological disorders (Clavaguera et al., 2009; Desplats 
et al., 2009; Jucker and Walker, 2013; Li et al., 2008; Ren et al., 2009; Volpicelli-Daley et al., 
2011).  
In conclusion, expression of WT and mutant SOD1 induced spontaneous aggregation of these 
proteins and cell death in NSC-34 cells. The release of SOD1 aggregates and their subsequent 
uptake in to naïve cells occurred at a time point that corresponded to a significant increase in 
cell death. It is therefore likely that aggregates are released via cell death however active 
release via exosomes cannot be ruled out. Furthermore, there are likely other pathways 
mediating the secretion of SOD1 in vivo and a range of mechanisms of SOD1 release, maybe 
potentially working in conjunction in vivo. The internalisation of both WT and mutant SOD1 
protein aggregates induced the rupture of endocytic vesicles to gain access to the cytosol. The 
ability of these aggregates to induce damage and rupture in vesicles and biological 
membranes was confirmed and thus may play a role in cellular dysfunction. The underlying 
mechanisms by which misfolding propagation exerts toxic effects, whether it be inducing the 
misfolding of endogenous proteins through template directed misfolding or through 
secondary nucleation in the recipient cell is yet to be determined. The similarities observed 
between both WT and mutant SOD1 may explain the clinically indistinguishable nature of 
sALS and fALS. 
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Chapter 4  
THE MISLOCALISATION AND 
AGGREGATION OF THE 
PRION-LIKE PROTEIN TDP-43 
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4.1 Background 
Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disorder characterized 
by the loss of both the upper and lower motor neurons in the brain and spinal cord 
respectively, resulting in the progressive paralysis of the muscles of speech, limbs, 
swallowing and respiration, due to the progressive degeneration of innervating motor neurons 
(Cleveland and Rothstein, 2001).  
The neuropathology of all cases of ALS are characterised by disease-specific proteins, mutant 
and wild type alike; mislocalised and abnormally accumulated as misfolded, insoluble 
aggregates in the cytoplasm of afflicted motor neurons (Bosco et al., 2010; Leigh et al., 1991; 
Ross and Poirier, 2004). Proteinaceous inclusions, containing misfolded aggregated proteins, 
peptides and fragments, also occur in many other neurodegenerative disorders including 
Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia (FTLD), 
Huntington’s disease (HD) (Forman et al., 2004); and prion diseases, such as Creutzfeldt-
Jakob disease, Kuru and fatal familial insomnia diseases (Prusiner, 1982; Prusiner, 1984). 
Mutations in several genes cause familial ALS (fALS) which account for 5-10% of total ALS 
cases and contribute to the development of sporadic ALS (sALS, 90% of ALS cases) 
(Andersen and Al-Chalabi, 2011). In fALS, mutations in the gene encoding the Cu/Zn 
superoxide dismutase (SOD1), a ubiquitously-expressed homodimeric enzyme, results in the 
misfolding and aggregation of this normally stable protein (Banci et al., 2009) found in 
patients carrying SOD1 mutations and in mutant SOD1 rodent disease models (Bruijn et al., 
1997; Wang et al., 2002). However, recently misfolded SOD1 species have been increasingly 
identified in non-SOD1 fALS and sALS cases (Bosco et al., 2010; Forsberg et al., 2010), 
suggesting that misfolded SOD1 may play a pathological role in all types of ALS 
(Pokrishevsky et al., 2012). 
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In addition to SOD1, TAR DNA binding protein (TDP-43) has been identified as a major 
component of cytoplasmic inclusions in sALS, SOD1-negative fALS and ALS with 
dementia; as well as most common pathological subtype of frontotemporal lobar dementia 
(FTLD) with ubiquitinated inclusions (Arai et al., 2006; Cairns et al., 2007; Davidson et al., 
2007; Mackenzie et al., 2010; Neumann et al., 2007; Neumann et al., 2006). Clinical and 
pathological overlap of these diseases has suggested a pathogenic mechanistic-link between 
these disorders and has prompted their reclassification as TDP-43-proteinopathies. These 
diseases exhibit the same pathological features in cells containing neuronal cytoplasmic 
inclusions (NCIs) including; loss of the normal nuclear TDP-43, co-localisation of TDP-43 
and ubiquitin, ubiquitinated and hyperphosphorylated TDP-43 proteins and lastly formation 
of abnormal fragments of TDP-43 in post-mortem tissue (Neumann et al., 2007; Nonaka et 
al., 2009a; Zhang et al., 2009). Of interest, AD associated Aβ has been implicated in 
triggering the phosphorylation and cytosolic accumulation of pathogenic TDP-43 in rodent 
models and in brain autopsies from AD patients, similar to other observations in ALS-FTLD 
(Herman et al., 2011). This may explain the presence of TDP-43 pathology in a proportion of 
AD cases (Wilson et al., 2011). 
TDP-43 is a conserved heterogeneous ribonucleoprotein that is ubiquitously expressed. TDP-
43 has two RNA recognition motifs and a glycine rich C-terminal domain (Ayala et al., 2008; 
Buratti and Baralle, 2001) and functions as a regulator of transcription (Ou et al., 1995) and 
alternative splicing (Buratti et al., 2001; Mercado et al., 2005), respectively. TDP-43 is also 
involved in nucleocytoplasmic shuttling of messenger RNA (Ayala et al., 2008) and 
participates in nuclear body formation (Buratti and Baralle, 2008; Ou et al., 1995). Of 
interest, the C-terminal region of TDP-43 contains a prion-like domain which is predicted to 
be prone to misfolding and aggregation (Mousavi and Hotta, 2005). In addition, the C-
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terminal fragments can bind with full-length TDP-43 to possibly facilitate the aggregation of 
full length TDP-43 (Nonaka et al., 2009b; Zhang et al., 2009). 
Furthermore, a number of dominant mutations in the gene encoding TDP-43 have been 
associated with fALS and FTLD, confirming the importance of the role TDP-43 in disease 
pathogenesis (Daoud et al., 2009; Gitcho et al., 2008; Kabashi et al., 2008; Sreedharan et al., 
2008; Van Deerlin et al., 2008; Yokoseki et al., 2008). Of note, TDP-43 pathology is not 
present in cases with SOD1 mutations, thus demonstrating TDP-43 inclusions are not 
required to initiate ALS (Lagier-Tourenne et al., 2010; Mackenzie et al., 2007).  
TDP-43 is largely restricted to the nucleus in healthy cells (Ayala et al., 2008). However, in 
afflicted cells in ALS, abnormal cellular distribution and post-translational modification(s) of 
TDP-43, result in the mislocalisation and subsequent deposition in the cytoplasm as insoluble 
misfolded aggregates (Arai et al., 2006; Gregory et al., 2012; Li et al., 2015; Neumann et al., 
2006). In TDP-43-positive cytoplasmic inclusions, TDP-43 is abnormally phosphorylated, 
unbiquitinated and truncated, resulting in the accumulation of both full-length TDP-43 and 
toxic TDP-43 fragments (Li et al., 2015). These fragments have been identified as a 25-kDa 
C-terminal fragment (CTF25) and a 35-kDa (CTF35) C-terminal fragment, in addition to 
other minor CTFs, in cytoplasmic aggregates (Li et al., 2015). Overexpression of full length 
TDP-43 in cultured cells and animals has been found to result in the production of CTF25, 
with current understanding suggesting that TDP-43 is capable of inducing the misfolding of 
SOD1 upon accumulation in the cytosol (Li et al., 2015). 
It is well established that TDP-43 redistributes and deposits as insoluble TDP-43 aggregates 
in the cytoplasm of affected motor neurons in the majority of cases of ALS. It has also been 
shown that TDP-43 pathology causes misfolding of WT SOD1 (Pokrishevsky et al., 2012), 
and separately shown that WT SOD1 misfolding can be propagated cell to cell (Grad et al., 
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2014). While previous work has shown that uptake of wild type SOD1 aggregates can cause 
endoplasmic reticulum (ER) stress (Sundaramoorthy et al., 2013), whether uptake of SOD1 
aggregates influence TDP-43 pathology is yet to be established.  
The presence of aberrant protein aggregates in affected neurons are characteristic of most 
neurodegenerative diseases, however, the mechanisms that underlie pathology are not yet 
completely understood. An increasing number of recent studies now support the prion-like 
propagation of a range of aggregated proteins associated with various neurodegenerative 
diseases (reviewed in Marciniuk et al., 2013). In addition to SOD1, the propagation of TDP-
43 aggregation has been likened to a prion-like seeding mechanism, with evidence of regional 
spreading of pathology occurring in a sequential pattern through the neuroaxis 
(Brettschneider et al., 2013). Recent evidence suggests that phosphorylated and ubiquitinated 
TDP-43 aggregates may propagate from cell to cell in cultured neuroblastoma cells and 
induce TDP-43 aggregation in the cells expressing human TDP-43 in a self-templating 
fashion (Nonaka et al., 2013). An additional study presented evidence to suggest that TDP-43 
can transfer between cells and induce the seeding of endogenous TDP-43 in a prion like 
manner (Feiler et al., 2015). More recently, it was observed that TDP-43 fibrils triggered the 
seed-dependant aggregation of WT TDP-43 or TDP-43 lacking a nuclear localisation signal 
and similar to prions, different peptides sequences of TDP-43 produce fibrils that induces 
different TDP-43 associated pathologies (Shimonaka et al., 2016).  
In the current study, we aimed to investigate whether exogenous recombinant SOD1 protein 
aggregates can induce and/or contribute to TDP-43 pathology, specifically its mislocalisation 
and aggregation. Upon incubation with large recombinantly formed SOD1 aggregates with 
cells we detected mislocalised WT TDP-43 in the cytoplasm of both mouse neuronal-like 
cells and human embryonic kidney cells. We also demonstrate that, upon addition of the 
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SOD1 aggregates, fragments of TDP-43 can be observed in the cytoplasm of NSC-34 cells. 
Thus, we conclude that addition of recombinant SOD1 aggregates to the extracellular 
environment of neuron like cells results in TDP-43 mislocalisation, aggregation and 
fragmentation. 
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4.2 Methods  
4.2.1 Reagents and Antibodies 
DMEM/F-12 medium, DMEM/F-12 without phenol red, 0.05% trypsin-EDTA, GlutaMAX, 
Lipofectamine 2000, Lipofectamine 3000, SuperSignal West Pico Chemiluminescent 
Substrate, Subcellular Protein Fractionation Kit for Cultured Cells, restriction endonucleases 
BamHI and HindIII, Ez- link- NHS- Biotin, SYTOX Red dead cell stain and Lab-Tek 
chambered coverglass 8 well with cover were purchased from ThermoFisher Scientific 
(Waltham, USA). Any kD Mini-PROTEAN TGX Precast Protein Gels and Precision Plus 
Protein dual color protein standard were from Bio-Rad (California, USA). Foetal Bovine 
Serum (heat-inactivated prior to addition in media; FBS) was from Bovogen Biologicals 
(East Keilor, Australia). Amersham Hyperfilm was obtained from GE Healthcare (Little 
Chalfont, Buckinghamshire, UK). Agar, Mg132, Ethidium Bromide, Casein (heat denatured 
before use; HDC), dimethyl sulfoxide (DMSO), bovine serum albumin (BSA), β-
mercaptoethanol, Brilliant blue R concentrate, paraformaldehyde (PFA) and dithiothreitol 
(DTT) were from Sigma-Aldrich (St. Louis, MO). Ethylenediaminetetraacetic acid (EDTA) 
was from Amresco (Solon, USA). All other reagents including salts, powders and chemicals 
were from Amresco, Sigma-Aldrich or Astral Scientific (Gymea, Australia). All reagents 
used were endotoxin free. Antibodies (Abs) and their respective manufacturing companies 
used in this current study are listed in Table 4.1.  
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Table 4.1 Antibodies used in this study to investigate the effect of SOD1 proteins on TDP-43 pathology 
Host species 
(clonality)
1
 
Antibody target 
(Immunogen)
2
 
Conjugate Manufacturer 
(product number)
3
 
Mouse (mAb) Beta Actin [AC-15] - Abcam (ab6276) 
Rabbit (pAb) Vimentin - Abcam (ab137321) 
Rabbit (pAb) EEA1 - Abcam (ab2900) 
Mouse (mAb) TARDBP  - Saphire Bioscience 
(K1B8) 
Goat (pAb) Rabbit IgG HRP Bio-Rad (1706515) 
Goat (pAb) Mouse  
(IgM, IgG, IgA) 
HRP Merck Millipore (AP501P) 
Sheep (pAb) SOD1 - Pierce (PAI-30817) 
1
 pAb, polyclonal antibody, mAb, monoclonal antibody; 
2
Ig, immunoglobulin; 
3 
Abcam, Cambridge, USA; 
Saphire Biosciences (Redfern, Australia), Bio-Rad (California, USA); Merck Millipore, Billerica, 
Massachusetts, USA. 
4.2.2 Cell Lines  
The mouse neuroblastoma x spinal cord hybrid cell line ( NSC-34 cells (Cashman et al., 
1992a) were routinely cultured in DMEM/F-12 supplemented with 10% (v/v) FBS and 2 mM 
GlutaMAX. Cells were maintained in an incubator at 37°C under a humidified atmosphere 
containing 5% (v/v) CO2. Human embryonic kidney (HEK)-293 cells were from the 
American Type Culture Collection (Manassas, VA). HEK-293 cells were cultured in 
DMEM/F-12 medium supplemented with 10% FBS and 2 mM GlutaMAX, in an incubator at 
37°C under a humidified atmosphere containing 5% (v/v) CO2. 
4.2.3 Aggregation and biotinylation of WT and mutant G93A SOD1 proteins 
WT and G93A SOD1 were expressed and purified from E.coli as previously outlined 
(Lindberg et al., 2002; Roberts et al., 2013). SOD1 aggregation was performed in vivo as 
previously described (Roberts et al., 2013). Briefly, solutions of purified WT or G93A mutant 
SOD1 protein (1 mg/mL) in PBS was co-incubated with 20 mM DTT and 5 mM EDTA for 
72 h at 37°C with shaking using a digital shaker (universal IKA
®
 MS 3, 230 V) (Sigma, St. 
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Louis, MO). The aggregated SOD1 was then labelled with biotinamidohexanoic acid 3-sulfo-
N-hydroxysuccinimide ester sodium salt (40 mg/mL) in DMSO for 2 h at RT. The 
unconjugated biotin was then separated from the aggregates by centrifugation (21 000 x g for 
30 min) and washed three times with PBS (300 x g for 5 min). The purified aggregates free of 
unconjugated biotin were then resuspended in PBS (1 mg/ml). A bicinchoninic acid (BCA) 
protein assay was performed to determine the amount of protein in solution.  
4.2.4 Cell Transfections 
4.2.4.1 Plasmid purification  
pCAG-RFP expression vectors containing WT TDP-43 cDNA was obtained from Addgene, 
provided by Zuoshang Xu (University of Massachusetts Medical School, Worcester, 
Massachusetts, USA)(Yang et al., 2010). pCMV6-AC-GFP expression vector containing WT 
TDP-43 cDNA was obtained from Origene. pCMV6-AC-EGFP expression vector containing 
TDP-43
WT
 cDNA was obtained from Origene. TDP-tomato red (TdTomato) constructs were 
created by replacing the EGFP sequences in the SOD1-EGFP plasmids with tdTomato (by 
Genscript, USA) and site directed mutagenesis was also performed by Genscript (Piscataway, 
NJ) to create the G124A mutant. Chemically competent DH5α Escherichia coli cells were 
provided by Jason McArthur (University of Wollongong, Wollongong, Australia). Cells were 
transformed with the TDP-43 containing plasmids as per manufacturer’s instructions, using 
the heat shock (42 ºC) method. Transformed cells were then transferred onto lysogeny broth 
(10% w/v tryptone, 10% w/v NaCl, and 5% w/v yeast; LB) agar plates with 50 µg/ml 
kanamycin sulphate and incubated overnight at 37°C under a humidified atmosphere 
containing 5% (v/v) CO2. Single-transformed bacterial colonies were selected and inoculated 
into sterile LB media containing 50 µg/ml kanamycin sulphate to prepare starter cultures. 
Plasmid DNA was then extracted from bacterial cells using the CompactPrep Plasmic Maxi 
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Kit (Qiageb, Hilden, Germany), as per manufacturer’s instructions. The purity (260/280 ratio) 
and concentration of extracted DNA was measured using the NanoDrop 2000c dual-mode 
UV-Vis Spectrophotometer (ThermoFisher Scientific, Waltham, USA). To further confirm 
the purity of the extracted DNA samples, a restriction digestion was carried out at 37ºC for 1 
h using enzymes HindIII and BamHI that correspond to specific restriction sites in the 
plasmids. Digested DNA samples were separated on a 1% agarose gel in tris-acetate-EDTA 
(TAE) buffer (1 mM ethylenediaminetetraacetic acid disodium salt, 40 mM Tris and 20 mM 
acetic acid). The resulting gel was them stained with ethidium bromide overnight and 
visualised using the GS-800 Calibrated Densitometer (Bio-Rad).  
4.2.4.2 Transfecting cells with Lipofectamine 2000 
 NSC-34 cells (2 – 3 x 10
4 
cells/ 0.2 mL/ chamber) were cultured in 8-well chamber slides in 
complete culture medium and were incubated overnight at 37°C under a humidified 
atmosphere containing 5% (v/v) CO2. Cells were then incubated in DMEM-F-12 serum-free 
culture medium containing 2 μg WT TDP tomato red (TR) plasmid DNA and Lipofectamine 
2000 for 5 h at 37°C under a humidified atmosphere containing 5% (v/v) CO2. Cells were 
then washed once with serum free media and replenished with complete culture medium. 
Cells were then incubated for a longer period of time either for 19 h, 43 h or 67 h (24 h, 48 h, 
and 72 h in total, respectively). 
4.2.4.3 Transfecting cells with Lipofectamine 3000 
Hek-293 cells (3 – 4 x cells/ 0.2 mL/ chamber) were cultured in 8-well chamber slides and 
were incubated overnight at 37°C/5% CO2. Cells were then incubated in complete DMEM/F-
12 culture medium containing 2 μg WT TDP GFP plasmid DNA, P3000 reagent and 
Lipofectamine 3000 (diluted in serum free DMEM/F-12 medium) for 24 h at 37°C/CO2. 
 
141 
 
Cells were then incubated for a longer period of time for either 19 h, 43 h or 67 h (24 h, 48 h, 
and 72 h in total, respectively).  
4.2.5 Treatment of transfected NSC-34 cells with SOD1 
Cells were visualised prior to experimentation using an Eclipse TE2000 inverted microscope 
(Nikon, Tokyo, Japan) to confirm transfection and determine transfection efficiency. NSC-34 
cells were incubated with labelled biotinylated aggregates, or soluble (non-aggregated) WT 
and mutant G93A SOD1 proteins (20 µg/mL) or no protein as a control at 37°C/CO2, for 
either 2 h or 72 h. Post incubation, cells were immediately fixed with 4% PFA in PBS for 20 
min at RT and washed twice with PBS over 5 min. Cells were incubated with Triton-X 100 
for 30 min at 4°C. Cells were incubated with blocking solution (5% FCS, 1% BSA and 0.3% 
triton-x100) for 20 min at RT. The cells were then probed with Alexa Fluor 488 streptavidin 
(1:1000 diluted in 1% BSA and 0.1% triton-x100) for the aggregates or sheep anti-SOD1 
(1:500 diluted in 4% BSA and 0.1% Triton-x100) for for 1 h at RT or overnight at 4°C 
respectively. Cells were then incubated with anti-sheep IgG conjugated to Alexa Fluor 488 
(1:500 diluted in 1% BSA and 0.1% Triton-x100) for 1 hr at RT for soluble proteins.  
4.2.6 Treatment of transfected HEK-293 cells with SOD1 proteins 
The medium was then replaced, and the transfected HEK-293 cells were incubated with 
labelled biotinylated aggregates of WT and mutant G93A SOD1 proteins (20 µg/mL) at 
37°C/CO2, or no protein as a control or MG132 (10 µM) for 24 h and imaged under live cell 
condition. Imaging was repeated at 48 h and 72 h. Post 72 h incubation, the cells were fixed 
with 4% PFA in PBS for 20 min at RT and washed twice with PBS over 5 min. Cells were 
incubated with Triton-X 100 for 30 min at 4°C. Cells were incubated with blocking solution 
(5% FCS, 1% BSA and 0.3% triton-x100) for 20 min at RT. The cells were then probed with 
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Alexa Fluor 488 streptavidin (1:1000 diluted in 1% BSA and 0.1% triton-x100) for the 
aggregates for 1 h at RT. 
4.2.7 TDP-43 Pathology by Confocal microscopy 
An inverted microscope (DM IBRE) and a Leica TCS SP confocal imaging system were used 
to visualise and image transfected dual colour NSC-34 cells (excitation 488, emission 
collected at 495-515 and 561 nm, emission collected at 590-630 nm) and HEK-293 cells 
(excitation 488, emission collected at 475-515). Fluorescence, bright field (differential 
interference contrast; DIC) and merged images were captures using Leica confocal software.  
4.2.8 Subcellular Fractionation assay of NSC-34 cells 
 NSC-34 cells were incubated with WT SOD1 in soluble and aggregated form (20 µg/mL) in 
PBS for 2 h at 37°C/5% CO2. Post incubation, the cells were washed three times with PBS 
(300 x g for 5 min) harvested using 0.5% trypsin and 5 mM EDTA and washed (500 x g for 5 
minutes). The cells were washed three times with ice cold PBS (500 x g for 3 minutes) for 
fractionation using a Subcellular Protein Fractionation Kit for Cultured Cells as per 
manufacturer’s instructions (Thermo Fisher Scientific). Initially, NSC-34 cells (10 x 10
6
 
cells/mL) were incubated with cytoplasmic extraction buffer (CEB) containing protease 
inhibitors for 10 min rotating at 4°C. The supernatant (cytoplasmic fraction) was collected 
(500 × g for 5 minutes). The cell pellet was then incubated with membrane extraction buffer 
(MEB) containing protease inhibitors for 10 min rotating at 4°C. Post incubation, the 
supernatant (extracted membrane fraction) was collected (3000 × g for 5 minutes). Ice cold 
nuclear extraction buffer (NEB) containing protease inhibitors was added to the cell pellet for 
30 min rotating at 4°C. The supernatant (extracted soluble nuclear fraction) was collected 
(5000 × g for 5 minutes). Chromatin-bound extraction buffer (NEB, 100mM CaCl2 and 300 
units of Micrococcal Nuclease) was added to the pellet for 15 mins at RT. The supernatant 
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(chromatin-bound nuclear extract) was collected (16,000 x g for 5 mins). Lastly, Pellet 
Extraction Buffer (PEB) containing protease inhibitors was added to the cell pellet for 10 
mins at RT. The supernatant (the cytoskeletal extract) was collected (16,000 x g for 5 mins).  
Protein concentration was determined using the BCA method. Supernatants (20 μg 
protein/lane) were separated under reducing conditions (5% β-mercaptoethanol) using Any 
kD Mini-PROTEAN TGX Stain-Free™ Precast Gels. Proteins were then transferred to 
nitrocellulose membranes using a Trans-Blot Turbo Transfer System (Bio-Rad,). Total 
protein per lane was then imaged and measured with a Bio-Rad Criterion Stain Free Imager 
and Image Lab software. Membranes were blocked with heat denatured casein (HDC) in for 
1 h at 37°C. To test the purity of the separation, mouse anti-TDP-43 mAb (1:200); rabbit 
anti-EEA1 pAb (1:500), rabbit anti-Vimentin pAb (1:500) and mouse anti-actin mAb 
(1:5000), diluted in HDC/PBS for 1 h at 37°C were used to probe the CE, ME, NE and PE 
fractions. Membranes were visualised using chemiluminescent substrate and Amersham 
Hyperfilm ECL (GE Healthcare). Images of films were collected using a GS-800 Calibrated 
Densitometer (Bio-Rad). The processing of films was achieved using GBX Developer and 
Replenisher and GBX Fixer and Replenisher (Kodak Australiasia, Collingwood, Victoria 
Australia). Images of the films were collected using a GS-800 Calibrated Densitometer (Bio-
Rad). 
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4.2.9 Presentation of data and statistical analyses 
Data is presented as the mean ± SD. ANOVA paired with Tukey’s HSD multiple comparison 
post-test tests were used to analyse and compare differences between multiple treatments. 
Unpaired student’s t-tests were performed for single treatment comparisons. Prism 5 for 
Windows (Version 5.01) (GraphPad Software, San Diego, CA) was used to generate these 
statistical analyses. Differences were defined as significant for P < 0.05.  
4.2.10 FloIT assay by flow cytometry 
The FloIT assay was performed as outlined in section 3.2.15. Briefly, NSC‐34 cells were 
transiently transfected with TDP-43 (TDP-43
WT
 tdtomato and TDP-43
G124A‐EGFP) using 
Lipofectamine 3000 (see above). Following transient transfection at 24h, 48 h and 72h in 
total, cells were harvested and then washed again using centrifugation. Cells were then 
washed twice and resuspended in PBS (0.5 mL/tube). An aliquot of cells (2 x 
10
5
cells/0.15mL) were collected then analysed for transfection efficiency. The remaining 
cells (4 x 10
5
cells/0.35mL) were washed as above and lysed prior to analysis in lysis buffer. 
Cell lysates were then incubated with RedDot2 (1:1000) at RT for 2 min. Events were 
collected using a LSRFortessa X‐20 Cell Analyzer (BD Biosciences) (excitation 488 nm, 
emission collected with 525/50 band-pass filter and excitation 561, emission collected with 
586/15 nm band-pass filter for EGFP and RedDot2, respectively). Lysates were firstly gated 
on forward and side scatter and then the fluorescence from RedDot2 were determined by flow 
cytometry. All parameters were set to log
10
 during acquisition from cell lysates. The forward 
scatter threshold was set to the minimum value (200 AU) to minimise the exclusion of small 
protein inclusions. Nuclei were identified and enumerated based on RedDot2 fluorescence 
and forward scatter and then excluded from further analysis. The remaining particles were 
analysed for the presence of inclusions based on GFP/ tdTomato fluorescence, forward 
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scatter and comparison lysates prepared from cells expressing only the corresponding 
fluorescent protein. The number of inclusions in the population can be normalised to the 
number of nuclei, and reported as inclusions/100 transfected cells (iFloIT) according to the 
equation outlined in section 0. Analysis of all events was determined using FlowJo software 
(Tree Star, Ashland, OR). 
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4.3 Results 
4.3.1 Transient expression of TDP-43 proteins induces endogenous TDP-43 aggregation 
and inclusion formation in NSC-34 motor neurons over time. 
TDP-43 is localised mostly in the nucleus where it can perform its normal functions including 
RNA processing (Buratti and Baralle, 2001; Lee et al., 2012). Under non-physiological and 
disease conditions however, TDP-43 is known to mislocalise to the cytosol and form 
insoluble aggregates (Neumann et al., 2006), although the mechanisms underlying TDP-43 
mislocalisation and aggregation are not completely understood. However, a previous study 
has reported that TDP-43 is intrinsically aggregation-prone and thus can spontaneously form 
aggregates; a property attributed to the C-terminal domain (Johnson et al., 2009). Here, the 
presence of inclusion bodies containing TDP-43 aggregates was initially investigated over 
time. To investigate the number of TDP-43 positive inclusions in murine NSC-34 cells, cells 
were transfected with TDP-43
WT
 and TDP-43
G124A
 for 24, 48 and 72 h and the number of 
inclusions were quantified using flow cytometric characterisation of inclusions and 
trafficking (FloIT) (Figure 4.1) as outlined in section 3.2.15. A significant amount of 
inclusions of both TDP-43
WT
 and TDP-43
G124A
 were observed in cells expressing EGFP 
fusion proteins. Consistent with mutant TDP-43 being aggregation prone a significantly 
greater number of inclusion bodies were identified in cells expressing mutant TDP-43
G124A
 
compared to cells expressing TDP-43
WT
. However, there was a significant decrease in the 
number of cells containing TDP-43
G124A 
inclusions measured at 72 h, possibly due to cell 
toxicity and death in cells containing inclusions. This is consistent with previous reports 
which demonstrate that ALS-linked TDP-43 mutations in the TDP-43 gene increase the 
number of TDP-43 aggregates and promote toxicity in vivo (Johnson et al., 2009). 
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Figure 4.1 Spontaneous aggregation of TDP-43 was examined by flow cytometry.  Following 
transfection, using Lipofectamine 3000, NSC‐34 transiently transfected with either TDP-43WT or TDP-43G124A 
for 24, 48 and 72 h and analysed using flow cytometry. Results shown as mean number of inclusions per 100 
transfected cells ± SEM, n = 3; 
***
P < 0.001, 
**
P < 0.01 and 
*
P < 0.05 compared to TDP-43
WT
. 
4.3.2 TDP-43 aggregates can transfer from cell to cell  
Next, the ability of TDP-43 to transfer from cell-to-cell in culture was examined. Transfer 
events were quantified as the percentage of transfected cells positive for both 
EGFP/tdTomato using the gating strategy outlined in Figure 3.5. Two cell populations 
transiently expressing either TDP-43
WT
 tdTomato or TDP-43
G124A
 EGFP proteins were co-
cultured at a ratio of 1:1 and analysed using flow cytometry (Figure 4.2). Control cells were 
also transfected separately, however, they were mixed immediately prior to flow cytometry 
analysis. Similar to previous findings for SOD1 (Figure 3.5), approximately 3.4 ± 0.3% at 24 
h and 3.1 ± 0.3% at 48 h acceptor NSC-34 cells were found to contain significant amounts of 
both TDP-43
WT
 tdTomato and TDP-43
G124A
 EGFP presumably from donor cells, and were 
scored as EGFP/tdTomato red double-positive (dual fluorescence). These results suggest that 
TDP-43 is capable of transferring between cells in culture. However at 72 h, the percentage 
of dual fluorescent cells significantly decreased, compared to 24 h and 48 h time points. This 
is likely due to cellular toxicity associated with the presence of aggregates.  
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Figure 4.2 TDP-43WT or TDP-43G124A proteins can transfer from donor to recipient 
NSC-34 motor neurons.  Following transfection, using Lipofectamine 3000, NSC‐34 transiently transfected 
with TDP-43
WT
 tdTomato or TDP-43
G124A
 EGFP were either co-cultured or cultured separately for 24, 48 and 72 
h. NSC-34 cells cultured separately were mixed prior to analysis (control). Results shown as mean percentage of 
cells ± SEM, n = 3; 
**
P < 0.01 compared to control (mixed population of cells).  
4.3.2.1 TDP-43
G124A
 GFP can induce aggregation of TDP-43
WT
 tdTomato protein in co-
cultured NSC-34 motor neurons 
The above data implies that TDP-43 or more likely TDP-43 protein aggregates can transfer 
between co-cultured NSC-34 motor neurons. Thus, whether mutant TDP-43 aggregates can 
induce the aggregation of TDP-43
WT
 in a manner that could be described as seeding 
behaviour was next investigated (Figure 4.3). To test this, cells were either co-transfected 
with TDP-43
WT
 tdTomato and TDP-43
G124A
 EGFP or transfected separately and populations 
mixed or not (control), cells were lysed and aggregates counted by FLoIT. In particular, the 
number of TDP-43
WT
 inclusions were counted to identify and measure seeding activity 
induced by mutant TDP-43
G124A
 EGFP. To calculate the average number of inclusions per 
100 transfected cells in the populations analysed, the number of inclusions acquired is simply 
divided by the transfection efficiency (separately determined by flow cytometry) of the 
sample, which is then multiplied by the corresponding number of cell nuclei enumerated. An 
almost two-fold significant increase in the amount of TDP-43
WT 
tdTomato
 
inclusions detected 
in the co-transfected treatment compared to the corresponding control was observed from 48 
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to 72 h. This suggests that within individual cells mutant TDP-43
G124A
 induced the 
aggregation of TDP-43
WT
. Interestingly, the control treatment (in which separately 
transfected populations are mixed just prior to analysis) showed an increase in inclusions 
through time likely indicative of cellular stress. Importantly, co-culture of cells expressing 
TDP-43
G124A 
induced cells with TDP-43
WT
 to significantly increase the number of inclusions 
formed compared to controls consistent with a cell-to-cell propagation of misfolding and 
aggregation.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 FloIT detects inclusions containing dual fluorescence from NSC -34 cells 
Following transfection, using Lipofectamine 3000, NSC‐34 cells expressing TDP-43WT tdTomato or TDP-
43
G124A
 EGFP were subsequently co-cultured, co-transfected or cultured separately together for 24, 48 and 72. 
The number of inclusions obtained were enumerated by FloIT method means ± SEM, n = 3; 
**
P < 0.01 or
*
P < 
0.05 compared to corresponding treatment.  
 
4.3.3 Transiently expressed TDP-43
WT
 is observed deposited in the cytosol of NSC-34 
cells upon treatment with recombinant SOD1 protein aggregates  
TDP-43 redistribution and aggregation is observed in the cytoplasm of affected cells in a 
diverse set of neurodegenerative diseases. However, the contributing factors responsible for 
TDP-43 mislocalisation and aggregation remain ambiguous. Both SOD1 and TDP-43 have 
been implicated in fALS and sALS pathogenesis, although whether SOD1 aggregates 
contribute to TDP-43 pathology is yet to be established. Thus the presence of SOD1 
aggregates and deposition of TDP-43 proteins in the cytosol of NSC-34 cells was thus 
investigated. (Figure 4.5). To confirm whether exogenously added SOD1 aggregates have an 
effect on TDP-43 cytosolic mislocalisation and aggregation, purified human WT TDP-43-
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tomato red (TDP-43
WT
 tdTomato) plasmid DNA was used to transiently transfect NSC-34 
cells (Figure 4.4A). Post transfection, cells were incubated with either WT or mutant G93A 
SOD1 in both their aggregated and soluble state (Figure 4.4B). The percentage of cells 
containing mislocalised TDP-43 into foci that measured >1µm per treatment was determined 
by confocal microscopy (Figure 4.5A and B). Mislocalised TDP-43 by this definition 
included both TDP-43
WT
 cleared from the nucleus and TDP-43 that had accumulated in the 
cytosol even though some nuclear TDP-43
WT
 remained. A summary of the methods is 
outlined in Figure 4.4. 
 
 
 
 
 
 
 
 
Figure 4.4 Treatment of  NSC-34 cells with large SOD1 protein aggregates induces TDP-43 
mislocalisation and aggregation . Immunofluorescence labelling of SOD1 (green) and TDP-43
WT
 (red) 
neuronal cytoplasmic inclusions (NCIs) in NSC-34 cells. Confocal microscopy of transfected NSC-34 cells 
expressing TDP-43
WT
 TR were incubated in complete DMEM medium in the (A) absence (control) or (B) 
presence of WT or G93A SOD1 proteins in their aggregated or soluble form (20 μg/mL) for 72 h. Bars represent 
10 µm. Outline of cells are indicated with white dashed lines. TEM bar represents 50 nm.  
Confocal microscopy and quantitative analysis was performed (Figure 4.5). The addition of 
SOD1 protein aggregates to NSC-34 cells resulted in a rapid and significant increase in 
percentage of cells that contained mislocalised TDP-43
WT
 (Figure 4.5A) when treated with 
either WT (23±5%) or G93A SOD1 (25±4%) aggregates compared to the control cells 
(absence of protein treatment; % cells with aggregates). In contrast, while there was a 
significant increase in cells displaying mislocalised TDP-43
WT
 when incubated with soluble 
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G93A SOD1 (16±3%) there was no significant difference between control cells and those 
treated with soluble WT SOD1 (10±2%) of transfected cells with mislocalised TDP-43
WT
. 
Furthermore, little to no cells were observed to contain TDP-43
WT
 positive cytoplasmic 
inclusions without protein treatment at 2h. While cells incubated with aggregated G93A 
SOD1 aggregates had more TDP-43
WT
 inclusions than those incubated with soluble G93A, 
no significant differences were detected between them. In contrast, cells treated with WT 
SOD1 aggregates had significantly more TDP-43
WT
 aggregates when compared to soluble 
SOD1 protein (Figure 4. 5B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Cytosolic mislocalisation and aggregation of TDP-43
WT
 in NSC-34 cells is 
observed upon addition of the recombinant SOD1 protein aggregates at 2h.  
Immunofluorescence labelling of SOD1 (green) and TDP-43
WT
 (red) neuronal cytoplasmic inclusions (NCIs) in 
NSC-34 cells. (A) Confocal microscopy of transfected NSC-34 cells expressing TDP-43
WT
 tdTomato were 
incubated in complete DMEM medium in presence of WT or G93A SOD1 proteins in their aggregated or 
soluble form (20 μg/mL) for 2h. Bars represent 20 µm. Outline of cells are indicated with white dashed lines. 
(B) The percentage of NSC-34 cells containing TDP-43
WT
 positive aggregates was assessed by the number of 
cells containing mislocalised TDP-43
WT
 into foci that measured >1µm per treatment including both TDP-43
WT
 
cleared from the nucleus and TDP-43
WT
 that had accumulated in the cytosol even though some nuclear TDP-
43
WT
 remained, as determined by Image J. Results shown as means ± SD, n = 3; 
***
P < 0.001 and
 **
P < 0.01 
compared to corresponding control (TDP-43
WT
 tdTomato), 
†††
P < 0.001 compared to corresponding soluble 
protein form.  
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Given TDP-43 translocation can be a rapid response to stress (Zhang et al., 2014) that can be 
reversible (Liu-Yesucevitz et al., 2010), we next tested whether the TDP-43
WT
 
mislocalisation associated with SOD1 aggregate treatment persisted for 72 h (Figure 4.6). 
After the extended incubation with SOD1 aggregates, a large number of cells still exhibited 
mislocalised TDP-43
WT
, which appeared as larger clusters of aggregates or inclusion bodies, 
when assessed by confocal microscopy (Figure 4.6A).  
Incubation of aggregated SOD1, both WT and G93A, resulted in a significantly higher 
percentage of transfected cells with miscolcalised TDP-43
WT
 compared to the control cells 
(Figure 4.6B). Although, no significant difference was detected in the percentage of 
transfected cells with mislocalised TDP-43
WT
 when treated with the WT (24±7%) and G93A 
(27±7%) soluble proteins compared to the control cells, some cells were observed to contain 
large TDP-43
WT
 positive inclusions in the cytosol of the soluble G93A treated cells (as shown 
in Figure 4.5).  
In contrast to the 2 h experiment, a significant difference was found to exist between the cells 
that were treated with the soluble and the aggregated form of the mutant G93A protein. Thus, 
incubating the cells with the aggregated form of SOD1 had a significant effect on TDP-43
WT
 
extranuclear accumulation in NSC-34 cells. However, it is important to note that complete 
loss of normal nuclear staining was still not observed. Addition of SOD1 aggregates leads to 
a variety of aggregation states outlined in Figure 4.7. 
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Figure 4.6 Cytosolic mislocalisation and aggregation of TDP-43 in NSC-34 cells is 
observed upon treatment with recombinant SOD1 protein aggregates at 72 hr.  
Immunofluorescence labelling of SOD1 (green) and TDP-43
WT
 (red) NCIs in NSC-34 cells. (A) Confocal 
microscopy of transfected NSC-34 cells expressing TDP-43
WT
 TR were incubated in complete DMEM medium 
in the absence (control) or presence of WT or G93A SOD1 proteins in their aggregated or soluble form (20 
μg/mL) for 72 h. Bars represent 20 µm. Outline of cells are indicated with white dashed lines. (B) The 
percentage of NSC-34 cells containing TDP-43
WT
 positive aggregates was assessed by the number of cells 
containing mislocalised TDP-43
WT
 into foci that measured >1µm per treatment including both TDP-43
WT
 
cleared from the nucleus and TDP-43
WT
 that had accumulated in the cytosol even though some nuclear TDP-
43
WT
 remained, as determined by Image J. Results shown as means ± SD, n = 3;
 ***
P < 0.001 or 
**
P < 0.01 
compared to corresponding control (TDP-43
WT
 TR), compared to corresponding soluble protein form.  
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Figure 4.7 TDP-43 redistribution and aggregation in various states in  NSC-34 cells. (A) 
Under normal conditions, TDP-43 localisation is limited to the nucleus. (B) Under temporary cellular stress 
conditions, TDP-43 can be mislocalised from the nucleus, however some TDP-43 may remain in the nucleus. 
(C-D) Under abnormal conditions, complete loss of nuclear TDP-43 is observed, and large inclusions bodies 
positive for TDP-43 are observed in the cytoplasm. (E-F) Inclusion bodies, containing TDP-43 can also be 
present diffusely throughout the cell under pathological conditions. (G-I) Distinct inclusions bodies can also be 
found diffusely surrounding the nucleus. (J-L) Large distinct clusters of TDP-43 positive inclusions can 
accumulate in the cytoplasm (foci > 20µm). These images are examples of the scoring system for mislocalisaed 
and aggregated TDP-43. Bars represent 10 µm 
4.3.4 Recombinant mutant SOD1 can seed aggregation and induce inclusion formation 
in NSC-34 cells expressing TDP-43
WT
 tdTomato protein 
Given that the above data demonstrates that the addition of SOD1 protein aggregates to NSC-
34 cells resulted in a rapid and significant increase in percentage of cells that contained 
mislocalised TDP-43
WT
, FloIT was next employed to confirm seeding behaviour and quantify 
these findings. To investigate whether mutant SOD1 aggregates can induce the aggregation 
of TDP-43
WT
 in NSC-34 motor neurons, cells were transiently transfected with TDP-43
WT
 
tdTomato protein and incubated with human recombinant G93A mutant SOD1 aggregates for 
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either 24, 48 or 72 h (Figure 4.8). As outlined above, the number of inclusions per transfected 
cell was determined by flow cytometry using the FLoIT technique. A significant increase in 
the number of TDP-43
WT
 inclusions were identified from 24 to 72 h in cells incubated in the 
presence of mutant SOD1 aggregates compared to the corresponding cells in the absence of 
mutant SOD1 aggregates. This increase in inclusion formation was almost five fold from 24 
to 72 h. This is therefore indicative of significant seeding events associated with mutant TDP-
43 induced aggregation of SOD1
WT
 tdTomato in NSC-34 cells. 
 
 
 
 
 
 
Figure 4.8 SOD1 aggregates are capable of inducing significant aggregation in TDP -43WT 
expressing NSC-34 cells using the Flo-it method. Following transfection (24 , 48 and 72 h) using 
lipofectamine 3000, adherent NSC-34 cells transiently transfected with TDP-43
WT
 were co-cultured with 20 
μg/ml and aggregated G93A SOD1 at indicated time intervals at 37°C. Cells were harvested for supernatant 
analysis and then lysed. Cell lysates were incubated with RedDot2 for 2 min at RT. Transfection efficiencies, 
the number of inclusions and nuclei were determined by flow cytometry and results means ± SD, n = 3, 
*
P < 
0.05 compared to corresponding control (no protein treatment).  
4.3.5 TDP-43
WT
 cytosolic mislocalisation and aggregation induced by exogenous SOD1 
recombinant proteins is not limited to the NSC-34 cell line  
The work presented above suggests that exogenously added SOD1 proteins induce the 
mislocalisation of TDP-43
WT
 in the NSC-34 cell line. It was therefore of interest to examine 
if these effects are limited to the mouse motor neuron like cell line (NSC-34). Thus, human 
embryonic kidney (HEK-293) cells were used to further investigate the effect of exogenous 
SOD1 on cell produced TDP-43 (Figure 4.10). In this experiment, a plasmid encoding a 
human TDP-43
WT
 GFP fusion was used to transiently transfect HEK-293 cells and SOD1 
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aggregates were used unlabelled. Post transfection, cells were incubated with either 
aggregated WT or mutant G93A SOD1 for either 24, 48 and 72 h, or the same time frames in 
the absence of protein as a control. In addition, MG132, an inhibitor of proteasome activity, 
which has been shown to induce TDP-43 aggregation (van Eersel et al., 2011) was used as a 
positive control. A summary of the methods is outlined in (Figure 4.9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Recombinant SOD1 aggregates induce aggregation in HEK293 cells.  
Immunofluorescence labelling of TDP-43
WT
 (green) neuronal cytoplasmic inclusions (NCIs) in HEK293 cells. 
Transfected HEK-293 cells in culture medium expressing TDP-43
WT
 eGFP were incubated in (A) the absence 
(control) or (B) presence of protein aggregates (20 μg/mL) for 72 h or (C) mg132 (10 µM). Arrows represent 
area of TDP-43 aggregates. Bars represent 10 µm. Outline of cells are indicated with white dashed lines. TEM 
bar represents 50 nm.  
 
As shown in Figure 4.10, incubation with either the WT (34±4%) or G93A (32±3%) SOD1 
protein aggregates resulted in a significantly higher percentage of cells containing 
mislocalised TDP-43
WT
 at 24 h, compared to the control (19±2%). Similarly, after 48 h SOD1 
aggregate treatment resulted in an increase in the percentage of cells with mislocalised TDP-
43
WT
 (G93A 38 ±3 %, WT 35± 3%) relative to the control (20±3%). However, at 72 h, 
although there was a significant difference in the percentage of cells containing mislocalised 
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TDP-43
WT
 when treated with G93A (38 ±2 %) SOD1 aggregates compared to the control, 
there was no difference in the percentage of cells when compared to the 48 h period. 
Interestingly, in cells incubated with aggregated WT SOD1 there was a 5% decrease between 
the 48 and 72 h time points suggesting cells were recovering or that cells with inclusions had 
died. The positive control, MG132, induced TDP-43
WT
 cytoplasmic inclusions in a time 
dependant manner with an almost two-fold increase in the percentage of cells containing 
mislocalised TDP-43
WT
 between the 24 and 72 h time points (from 23±2% to 59.08±5%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Aggregate formation is also induced in human HEK-293 cells expressing TDP-
43WT GFP in the presence of recombinant SOD1 aggregates . (A) Transfected HEK-293 cells in 
DMEM/F12 expressing TDP-43
WT
 GFP were incubated in the absence (control) or presence of WT or mutant 
G93A SOD1 protein aggregates (20 μg/mL) for 24-72 h (as indicated). Bars represent 20 µm. Outline of cells 
are indicated with white dashed lines, arrows indicate TDP-43
WT 
positive
 
inclusions. (B) The percentage of 
HEK-293 cells containing TDP-43-positive inclusions was assessed by the number of cells containing 
mislocalised TDP-43
WT
 into foci that measured >1µm per treatment including both TDP-43
WT
 cleared from the 
nucleus and TDP-43
WT
 that had accumulated in the cytosol, as determined by Image J. Results shown as means 
± SD, n = 3; 
***
P < 0.001 or 
**
P < 0.01 or 
*
P < 0.05 compared to corresponding control (TDP-43
WT
 TR).  
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4.3.6 Exogenous recombinant SOD1 aggregates induce the cytosolic mislocalisation and 
fragmentation of endogenous TDP-43 in naive NSC-34 cells. 
Current understanding suggests that the accumulation of the truncated TDP-43 fragment; 
CTF25 is a pathological feature detected in proteinopathies. Since this fragment has been 
suggested to play a critical role in ALS pathogenesis, we investigated whether adding 
aggregated SOD1 to NSC-34 cells had any effect on the formation of CTF25. We have 
previously shown that exogenously-added recombinant SOD1 proteins are capable of 
entering into NSC-34 cells and escaping into the cytosol (Zeineddine et al., 2015). To begin 
to investigate the effect of SOD1 aggregates on TDP-43 location and truncation, a subcellular 
fractionation assay and western blot was carried out on NSC-34 cell lysates (Figure 4.11). 
Given that the response of NSC-34 cells to WT and mutant G93A SOD1 proteins were 
similar, in the following experiment NSC-34 cells were treated with exogenous soluble and 
aggregated WT SOD1 for 2 h. 
The presence of endogenous TDP-43 protein was then investigated by immunoblotting of the 
cytosolic, membrane (ER/Golgi), nuclear and cytoskeletal supernatant fractions. In the SOD1 
aggregate-treated fractions (Figure 4. 11A), TDP-43 was detected as a range of bands but 
predominantly as distinct bands at 43 kDa and ~25 kDa. In contrast to the untreated controls 
where TDP-43 is found in the nuclear fraction (Figure 4.11C), after treatment with SOD1 
aggregates TDP-43 is found in all the fractions. In the ME fraction additional bands were 
present at approximately 40 kDa and 18 kDa. The additional 40 kDa band was also present in 
the NE and PE supernatant fractions. Interestingly, the full length TDP-43 was predominantly 
cytosolic suggesting a rapid movement from the nucleus after SOD1 aggregate addition. In 
comparison, treatment with the WT SOD1 soluble protein (Figure 4.11B), resulted in the 
detection of only one band immunoreactive for endogenous TDP-43 in the NE fraction at 
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approximately 43 kDa similar to the untreated control with no evidence of bands at 25 kDa. 
To further confirm the purity of the supernatants, fractions were immunoblotted using an 
anti-actin, anti-EEA1 and anti-vimentin Ab (Figure 4.12D). These bands were detected in the 
ME fraction for EEA1 (180 kDa), vimentin (54 kDa) in the PE fraction and actin (42 kDa) as 
a loading control.  
 
 
 
 
 
 
 
 
 
Figure 4.11 Exogenous recombinant SOD1 proteins induce TDP-43cytosolic 
mislocalisation in NSC-34 cells.  Cytoplasmic extract (CE), membrane extract (ER/Golgi) (ME), nuclear 
extract (NE) and pellet extract (cytoskeleton) (PE) fractions by centrifugation from NSC-34 cells treated with 
either (A) WT SOD1 aggregates or (B) WT SOD1 soluble (20 μg/mL) or (C) no added protein were separated 
by SDS PAGE under reducing conditions, transferred to nitrocellulose membrane and incubated with anti-TDP-
43 and (D) control Ab anti-actin, anti-EEA1 or anti-vimentin Abs (as indicated). Results are representative of at 
least 6 experiments. 
 
 
 
 
 
 
 
 
 
 
 
160 
 
4.4 Discussion 
Mutations in the TDP-43 gene are found in sporadic and non-SOD1 familial ALS, 
implicating TDP-43 as a contributing factor to disease (Kabashi et al., 2008; Sreedharan et 
al., 2008). TDP-43 has previously been reported to spontaneously form aggregates that 
resemble TDP-43 deposits in degenerating neurons in ALS FTLD-U patients (Johnson et al., 
2009). Furthermore, previous studies have reported that in the TDP-43 protein sequence, the 
C-terminal domain is critical for spontaneous aggregation and therefore TDP-43 is 
intrinsically aggregation prone (Ivanova et al., 2014; Johnson et al., 2009). In addition, 
previous work indicates that ALS associated mutations in TDP-43 can increase the number of 
discrete aggregates in the cytoplasm of yeast (Johnson et al., 2009) suggesting that ALS 
mutations increase the aggregation propensity of TDP-43. The work presented here is 
consistent with this; inclusions were detected in cells expressing WT and mutant TDP-43, 
with mutation increasing inclusion formation. 
The in vivo cell-to-cell transmission of TDP-43 and induction of TDP-43 aggregation in 
recipient cells was observed in the current study. Similarly, the ability of TDP-43 to transfer 
between cultured SH-SY5Y (human neuroblastoma) cells in co-cultured experiments was 
demonstrated in another study, which found that phosphorylated TDP-43 aggregates could be 
released from donor cells and taken up into recipient cells (Nonaka et al., 2013). In addition, 
mutant TDP-43
G124A
 was shown to induce the aggregation of TDP-43
WT
 in NSC-34 motor 
neurons when co-cultured together. Similarly, conditioned media containing TDP-43–from 
cultured cells or lysates from ALS patient brain lysate have been shown to induce 
oligomerisation in recipient cells (Feiler et al., 2015). Furthermore, another study 
demonstrated that pathological TDP-43 aggregates from diseased brains exhibit prion-like 
properties when added to cultured cells containing plasmid-derived TDP-43 (Nonaka et al., 
 
161 
 
2013). In the latter study, detergent-insoluble TDP-43 prepared from cells containing TDP-43 
aggregates as well as seeds from brains were shown to induce the formation of self-
templating intracellular TDP-43 aggregation in cultured cells (Nonaka et al., 2013). These 
findings together therefore support a role for the prion-like seeding of mutant TDP-43 
induced aggregation of TDP-43
WT
.  
Consistent with misfolded SOD1 detected in sALS, previous work has demonstrated that WT 
SOD1 misfolding can be propagated cell to cell (Grad et al., 2014). Here we have shown that 
exogenously added large-SOD1 protein aggregates are capable of inducing the cytoplasmic 
mislocalisation and accumulation of cytosolic TDP-43 in both the motor neuron-like cell line 
(NSC-34 ) and in human embryonic kidney cells (HEK-293). Furthermore, the present study 
demonstrates that the addition of large SOD1 aggregates induces rapid fragmentation of 
TDP-43 in the cytoplasmic fraction of NSC-34 cells. Collectively, this suggests that 
exogenous SOD1 protein aggregates are capable of stimulating TDP-43 pathology through an 
unknown mechanism(s), resulting in their redistribution, fragmentation and aggregation, 
similar to what has been observed in most cases of ALS (Arai et al., 2010; Correia et al., 
2015; Nonaka et al., 2009a; Pokrishevsky et al., 2012). 
An association between misfolded and/or aggregated SOD1 and TDP-43 mislocalisation has 
been previously suggested. For example, a study has reported that TDP-43 cytoplasmic 
mislocalisation and deposition into ubiquitin immunoreactive inclusions were observed in 
lower motor neurons of end stage mutant SOD1 transgenic mice (Shan et al., 2009). In 
addition to this, misfolded human WT SOD1 has been observed in association with cytosolic 
accumulation of mutant TDP-43 in TDP-43-fALS and WT TDP-43 in sALS (Pokrishevsky et 
al., 2012). It has been suggested that mutant TDP-43 may indirectly induce the propagation 
of WT SOD1 misfolding in fALS and sALS (Pokrishevsky et al., 2012). Given that the 
 
162 
 
aggregation of TDP-43 and SOD1 appear to be distinct processes with structurally and 
morphologically discrete aggregates (Farrawell et al., 2015), it is unlikely that one will seed 
aggregation of the other in a conventional manner and therefore must be explained by an 
alternate mechanism, possibly through exerting stress. 
The deposition of TDP-43 into the cytoplasm of NSC-34 cells was dependant on the length of 
time exposed to the SOD1 aggregates. The 2 h incubation with SOD1 aggregates was 
sufficient to induce aberrant TDP-43 mislocalisation in a proportion NSC-34 cells. Further, 
we have shown using a subcellular fractionation assay on NSC-34 cells at 2 h treated with 
SOD1 aggregates, that a distinct truncation product at ~25 kDa, was present in the 
cytoplasmic fraction as previously reported in sALS and SOD1-negative fALS (Kwong et al., 
2008; Mackenzie et al., 2010; Neumann et al., 2006).  
In contrast, after 72 h incubation with SOD1 aggregates TDP-43 mislocalisation was 
observed in a significantly higher percentage of cells; equating to an almost two fold increase 
for the WT SOD1 and the G93A aggregate treated cells from 2 to 72 h. This effect may be 
due to the stress imposed on cells by the uptake of SOD1 aggregates (Stieber et al., 2000), 
consistent with a direct relationship between SOD1 aggregates and cellular toxicity that has 
been previously reported (Bruijn et al., 2004; Cleveland and Rothstein, 2001). Similarly, 
incubation with SOD1 aggregates induced similar pathological features in HEK-293 cells. 
However, the effect was apparent at 24 h and changed little in over 72 h incubation period. 
The cell type specific differences may reflect differences in proteostasis capacity between 
different cell types; neurons have a relatively high threshold for inducing the heat shock 
response (Yerbury et al., 2016). Regardless, while there is a clear effect of SOD1 aggregate 
uptake on TDP-43 distribution the precise mechanism underlying this remains unclear.  
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Cytoplasmic accumulation of WT TDP-43 as a local response to injury or cell stress has been 
previously described in sporadic ALS (Liu-Yesucevitz et al., 2010). In addition to this, 
misfolded and aggregated WT and mutant SOD1 are well known to induce ER stress and 
dysfunction and stress granule formation in cell culture (Nishitoh et al., 2008), rodent ALS 
models at symptom onset and disease end stage and human ALS patients (Atkin et al., 2006; 
Atkin et al., 2008; Ilieva et al., 2007; Kaus and Sareen, 2015; Saxena et al., 2009). 
There is evidence that the uptake of extracellular misfolded WT and mutant G93A SOD1 into 
human and mouse neuronal cells causes disruptions to protein transport between the ER and 
Golgi apparatus, resulting in ER stress, Golgi fragmentation, and subsequent apoptotic cell 
death (Sundaramoorthy et al., 2013). ER stress is activated when proteins accumulate within 
the ER lumen, thus triggering the unfolded protein response (UPR), which in turn may lead to 
cellular apoptosis if unresolved (Atkin et al., 2014). There is a strong link between ALS 
pathology and ER stress (Walker and Atkin, 2011) and it has been proposed that prolonged 
ER stress leads to motor neuron death in ALS (Walker and Atkin, 2011). While generally the 
unfolded protein response activated by ER stress is a protective response able to rescue cells 
from proteotoxicity, in the ALS context this can lead to further aggregation of ALS 
associated proteins such as TDP-43 (Suzuki et al., 2011). Taken together, these data are 
consistent with the idea that ER stress caused by uptake and maintenance of SOD1 
aggregates may trigger TDP-43 mislocalisation and accumulation.  
In fact, TDP-43 mislocalisation is a common response to a variety of stressors including 
oxidative stress (Colombrita et al., 2009), heat shock stress (Chang et al., 2013), and 
proteosomal stress (Scotter et al., 2014). Indeed extranuclear accumulation of WT TDP-43 
has been shown to be a common pathology in sALS, FTLD and Alzheimer’s disease, and 
therefore may be a general consequence of cellular stress (Wilson et al., 2011). Interestingly, 
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exogenously applied Aβ amyloid aggregates associated with Alzheimer’s disease have also 
been shown to induce TDP-43 mislocalisation (Herman et al., 2011) suggesting that uptake of 
any aggregate regardless of which protein they are made from might be enough to trigger 
TDP-43 mislocalisation.  
In conclusion, the work presented here demonstrates that TDP-43 can form aggregates 
spontaneously, transfer between cells in culture and induce the misfolding of their WT 
counterpart, similar to that reported for SOD1 and prions. In addition, the work presents 
findings to support the notion that aggregates made from SOD1 are able to induce TDP-43 
mislocalisation and rapid fragmentation consistent with TDP pathology observed in sporadic 
disease. However, the exact mechanism(s) for this observation were not determined. It is 
likely that the stress induced by aggregate uptake was enough to trigger the mislocalisation of 
TDP-43. However, it should be noted that a high concentration (20 µg/ml) of large SOD1 
protein aggregates were used in the current study to induce TDP-43 pathology, as 
demonstrated above. This concentration is higher than that used in a number of similar 
studies (Münch et al., 2011; Nonaka et al., 2013) and in vivo. Future investigations into the 
mechanism(s)/role of SOD1 aggregates on the formation of pathological TDP-43 are 
therefore warranted. 
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Chapter 5  
 
THE ABILITY OF PROTEIN 
AGGREGATES TO TRIGGER 
MACROPINOCYTOSIS IS 
GENERIC 
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5.1 Background 
Amyotrophic Lateral Sclerosis (ALS) is characterised by the selective death and degeneration 
of upper and lower motor neurons (Cleveland and Rothstein, 2001). There is now significant 
evidence that protein aggregation is linked closely to motor neuron death in ALS 
(Abdolvahabi et al., 2016; Sundaramoorthy et al., 2013; Walker et al., 2013). In addition, 
other common neurodegenerative diseases, including Alzheimer’s, Tauopathies such as 
Frontotemporal Dementia, Parkinson’s, Huntington’s diseases, and transmissible spongiform 
encephalopathies (TSEs), have common pathological changes such as loss of neurons and the 
presence of pathological protein aggregates into either intracellular inclusions bodies or 
extracellular plaques. Although the peptides and proteins that aggregate are unrelated in 
terms of their native structure, often the resulting deposits are very similar, sharing a rope-
like fibrillar morphology, a common cross-β core structure, and the ability to bind specific 
dyes such as thioflavin T and Congo red (Dobson, 2003). In addition, these common 
neurodegenerative diseases, including ALS, exhibit distinctive anatomical patterns of disease 
progression which are consistent with a spreading of pathology between nearby cells and 
remotely connected regions of the brain along axonal pathways (Brettschneider et al., 2015; 
Brundin et al., 2010). These patterns are consistent with the propagation of the protein 
misfolding, aggregation and spread reminiscent of those underpinning prion disease. 
(reviewed in Zeineddine and Yerbury, 2015). Furthermore, proteins known to aggregate in 
these disorders including 𝛽-amyloid, tau, α-synuclein and proteins with polyQ expansions are 
suggested to propagate the misfolding of their native soluble counterparts (see Aguzzi and 
Calella, 2009; Brundin et al., 2010). In addition, it has been shown that these protein 
aggregates can enter into cells, cross cellular membranes to transmit pathogenic proteins in a 
‘prion-like’ manner through the triggering the misfolding of their normally structured 
counterparts in cells, tissues, and animal models (Brettschneider et al., 2015).  
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In order to facilitate the propagation of intracellular aggregation in neurodegenerative 
diseases, such as ALS, Parkinson’s, Alzheimer’s and Huntington’s diseases, active aggregate 
nuclei or seeds must gain access to the cytosol of naïve cells. Active nuclei could be large 
aggregates such as those macroscopically visible accumulating in neurons (> 2 microns in 
size) or small soluble oligomeric aggregates that might diffuse between cells. Fibrillar 
aggregates are generally 1-20 nanometre across and can be hundreds of nm long and large 
aggregates that accumulate many fibrils in cells can be several micrometres in diameter. 
Thus, given that neurons are not professional phagocytes it would be reasonable to assume 
that endocytosis of protein aggregates by neurons would be almost impossible.  
A role for macropinocytosis in the uptake of protein aggregates associated with various 
neurodegenerative diseases has been highlighted in several studies and the work presented in 
earlier chapters (Grad et al., 2014; Holmes et al., 2013; Münch et al., 2011; Sundaramoorthy 
et al., 2013). The study on the propagation of SOD1 aggregation by Münch et. al (2011) was 
the first to demonstrate that mutant SOD1 ALS protein aggregates enter into N2A cells via 
endocytic vesicles mediated by ATP and lipid raft dependent macropinocytosis (Münch et al., 
2011). The study utilised a wide panel of inhibitors of a range of cellular functions to identify 
potential pathways of endocytosis specific for SOD1 (Münch et al., 2011). Subsequently, 
these results were confirmed by an additional study which showed that uptake of both 
extracellular wildtype and mutant SOD1 soluble forms into NSC-34 cells can be inhibited by 
small molecule inhibitors of macropinocytosis EIPA and rottlerin (Sundaramoorthy et al., 
2013). Similarly, EIPA was shown to inhibit the uptake of human WT SOD1 aggregates into 
NSC-34 cells (Grad et al., 2014) consistent with macropinocytosis. EIPA 
(ethylisopropylamiloride) is an analogue of amiloride that is an inhibitor of Na
+
/H
+
 
exchangers. EIPA is well-recognised as specific to macropinocytosis (compared to other 
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forms of endocytosis) as a result of the susceptibility of GTPases such as RAC1 to pH 
changes (Koivusalo et al., 2010).  
More broadly, uptake and cell-to-cell transmission of α-synuclein into neurons has been 
shown to be mediated via an unconventional endocytosis (Desplats et al., 2009; Lee et al., 
2008). Also, while initially synthetic polyQ fibrils were proposed to enter cells via direct 
penetration of the lipid bilayer (Ren et al., 2009) recently cell surfaces structures have been 
implicated in the binding and internalisation of both synthetic polyQ (K2Q44K2) and 
huntingtin exon 1 Q44 (Htt exon1Q44) fibrils suggesting a role for endocytosis mediated 
uptake (Trevino et al., 2012). Further, exogenously added AD associated-recombinant Tau 
fibrils have also been shown to be taken up by cultured cells in a process consistent with 
pinocytosis suggested by the co-localisation of Tau aggregates with Dextran, a marker of 
fluid phase endocytosis (Frost et al., 2009). In support of these findings, a recent study was 
able to show that small misfolded Tau species are also internalised through the process of 
bulk endocytosis (Wu et al., 2013). Further to this, uptake of fibrillar Tau into C17.2 cells 
(mouse neural stem cells) could be inhibited by both amiloride and rottlerin consistent with 
macropinocytosis (Holmes et al., 2013). The same study demonstrates that Tau fibrils could 
be observed in vacuoles and invaginations with diameters of approximately 5 μm also 
consistent with macropinocytosis. Lastly, in a result that suggests stimulated 
macropinocytosis has been activated, the uptake of the fluid phase marker dextran was 
increased with increased doses of Tau fibrils (Holmes et al., 2013). This uptake could be 
inhibited by suppressing cell binding of Tau fibrils by blocking binding to heparan sulfate 
proteoglycans, indeed this also blocked uptake when aggregates were injected in to the brains 
of mice (Holmes et al., 2013). However, how the binding to heparan sulfate proteoglycans on 
the cell surface relate to activation of macropinocytosis remains unclear.  
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The fact that neurons can engulf large particles such as protein aggregates seems 
counterintuitive. Macropinocytosis of large particles is usually thought of as restricted to 
professional phagocytes such as macrophages and microglia. This endocytic pathway is 
useful for engulfment of viral particles, bacteria, and fragments of dying cells in order to 
degrade and remove them from the cell. Without extensive degradation machinery, such as in 
macrophages, neurons are seemingly left vulnerable with the ability to take up large particles 
whilst not built to remove them. Irrespective of the ability of neurons to perform such a 
function, it is unlikely that neurons have evolved to specifically endocytose pathogens and 
large protein aggregates. Although, several viruses are known to enter neurons via 
macropinocytosis (Hollidge et al., 2012; Kalia et al., 2013; Talekar et al., 2011), this is likely 
due to the hijacking of machinery involved in macropinocytosis evolved for other purposes.  
Macropinocytosis, or closely related processes, are thought to regulate growth cone 
membrane recycling and is an integral part of growth cone collapse and axon retraction and 
turning during development and injury (Jurney et al., 2002; Kabayama et al., 2011; Kolpak et 
al., 2009; Tom et al., 2004). The membrane recycling process in growth cones is associated 
with actin-dependent membrane ruffles that fuse back on the plasma membrane creating large 
pinosomes dependent on PI3K and RAC1; all characteristic of macropinocytosis. Upon 
synaptogenesis this process is supressed, consistent with the idea that mature neurons do not 
undergo bulk changes in the membrane via macropinocytosis. However, axonal injury in in 
vivo and in vitro models triggers axonal remodelling in adult neurons that is associated with 
large amounts of fluid uptake (Tom et al., 2004) consistent with macropinocytosis. 
Interestingly, some disease associated mutations such as those in ALS2 (Amyotrophic lateral 
sclerosis) and γPKC (Spinocerebellar ataxia 14) result in dysregulation of macropinocytosis 
(Otomo et al., 2008; Yamamoto et al., 2014) suggesting dysfunction of these processes are 
detrimental to large neurons. In addition, a cell culture model of methamphetamine toxicity 
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suggested that meth induced over stimulation of macropinocytosis could lead to lysosomal 
exhaustion and cell death (Nara et al., 2012).  
Most protein aggregation studies associated with these neurodegenerative disorders to date 
have been performed in vivo or in vivo using rodent models of ALS. However, given the 
unnatural (induced) nature of the ALS-like disease in rodents and differences between 
rodents and humans, there is a need for more applicable human models. Humanised models 
of ALS have been generated in the last few years, through the use of reprogramming biology 
and development of humanised models of ALS has been established. The generation of 
patient specific induced pluripotent stem cells (iPSCs) derived from reprogrammed somatic 
cells from a range familial and sporadic ALS patients now represent a more effective disease 
model of ALS (Hedges et al., 2016; Lee and Huang, 2015). A range of disease-relevant cell 
types including neurons and motor neurons can be differentiated from human induced 
pluripotent stem cells which can be used to study pathogenic mechanisms and elucidate 
specific drug targets. 
4.1.1 Aims 
Results presented in Chapter 2 indicate that SOD1 aggregates enter NSC-34 cells via 
macropinocytosis. Here, this work aimed to determine if activation of macropinocytosis by 
protein aggregates was a generic phenomenon. To test this, aggregates found to trigger 
macropinocytosis in cell lines were tested on human neurons, both iPSC derived motor 
neurons and primary neurons. In addition, given the generic role of protein aggregates 
associated with other neurodegenerative diseases in mediating disease progression, such as 
TDP-43, huntingtin and α-synuclein, this work aimed to further investigate the mechanisms 
of uptake and further characterise the activation of macropinocytosis by these protein 
aggregates into NSC-34 motor neurons. Lastly, this study aimed to confirm that activation of 
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macropinocytosis was not limited to specific disease associated protein species by using the 
non-disease protein α-lactalbumin in its amorphous and fibrillar aggregation state. 
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5.2 Methods 
5.2.1 Reagents and Antibodies  
DMEM/F-12 medium, DMEM/F-12 without phenol red, Neurobasal Medium, B-27 
supplement, Glucose powder, 0.05% trypsin-EDTA, GlutaMAX, SuperSignal West Pico 
Chemiluminescent Substrate, SYTOX Red dead cell stain, FM
®
 1-43FX, fixable analog of 
FM
® 
1-43 membrane stain, 10 kDa 647-dextran, Image-iT ™ LIVE Red caspase detection kit 
Laminin, fibronectin and Lab-Tek chambered coverglass 8 well with cover were purchased 
from ThermoFisher Scientific (Waltham, USA). Any kD Mini-PROTEAN TGX Precast 
Protein Gels and Precision Plus Protein dual color protein standard were from Bio-Rad 
(California, USA). Foetal Bovine Serum (heat-inactivated prior to addition in media; FBS) 
was from Bovogen Biologicals (East Keilor, Australia). Amersham Hyperfilm was obtained 
from GE Healthcare (Buckinghamshire, UK)). RedDot 2 was from Biotium (Hayward, CA). 
Sterile cell culture plates were from Greiner Bio-One (Frickenhausen, Germany). Casein 
(heat denatured before use; HDC), dimethyl sulfoxide (DMSO), bovine serum albumin 
(BSA), β-mercaptoethanol, Brilliant blue R concentrate, paraformaldehyde (PFA), 
biotinamidohexanoic acid 3-sulfo-N-hydroxysuccinimide ester sodium salt, Bicinchoninic 
Acid Kit, Glutaraldehyde solution (50% in H2O), Propidium iodide, Osmium tetroxide 
solution (4 WT. % in H2O) and dithiothreitol (DTT) were from Sigma-Aldrich (St. Louis, 
MO). Ethylenediaminetetraacetic acid (EDTA) was from Amresco (Solon, USA). Digitonin, 
High Purity was from Calbiochem was from San Diego, CA, USA. Uranyl acetate and 19 
mm glass coverslips were from ProSciTech (Kirwan, Australia). mRNA was purchased from 
Miltenyi Biotec Australia (Macquarie Park, Australia) (Protease inhibitor cocktail tablets 
(complete, Mini, EDTA-free) was from Roche Diagnostics (Penzberg, Germany). RAC1 G-
LISA Activation Assay Kit (Colorimetric Based) was purchased from Cytoskeleton (Denver, 
CO). ISOLATE II RNA Mini Kit was purchased from Bioline (Alexandria, Australia). 
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Reagents for cDNA preparation were obtained from Promega (USA). All other reagents 
including salts, powders and chemicals were from Amresco, Sigma-Aldrich or Astral 
Scientific (Gymea, Australia). All reagents used were endotoxin free. Antibodies (Abs) and 
inhibitor compounds and their respective manufacturing companies used in this current study 
are listed in Table 5.1 and Table 5.2 respectively. 
Table 5.1 Antibodies used in this study to investigate the effect of SOD1 proteins on TDP-43 
pathology 
Host species 
(clonality)
1
 
Anti-body target 
(Immunogen)
2
 
Conjugate Manufacturer 
(product number)
3
 
Sheep (pAB) SOD1 - ThermoFisher Scientific 
(PAI-30817) 
Mouse (mAb)  RAC1 - Cytoskeleton 
(ARC03) 
Rabbit (mAb) Islet 1 - Abcam [EP4182] 
(ab109517) 
Mouse (mAb) SMI32 - Abcam (ab73273) 
Mouse (mAb) Human OCT4 Alexa Fluor 488 STEMCELL Technologies 
Australia (3A2A20) 
Goat (pAB) Mouse IgG Alexa Fluor 488 ThermoFisher Scientific A-
(11001) 
Goat (pAB) Rabbit IgG Alexa Fluor 488 ThermoFisher Scientific 
( A-11008) 
Donkey (pAb) Sheep IgG Alexa Fluor 488 Abcam (150177) 
Goat (pAb) Mouse IgG Alexa Fluor 633 ThermoFisher Scientific 
( A-21052) 
Donkey (pAb) Sheep IgG HRP Abcam (97125) 
Goat (pAb) Mouse IgG HRP Merck Millipore (12-349) 
1
 pAb, polyclonal anti-body, mAb, monoclonal anti-body; 3 Abcam, Cambridge, USA; ThermoFisher Scientific 
(Waltham,MA, USA); BD Biosciences San Jose, CA, USA; Merck Millipore, Billerica, Massachusetts, USA; Cytoskeleton 
(Denver, CO,USA), STEMCELL Technologies Australia, Tullamarine, VIC, Australia.  
 
Table 5.2 Pharmacological inhibitors used in this study to investigate the mechanisms of SOD1 
uptake 
Compound Manufacturer 
(product number)
1
 
5-N-ethyl-N-isopropyl-amiloride (EIPA) Sigma (A3085) 
Chlorpromazine hydrochloride (Chlorp HCL) Sigma (C8138) 
Genistein (Gen) Sigma (G6649) 
Rottlerin (Rot) Sigma (R5648) 
 RAC1 inhibitor W56 Tocris Bioscience (2221) 
1
Sigma, (St. Louis, MO, USA), Tocris Bioscience (Avonmouth, Bristol,UK) 
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5.2.2 Cell Lines  
The mouse neuroblastoma x spinal cord hybrid cell line (NSC-34 cells) (Cashman et al., 
1992) were routinely cultured in DMEM/F12 supplemented with 10% (v/v) FBS and 2 mM 
GlutaMAX. Cells were maintained in an incubator at 37°C under a humidified atmosphere 
containing 5% (v/v) CO2. Human primary neurons were cultured from 14 to 18 week foetal 
brains collected after therapeutic termination with informed consent and were prepared with 
the approval from Human Ethics Committees at the Universities of Sydney and New South 
Wales (Sydney, Australia), as previously described (Guillemin et al., 2005). Briefly, neurons 
were isolated from mixed foetal brain cells using a neuron isolation kit (Miltenyi Biotec, 
Australia). Human primary neurons were plated in culture flasks coated with Matrigel (BD 
Biosciences, CA) (1/20 in Neurobasal medium) for an hour at 37°C prior to seeding. Cells 
were maintained in neurobasal medium supplemented with 2% B-27 supplement, 2 mM 
Glutamax, and 5 mM glucose (complete medium) at 37
o
C at 5% CO2. Cells were cultured in 
complete medium for up to 10 weeks. The medium was changed once a week. 
Human fibroblasts were sourced from non-ALS individuals (female aged 62 and male aged 59 
at the time of collection) and reprogrammed into induced pluripotent stem cells using mRNA 
(Miltenyi Biotec, Australia). Pluripotency was confirmed by PluriTest Bioline RNA 
purification kit Genea and differentiation of the cells (Muller et al., 2011). Karyotyping was 
carried out in iPSCs, to ensure chromosomal abnormalities were not introduced during 
reprogramming and culture. Immunocytochemistry confirmed the expression of the 
pluripotency marker Oct4 (STEMCELL Tech). Differentiation of pluripotent stem cells into 
motor neurons was carried out as in (Bilican et al., 2014) and one clone from each line was 
used in experiments. Motor neurons (1.5 x 10
4
 cells/ well) were plated onto laminin (20 
µg/mL) and fibronectin (10 µg/mL) coated 13 mm coverslips. The timeline (Figure 5.1B) 
summarizes the differentiation stages and the growth factor conditions used during 
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differentiation. The morphological changes of each cell line were examined at each stage of 
the differentiation process. 
Confirmation of motor neuron phenotype was carried out, including expression analysis by 
quantitative reverse transcription PCR and immunocytochemistry. The differentiated neurons 
expressed the motor neuron specific markers neurofilament heavy and islet 1. 
Immunocytochemistry identified the presence of extended dendrites ~100 µm in length. 
Quantitative reverse transcription PCR analysis identified the expression of the motor neuron 
specific gene MNX1 (that encodes the transcription factor homeobox 9, HB9) (Arber et al., 
1999). MNX1 was specifically expressed in motor neurons and MNX1 was silent in 
pluripotent stem cells. The cholinergic specific marker acetylcholine esterase (ACHE that 
encodes the enzyme responsible for the degradation of the neurotransmitter acetylcholine) 
was expressed in cholinergic motor neurons. The expression levels for both MNX1 and 
ACHE, were normalized to the housekeeper gene GAPDH.  
5.2.3 Fixed cell antibody staining of iPSCs.  
The iPSCs were plated on matrigel-coated 8 mm coverslips at a density of 2.5x 10
4
 cells/cm
2
 
and cultured for 3 days prior to staining. Cells were fixed with 4% PFA in PBS for 20 min at 
RT and washed twice with PBS over 5 min. Cells were washed once with ice-cold PBS and 
then incubated with 0.5% Triton-X 100 for 30 min at 4°C. Cells incubated with blocking 
solution (5% BSA) for 20 min at RT. The iPSC colonies were incubated with anti- Oct3/4 
IgG Ab (1:500 diluted in 4% BSA and 0.1% Triton X-100) overnight at 4°C. Cells were 
washed again in ice cold PBS and incubated with anti-mouse IgG conjugated to Alexa Fluor 
488 (1:1000 diluted in 1% BSA and 0.1% Triton X-100) for 1 h at RT protected from light. 
An inverted microscope (DM IBRE) and a Leica TCS SP confocal imaging system were used 
to visualise and image cells (excitation 488, emission collected at 520-545 nm). 
 
176 
 
Fluorescence, bright field (differential interference contrast; DIC) and merged images were 
captured using Leica confocal software. 
5.2.4 Fixed cell antibody staining of motor neurons.  
Cells were plated on coverslips coated with laminin (20 µg/mL) and fibronectin (10 µg/mL) 
at a density of 4.2 x 10
4
 cells/cm
2
. Cells were fixed with 4% PFA in PBS for 20 min at RT 
and washed twice with PBS over 5 min. Cells were washed once with ice-cold PBS and then 
incubated with 0.5% Triton-X 100 for 30 min at 4°C. Cells incubated with blocking solution 
(5% BSA) for 20 min at RT. Cells were incubated with anti- NFH (SMI32) IgG Ab (1:800 
diluted in 4% BSA and 0.1% Triton X-100) overnight at 4°C. Cells were washed again in ice 
cold PBS and incubated with anti-mouse IgG conjugated to Alexa Fluor 488 (1:1000 diluted 
in 1% BSA and 0.1% Triton X-100) for 1 h at RT protected from light. An inverted 
microscope (DM IBRE) and a Leica TCS SP confocal imaging system were used to visualise 
and image cells (excitation 488, emission collected at 520-545). Fluorescence, bright field 
(differential interference contrast; DIC) and merged images were captured using Leica 
confocal software. 
5.2.5 Quantitative RT-PCR 
RNA was extracted and purified from differentiated cell using the ISOLATE II RNA Mini 
Kit (Bioline, USA), as per manufacturer’s instructions. The purified RNA was quantified 
using NanoDrop 2000c dual‐mode UV‐Vis Spectrophotometer (ThermoFisher Scientific). 
RNA was reverse transcribed into complementary DNA (cDNA) for subsequent analysis. 5 
µg of purified RNA was annealed to random primers (0.75 µg) and oligo dT primers (0.75 
µg) by incubating at 65°C for 4 min, followed by 1 min incubation on ice. For reverse 
transcription, Moloney-murine leukaemia virus reverse transcriptase (M-MLV RTase) (150 
U), 96 nmol dNTPs, RNasin (60 U) and 1x MMLV RTase Buffer were added to the reaction 
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mixture and then incubated at 37 ºC for 100 min. Primers used in Chapter 5 for qRT-PCR 
were obtained from Sigma Aldrich (USA) (unless stated otherwise) and sequences are 
outlined in Table 5.3. 
Table 5.3 Primers used in Chapter 5 for qRT-PCR had the following sequences:  
Gene Forward Reverse 
Acetylcholinest
erase (AChE) 
5’-
GGAACCGCTTCCTCCCCAAAT
TG-3’ 
5’-
TGCTGTAGTGGTCGAACTGGTTCTTC-
3’ 
Homeobox 9 
(MNX1) 
5’-
GTTCAAGCTCAACAAGTACC-
3’ 
5’-GGTTCTGGAACCAAATCTTC-3’ 
GFAP 5’-
CTGGATCTGGAGAGGAAGATT
GAGTCG-3’ 
5’-
CTCATACTGCGTGCGGATCTCTTTCA-
3’ 
glyceraldehyde 
3-phosphate 
dehydrogenase 
GAPDH 
5’-
GAGCACAAGAGGAAGAGAGA
GACCC-3’ 
5’ 
GTTGAGCACAGGGTACTTTATTGATG
GTACATG-3’ 
 
The final qRT-PCR reaction consisted of 10 µL of SYBR Select Master Mix, 800 nM of each 
forward and reverse primer, 2 µL of cDNA in a final reaction volume of 20 µL. Each reaction 
was run in duplicate and a negative control (water) and no reverse transcription (RNA) 
control was included as well as a positive control using cDNA of human putamen. The 
amplification consisted of 40 cycles, of 95ºC for 15 s (activation step), 58ºC for 15 s 
(annealing step) and 72ºC for 1 min. A melting curve analysis was conducted to confirm the 
presence of the appropriate amplified target. The acquired data was normalized against 
quantitative expression levels of the housekeeping gene GAPDH and analyzed using the 
comparative threshold cycle method. 
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5.2.6 Aggregation and biotinylation of SOD1, Httex146Q, α-synuclein, TDP-43, and α-
lactalbumin aggregates  
WT and G93A SOD1 were purified and labelled as outlined in section 2.3.3. Proteins α-
synuclein and α-lactalbumin protein aggregates were kindly provided by Dr Heath Ecroyd 
(University of Wollongong, Wollongong, Australia). TDP-43 was produced by Melbourne 
Protein Production Unit (Monash University) and kindly provided by Natalie Farrawell. 
Monomeric Httex146Q-Cerulean-MBP fusion protein was kindly provided by Danny M. 
Hatters (The University of Melbourne, Melbourne, Australia). Monomeric Httex146Q-
Cerulean-MBP fusion protein aggregation of Httex146Q was performed as previously 
described (Ramdzan et al., 2010). Briefly, Httex146Q-Cerulean-MBP was thawed from frozen 
stocks, diluted to 9 μM, and rapidly mixed with a 1/20 stock of TEV protease. After 15 min 
incubation at RT, the resulting cleaved fusion protein (Httex146Q-Cerulean) was diluted to 2 
µM and divided into single use aliquots, snap frozen in liquid nitrogen and stored at -80°C 
for later use in experiments.  
5.2.7 Transmission electron microscopy of Httex146Q, α-synuclein, TDP-43, and α-
lactalbumin RCM and amorphous protein aggregates 
Negative staining transmission electron microscopy (TEM) was performed as outlined in 
section 2.2.5. Briefly, 2 µl aliquots of Httex146Q, α-synuclein, TDP-43, and α-lactalbumin 
RCM and amorphous proteins (1 mg/ml) were loaded onto carbon-coated nickel grids for 1 
min at RT, washed 3 times with filtered Milli-Q water and negatively stained using 2% (w/v) 
uranyl acetate diluted in Milli-Q water for 2 min at RT. Grids were then dried and stored until 
processing. Protein structure and morphology was then analysed using a JEOL 2011 TEM 
(Tokyo, Japan) operated at 200kV. Images were taken using Gatan Microscopy Suite 
(Version 2.30.542.0) (California, USA). 
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5.2.8 Httex146Q, α-synuclein, TDP-43, and α-lactalbumin RCM and amorphous 
aggregated protein detection in NSC-34 cells by confocal microscopy  
NSC-34 cells (2–3 x 10
4
 cells/0.2 ml/chamber) were cultured in chamber slides at 
37°C/5%CO2 overnight. Briefly, cells were incubated with 20 μg/ml of biotin-conjugated 
aggregates of Httex146Q, α-synuclein, TDP-43, α-lactalbumin RCM and amorphous proteins 
or PBS (no protein, control) for 2 h at 37°C. Cells were fixed with 4% PFA, incubated with 
Triton X-100 and blocked for detection with 1 µg/ml Alexa Fluor 488 streptavidin (diluted in 
1% BSA and 0.1% Triton X-100) for 1 h at RT protected from light. An inverted microscope 
(DM IBRE) and a Leica TCS SP confocal imaging system were used to visualise and image 
cells (excitation 488, emission collected at 520-545 nm). Fluorescence, bright field 
(differential interference contrast; DIC) and merged images were captured using Leica 
confocal software. 
5.2.9 Fluid phase uptake assays  
Fluid phase uptake assay was performed as outlined in section 2.2.17. Briefly, NSC-34 cells 
(2–3 x 10
4
 cells/0.2 ml/chamber) were incubated with 20 µg/ml of Httex146Q, α-synuclein, 
TDP-43, α-lactalbumin RCM and amorphous aggregates in PBS alone or a positive control, 
200 nM PMA, for 30 min. Prior to harvesting or fixation, cells were then co-incubated for 15 
min with 0.5 mg/ml 10 kDa dextran conjugated to Alexa Fluor 647 (10 kDa 647-dextran) at 
37°C/5% CO2. The cells were then placed on ice, washed three times with ice cold PBS and 
once with low pH buffer (0.1 M sodium acetate, 0.05 M NaCl, pH 5.5) for 10 min. The cells 
were then fixed with 4% PFA and permeabilised with 0.5% Triton-X 100. Cells were then 
incubated with anti-SOD1 IgG Ab overnight at 4°C. Cells were washed again in PBS and 
incubated with Alexa Fluor 488 streptavidin for 1 h at RT. This same assay was performed on 
human iPSC-derived and primary motor neurons incubated with 20 µg/ml of SOD1 
 
180 
 
aggregates. An inverted microscope (DM IBRE) and a Leica TCS SP confocal imaging 
system were used to visualise and image cells (excitation 488, emission collected at 495-515 
and 650-668 nm). Fluorescence, bright field (differential interference contrast; DIC) and 
merged images were captured using Leica confocal software. In addition, cellular events were 
collected in a separate study using a LSR II flow cytometer as outlined in section 0. 
5.2.10 Quantifying Inhibition of Httex146Q, α-synuclein, TDP-43, α-lactalbumin RCM 
and amorphous aggregated protein uptake 
Inhibitor assays were performed as outlined in section 2.2.13. Briefly, NSC-34 cells were 
pre-treated with 100 µM 5-N-ethyl-N-isopropyl-amiloride (EIPA), 5 µM chlorpromazine 
hydrochloride (Chlorp HCl), 10 µM genistein (Gen) or 3 µM rottlerin (Rot) diluted in 1% 
BSA/PBS for 30 min. Cells were then co-incubated with by 20 μg/ml Httex146Q, α-synuclein, 
TDP-43, α-lactalbumin RCM and amorphous aggregated proteins for an additional 30 min. 
Aggregates were only incubated for 30 mins (shorter time) as uptake of aggregates is 
proposed to occur within this timeframe. Cells were immediately fixed with 4% PFA, washed 
twice with PBS and incubated with Triton X-100 for 30 min at 4°C. Cells were then 
incubated with blocking solution (5% FCS, 1% BSA and 0.3% Triton X-100) for 20 min. 
Cells were incubated with with Alexa Fluor 488 streptavidin for 1 h. Sytox Red (5 nM) was 
used as a counter stain, and incubated with cells for 10 min at RT. This same assay was 
performed on human iPSC-derived and primary motor neurons incubated with 20 µg/ml of 
SOD1 aggregates. An inverted microscope (DM IBRE) and a Leica TCS SP confocal 
imaging system were used to visualise and image cells (excitation 488, emission collected at 
520-545). Fluorescence, bright field (differential interference contrast; DIC) and merged 
images were captured using Leica confocal software. In addition, cellular events were 
collected in a separate study using a LSR II flow cytometer as outlined in section 5.2.9. 
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5.2.11 Membrane activity quantification 
Membrane dye uptake assay was performed as outlined in section 2.2.16. Briefly, human 
iPSC-derived motor neurons and human primary neurons were cultured as described above 
(see section 5.2.2). Cells were incubated with 20 µg/ml of SOD1, PBS alone, or PMA (200 
nM) in PBS for 2 h at 37°C/5% CO2. Cells were then washed, incubated with 10 µM of FM 
1-43FX membrane stain diluted in PBS for 7 min and excess dye was removed by several 
washes in PBS and incubated in ice-cold PBS. Cells were then fixed in 4% PFA for 20 min at 
4°C. Post fixation, cells were washed twice in PBS and incubated with 1x Red Dot 2 for 10 
min at RT.  
5.2.12 Field emission scanning electron microscopy (FESEM)  
FESEM assay was performed as outlined in section 2.2.15. Briefly, NSC-34 cells were serum 
starved in phenol red free culture medium for 24 h and incubated with 20 µg/ml Httex146Q, α-
synuclein, TDP-43, α-lactalbumin RCM and amorphous aggregated proteins in PBS or PBS 
containing 200 nM PMA for 2 h. Post incubation, cells were fixed in 2.5% 
glutaraldehyde/4% PFA in 0.1 M phosphate buffer for 3 h at 4°C. Cells were then washed 
and postfixed in 2% OsO4/water at RT for 1 h. After washing with water, the cells were 
dehydrated using a gradient of ethanol, critical point dried for 2 h using a LEICA CPD030 
and coated with graphite-gold in a sputter coater. This same assay was performed on human 
iPSC-derived and primary motor neurons incubated with 20 µg/ml of SOD1 aggregates 
Cellular structures were visualised with a JEOL 6490LV SEM (Tokyo, Japan) microscope 
operated at 10 kV at a 10 mm working distance and a spot size setting of 35.  
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5.2.13 RAC1 activation Elisa assays 
 RAC1 activation assay was performed as outlined in section 2.2.20. Briefly, NSC-34 cells 
serum starved in phenol red free culture medium for 24 h and incubated with 20 µg/ml of 
Httex146Q, α-synuclein, TDP-43, α-lactalbumin RCM and amorphous aggregated proteins for 
30 min at 37°C/5% CO2. Cells were washed, harvested by treatment with 0.05% trypsin for 
10 min and washed again (300 x g for 5 min) in PBS. RAC1 activation was measured using a 
G-LISA activation kit (Kit #BK128 Cytoskeleton, Inc. Denver, USA) as per the 
manufacturer’s recommendations. Absorbance values of wells were recorded with a 
SpectraMax Plus 384 Microplate Reader and SoftMax Pro software (Molecular Devices, 
Silicon Valley, CA) (490nm). 
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5.3 Results 
5.3.1 SOD1 aggregates are internalised via macropinocytosis pathways in iPSC-derived 
and primary human motor neurons  
5.3.1.1 Characterisation of a motor neuron phenotype in iPSC-derived motor neurons  
The results of investigations presented in detail in Chapter 2, demonstrate that SOD1 
aggregates enter NSC-34 cells via macropinocytosis. To determine whether or not these 
findings extend to human neurons, SOD1 uptake pathways were next investigated in human 
cultured iPSC-derived motor neurons and human primary neurons. Prior to investigating the 
uptake pathways of SOD1 in human iPSC-derived motor neurons, the pluripotency and 
differentiation of the cells was characterised (Figure 5.1). Initially, karyotyping (StemCore, 
Australian Institute for Bioengineering and Nanotechnology, Australia) demonstrated that 
chromosomal abnormalities were not introduced during reprogramming and culture (data not 
shown). Immunocytochemistry confirmed the expression of the pluripotency marker Oct4 in 
iPSCs (Figure 5.1A). Differentiation of pluripotent stem cells into motor neurons was carried 
out as in (Bilican et al., 2014) and outlined in Figure 5.1B. The differentiated neurons 
expressed the motor neuron specific marker SMI32 (Figure 5.1C). Immunocytochemistry 
identified the presence of extended dendrites ~100 μm in length. Quantitative reverse 
transcription PCR analysis identified the expression of the motor neuron specific gene MNX1 
(that encodes the transcription factor homeobox 9, HB9) (Arber et al., 1999). MNX1 was 
specifically expressed in motor neurons and MNX1 was silent in pluripotent stem cells. The 
cholinergic specific marker acetylcholine esterase (ACHE that encodes the enzyme 
responsible for the degradation of the neurotransmitter acetylcholine) was specifically 
expressed in cholinergic motor neurons. The expression levels for both MNX1 and ACHE, 
were normalized to the housekeeper gene GAPDH (Figure 5.1D). 
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Figure 5.1 Characterisation of iPSC derived motor neurons.  (A) Immunocytochemistry 
confirmed the expression of the pluripotency marker Oct4. Human induced pluripotent stem cells were cultured 
in TeSR-E8 on glass coverslips coated with Matrigel, fixed and stained with Alexa Fluor 488-conjugated Oct4 
antibody. Confocal and brightfield images were taken on a Leica SP5 confocal microscope. Scale bar is 60 mm. 
(B) The timeline summarises the differentiation stages and the growth factor conditions used during 
differentiation (Billican et al.). Example images of cellular morphological changes during differentiation are 
shown. Scale bars are 100 mm, 50 mm, 50 mm respectively. (C) Motor neurons were cultured on glass 
coverslips coated with laminin, collagen and fibronectin. Immunocytochemistry confirmed the expression of the 
motor neuron marker SMI-32. Scale bars are 30 mm. (D) Expression of neuronal and cholinergic markers were 
quantified using quantitative RT-PCR. Data plotted as mean relative gene expression in motor neurons 
normalised to GAPDH (± SEM, n=3). MNX1 and ACHE expression was silent in pluripotent cells. This work 
was performed by Dzung Do-Ha, Monique Bax and Lezanne Ooi. 
Next, the purity of the resulting motor neuron cultures was assessed by microscopy. 
Immunocytochemical analysis confirmed that the majority of the motor neuron cultures were 
positive (90.5 ± 1.4 %) for the motor neuronal marker SMI32 and 88.8 ± 1.4 % of cells were 
positive for neural stem cell marker Islet 1, with large cell bodies, consistent with a large 
proportion of the cells having a motor neuron morphology (Figure 5.2). 
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Figure 5.2 Characterisation of iPSC derived motor neurons. Quantification of Islet 1 (A) and 
SMI32 (B) positive cells was performed using immunocytochemistry and analysis using Image J software. Islet 
1 and SMI32 positive cells were calculated as a percentage of the total number of cells (determined by nuclear 
stain) from motor neuron cultures generated from six donor cell lines, using 6-10 images from each technical 
replicate (separate differentiation experiments using 3 technical replicates for Islet 1 and 2 technical replicates 
for SMI32). The motor neuron cultures contained 90.5 ± 1.4 % SMI32-positive cells and 88.8 ± 1.4 % Islet 1-
positive cells. Scale bars are (A) 100 mm and (B) 50 mm respectively. This work was performed by Dzung Do-
Ha, Monique Bax and Lezanne Ooi. 
 
5.3.1.2 Pharmacological inhibitors of Macropinocytosis reduce SOD1 aggregate uptake in 
human iPSC-derived and primary motor neurons 
To examine the pathway of SOD1 uptake in human neurons, iPSC-derived motor neuron 
cultures (Figure 5.3A) and primary motor neurons (Figure 5.3B) were in pre-incubated in the 
absence or presence of the Na+/H+ exchange inhibitor; EIPA and the RAC1 inhibitor W56 
which specifically inhibits RAC1 activity. Cells were firstly incubated with SOD1 aggregates 
in the absence or presence of EIPA and W56 and then the mean fluorescence intensity for the 
SOD1 aggregates was examined by confocal microscopy analysis. Relative SOD1 uptake was 
quantified from these images using ImageJ software. 
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Firstly, the uptake of WT and mutant SOD1 aggregates into human cultured iPSC-derived 
motor neurons and primary neurons was assessed. Similar to previous observations reported 
in Chapter 1, pre-incubation of human iPSC-derived motor neuron cells with 100 µM EIPA 
and 200 nM W56 significantly reduced WT SOD1 aggregate uptake by 17 ± 0.4% and 41 ± 
0.5%, respectively. Similarly, incubation with EIPA and W56 significantly inhibited mutant 
G93A SOD1 aggregate uptake by 52 ± 0.7% and 58 ± 0.6%, respectively. In addition, human 
primary neurons were pre-incubated in the absence or presence of EIPA and W56 before 
addition of SOD1 aggregates. Incubation with EIPA and W56 significantly reduced WT 
SOD1 aggregate uptake by 56 ± 1% and 13 ± 0.9% and the uptake of mutant G93A SOD1 
aggregate by 23 ± 1% and 35 ± 1%, respectively . Thus, given the large size of the aggregates 
and the ability of EIPA and W56 to modulate uptake, this suggests that macropinocytosis-like 
pathways play a role in the uptake of WT and mutant SOD1 aggregates in human neurons, 
similar to observations made in the mouse motor neuron-like (NSC-34) cell line (Chapter 1). 
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Figure 5.3 Small molecule inhibitors block macropinocytosis.  (A) iPSC-derived and (B) primary 
human motor neurons were incubated with 20 μg/ml of aggregated SOD1 proteins (20 µg/ml) for 30 min at 
37
o
C, in the absence (control) or presence of a pre-incubation step with either EIPA (100 µM) or RAC1W56 
(200nm) inhibitor, fixed with 4% PFA, permeabilised and labelled with either anti-human SOD1 Ab (non-
aggregated/ soluble) or Alexa Fluor 488 streptavidin. Slides were analysed by confocal microscopy. Outline of 
cells are indicated with white dashed lines. Bars represent 20 µm. Results are representative of at least n = 3. 
Uptake of proteins under the same conditions were determined by flow cytometry and results shown as mean 
fluorescence intensity ± SD, n = 6, 
***
P < 0.001 or 
*
P < 0.05 compared to corresponding control. 
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5.3.2 SOD1 aggregates trigger cell surface ruffling in human cultured iPSC-derived 
motor neurons and primary neurons  
5.3.2.1 SOD1 aggregates induce cell surface ruffles and blebs in the membrane to enter into 
human cultured iPSC-derived motor neurons and primary motor neurons 
Since membrane ruffling associated with macropinocytosis was implicated in SOD1 uptake 
into NSC-34 cells, the role of SOD1 aggregates in triggering actin-mediated membrane 
ruffling and blebbing in the plasma membrane of human cultured iPSC-derived motor 
neurons and primary neurons was tested. To investigate this, initially the detailed morphology 
of the cell surface was examined by field emission scanning electron microscopy (FESEM) 
(Figure 5.4). Incubation of human cultured iPSC-derived motor neurons (Figure 5.4A) with 
WT and mutant G93A SOD1 aggregates induced significant membrane perturbations in the 
form of systemic blebbing and lamellipodia-like membrane protrusions similar to that 
observed for cells treated with positive control; PMA. However, no obvious membrane 
perturbations were seen in cells incubated in the absence of protein treatment.  
Similarly, primary neurons (Figure 5.4B) incubated in the presence of WT and mutant G93A 
SOD1 aggregates displayed lamellipodia- like ruffling and blebbing in the cell surface. These 
membrane perturbations were more prominent in cells treated with PMA, which present in 
the form of systemic blebbing and ruffling in the cell surface relative to the cells treated in 
the absence of protein.  
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Figure 5.4 Aggregated SOD1-induced macropinocytosis involves ruffles in the plasma 
membrane of human iPSC-derived and primary motor neurons.  (A) iPSC-derived and (B) 
primary human motor neurons were serum starved for 24 h and were incubated with PBS (control, no protein), 
PBS containing 200 nm phorbol 12-myristate 13-acetate (PMA) or 20 μg/ml of aggregated SOD1, for 2 h, fixed 
with 2.5% glutaraldehyde/4% PFA in 0.1 M phosphate buffer for 3 h, postfixed in 2% OsO4/ water, dehydrated 
using a gradient of ethanol (30-100%, 30 min per treatment), critical point dried for 2 h and coated with 
graphite-gold. Increases in membrane perturbations can be observed, such as ruffles and blebs. Slides were 
analysed by field emission scanning electron microscopy. Bars represent 1 µm. Results are representative of n = 
2. 
Next, to quantify the extent of the observed membrane ruffling and blebbing in the plasma 
membrane, human cultured iPSC-derived motor neurons and primary neurons were 
pretreated with membrane dye FM 1-43FX, which has been used in previously for studies of 
membrane perturbation during growth cone ruffling (Kolpak et al., 2009). Cells were then 
incubated with SOD1 aggregates or PMA for 2 h (Figure 5.5). Incubation with SOD1 
aggregates induced significantly higher membrane perturbations, as measured by an increase 
in cellular fluorescence compared to controls, in both human cultured iPSC-derived motor 
neurons (Figure 5.5A) and primary neurons Figure 5.5B). This finding reflected the FESEM 
data above and is consistent with increased ruffles and blebs at the cell surface. 
 
 
 
190 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 SOD1 aggregates induce membrane perutbations in the cell surface of iPSC -
derived and primary human motor neurons  (A) iPSC-derived and (B) primary human motor neurons 
were incubated with PBS alone, 200 nM PMA or 20 μg/ml of aggregated SOD1for 2 h at 37°C, incubated with 
the membrane dye FM1-43FX and fixed with 4% PFA. Outline of cells are indicated with white dashed lines. 
Bars represent 20 µm. Mean fluorescence intensities (MFI) of membrane dye per cell were quantified from 
these images using ImageJ software (Version 1.48) (National Institutes of health, Bethesda, MD). A minimum 
of 200 cells were scored per treatment. Results shown as mean cellular fluorescence intensity means ± SD, n = 
3, 
***
P <0.001 compared to corresponding control (no protein treatment). 
5.3.2.2 SOD1 protein aggregates induce fluid uptake in human cultured iPSC-derived motor 
neurons and primary neuronal cells 
One of the consequences of macropinocytosis is the non-selective internalisation of 
significant amounts of fluid and membrane (Swanson and Watts, 1995), thus fluid uptake into 
human cultured iPSC-derived motor neurons and primary neurons cells was next investigated 
(Figure 5.6). To investigate fluid uptake, internalization of fluorescently labeled dextran (a 
fluid-phase marker) into cells was assessed, as previously used in Chapter 2. In both human 
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cultured iPSC-derived motor neurons (Figure 5.6A) and primary neuron cells (Figure 5.6B), 
WT and mutant SOD1 aggregates induced a significantly higher uptake of 10 kDa 647-
dextran compared to cells treated in the absence of protein, consistent with the triggering of 
macropinocytosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 SOD1 aggregates trigger fluid phase uptake in iPSC -derived and primary 
human motor neurons using fluorescently labelled dextran . (A) iPSC-derived and (B) primary 
human motor neurons were incubated with PBS alone (mock) or 20 μg/ml of aggregated SOD1 for 30 min at 
37°C, co-incubated with dextran Alexa-647 for 15 min, fixed with 4% PFA, permeabilised and labelled with 
Alexa Fluor 488 streptavidin. Slides were analysed by confocal microscopy. Outline of cells are indicated with 
white dashed lines. Bars represent 10 µm. Results are representative of at least n = 3, 
***
P <0.001 or 
**
P < 0.01 
compared to corresponding mock (no protein treatment);. Mean fluorescence intensities (MFI) per cell of 
dextran uptake were quantified from confocal images using ImageJ software (Version 1.48) (National Institutes 
of health, Bethesda, MD). 
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5.3.3 Activation of membrane ruffling is not restricted to SOD1 aggregates 
There is now substantial evidence that SOD1 aggregates can enter into neuronal cells via 
macropinocytosis (Grad et al., 2014; Münch et al., 2011; Sundaramoorthy et al., 2013), with 
evidence from the study in Chapter 2 demonstrating that this process is not a passive one but 
that SOD1 aggregates can trigger the activation of membrane ruffling and entry via 
macropinocytosis. The possibility that the triggering of membrane ruffling is a generic 
cellular response to protein aggregates was then next investigated. 
5.3.3.1 Purified Httex146Q, α-synuclein, TDP-43, and α-lactalbumin RCM and amorphous 
aggregates are heterogeneous in morphology 
To determine the morphology of the purified recombinant Httex146Q, TDP-43, α-synuclein 
and the model proteins RCM induced fibrillar or amorphous α-lactalbumin protein 
aggregates, negative staining TEM was performed (Figure 5.7). Representative TEM images 
of endpoint aggregates for Httex146Q (Figure 5.7A), TDP-43 (Figure 5.7B), α-synuclein 
(Figure 5.7C), and the model protein α-lactalbumin RCM (Figure 5.7D) were found to consist 
of long fibril structures, similar to those seen in neurodegenerative diseases (reviewed in 
Brettschneider et al., 2015). The amorphous α-lactalbumin (Figure 5.7E) model protein was 
observed to have an amorphous structure but clumped together in large aggregates. 
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Figure 5.7 Fibrillar and amorphous Morphology of protein aggregates using  TEM (A) 
Purified Httex146Q , (B) TDP-43, (C) α-synuclein, , and (D) α-lactalbumin RCM and (E) amorphous proteins (1 
mg/ml). Representative TEM image of endpoint aggregates. Protein aggregate (1 mg/ml) samples (2 µl) were 
loaded onto carbon-coated nickel grids for 1 min at RT and negatively stained using 2% uranyl acetate for 2 min 
at RT. Bars represent 20nm. 
 
5.3.3.2 Httex146Q, α-synuclein, TDP-43, and α-lactalbumin RCM and amorphous 
aggregates are detected in motor-neuron like NSC-34 cells 
Next, the putative uptake of disease-associated fibrillar aggregates formed by Httex146Q 
TDP-43, α-synuclein, and also of amorphous and fibrillar aggregates formed from the model 
protein α-lactalbumin (Kulig and Ecroyd, 2012) into NSC-34 cells was examined by confocal 
microscopy using Alexa Fluor 488 streptavidin (Figure 5.8). Httex146Q (Figure 5.8A), TDP-
43 (Figure 5.8B), α-synuclein (Figure 5.8C), and also both amorphous (Figure 5.8D) and 
RCM α-lactalbumin (Figure 5.8E) aggregates were observed to be internalised by NSC-34 
cells after 2 h incubation.  
 
194 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Htt e x146Q , α-synuclein, TDP-43, and α-lactalbumin RCM and amorphous 
aggregate protein aggregates enter into NSC-34. NSC-34 cells treated with 20 μg/ml of (A-E) 
aggregated proteins (20 µg/ml) for 2 h at 37
o
C, fixed with 4% PFA, permeabilised and labelled with Alexa Fluor 
488 streptavidin. Chamber wells were analysed by confocal microscopy. Outline of cells are indicated with 
white dashed lines. Bars represent 20 µm. Results are representative of at least n = 2.  
5.3.3.3 Pharmacological inhibitors of macropinocytosis reduce Httex146Q, α-synuclein, TDP-
43, and α-lactalbumin RCM and amorphous aggregate uptake in to NSC-34 cells 
Uptake of SOD1 aggregates into NSC-34 cells (Chapter 2) and in to human neurons (Figure 
5.8) has been shown to be reduced in the presence of small molecule inhibitors of pathways 
involved in the regulation of macropinocytosis. Given that NSC-34 cells can efficiently take 
up of a variety of protein aggregates (Figure 5.8), it was next investigated whether small 
molecule inhibitors of macropinocytosis have an effect on the uptake of Httex146Q, TDP-43, 
α-synuclein, and amorphous and fibrillar α-lactalbumin aggregates (Figure 5.9). NSC-34 cells 
were firstly incubated with aggregates in the absence or presence of EIPA (an inhibitor of the 
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Na+/H+ pumps, essential for macropinocytosis) and then mean fluorescence intensity for 
uptake of protein aggregates uptake were examined by confocal microscopy (Figure 5.9A). 
Relative aggregate uptake was quantified from these images using ImageJ software (Figure 
5.9B). Incubation with EIPA resulted in significant reductions in the uptake of Httex146Q (51 
± 1.6%), TDP-43 (26 ± 1.3 %), α-lactalbumin amorphous (35 ± 1.3 %) and fibrillar (14 ± 1.9 
%) aggregates. However, in contrast incubation with EIPA was not observed to inhibit the 
internalisation of α-synuclein 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 Small molecule inhibitors block macropinocytosis and entry of Htt ex146Q , 
TDP-43, α-lactalbumin RCM and amorphous aggregated proteins.  (A) NSC-34 cells treated 
with 20 μg/ml Httex146Q , α-synuclein, TDP-43, α-lactalbumin RCM and amorphous aggregated protein for 30 
min at 37
o
C, in the absence (control) or presence of a pre-incubation step with EIPA (100 µM) a Na+/H+ 
exchange inhibitor, fixed with 4% PFA, permeabilised and labelled with Alexa Fluor 488 streptavidin. Slides 
were analysed by confocal microscopy. Outline of cells are indicated with white dashed lines. Bars represent 20 
µm. Results are representative of at least n = 3 (B) Uptake of proteins under the same conditions were 
determined by flow cytometry and results shown as mean fluorescence intensity ± SD, n = 6,
 ***
P < 0.001 or 
*
P 
< 0.05 compared to corresponding control.  
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5.3.3.4 Httex146Q, α-synuclein, TDP-43, and α-lactalbumin fibrillar and amorphous 
aggregates trigger cell surface ruffling activation of RAC1 and fluid uptake in NSC-34 cells 
Given that above data implicates a role for a more general role of macropinocytosis in the 
uptake of protein aggregates, the association of aggregates with induction of plasma 
membrane ruffling and/ or blebbing was next examined. To investigate whether there were 
any perturbations to the cell surface membrane caused by incubation with a variety of protein 
aggregates, cells were treated with either PMA or protein aggregates for 2 h and then the 
detailed morphology of cells was examined by FESEM (Figure 5.10). NSC-34 cells 
incubated with Httex146Q and TDP-43 aggregates displayed large planar lamellipodia-like 
ruffles. Similarly, α-synuclein induced cell-wide systemic blebbing and ruffles, similar to 
cells incubated with α-lactalbumin RCM. However, a small amount of membrane 
perturbations were observed for cells incubated with amorphous α-lactalbumin compared to 
the cells incubated in the absence of protein.  
 
 
 
 
 
 
 
 
 
 
Figure 5.10 Aggregated Htt e x146Q, α-synuclein, TDP-43, α-lactalbumin RCM and 
amorphous proteins induce ruffles in the plasma membrane of NSC -34 cells. NSC-34 cells 
were serum starved for 24 h and were incubated with PBS (control, no protein) or 20 μg/ml of aggregated 
Httex146Q, α-synuclein, TDP-43, α-lactalbumin RCM and amorphous proteins for 2 h, fixed with 2.5% 
glutaraldehyde/4% PFA in 0.1 M phosphate buffer for 3 h, postfixed in 2% OsO4/ water, dehydrated using a 
gradient of ethanol (30-100%, 30 min per treatment), critical point dried for 2 h and coated with graphite-gold. 
Increases in membrane perturbations can be observed, such as ruffles and blebs. Slides were analysed by field 
emission scanning electron microscopy. Bars represent 2 µm. Results are representative of n = 2. 
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Since activation of the Rho GTPase RAC1 is involved in regulating macropinocytosis, the 
activation of RAC1, via cellular interaction with protein aggregates was next assessed. To 
investigate whether Httex146Q, α-synuclein, and TDP-43 protein aggregates induce the 
activation of RAC1 upon entry into NSC-34 cells, cells were incubated with these aggregates 
and RAC1 activation was probed for using a G-LISA based assay (Figure 5.11). Compared to 
control cells, a significantly increased amount of activated RAC1 was detected in cells 
incubated with Httex146Q, α-synuclein, and TDP-43 aggregates. However, while the mean 
level of activated RAC1 was increased when cells were incubated with α-lactalbumin RCM 
and amorphous aggregates, this increase was not significant.  
 
 
 
 
 
 
 
 
 
 
Figure 5.11 RAC1 also has an important role in Htt e x146Q, TDP-43, α-lactalbumin RCM 
and amorphous proteins entry into NSC-34 cells. NSC-34 cells were serum starved 24 h, incubated 
with PBS alone (control) or 20 μg/ml of Httex146Q, α-synuclein, TDP-43, α-lactalbumin RCM and amorphous 
proteins for 30 min at 37°C and lysed. RAC1 activation was measured using a RAC1 activation G-LISA kit 
activation assay that probes for RAC1-GDP. Absorbance values of anti- RAC1 HRP at 490 nm were determined 
by spectrometry and results are shown as mean absorbances (490 nm) ± SD of 6 experiments,
 ***
P < 0.001 or 
*
P 
< 0.05, compared to corresponding control (mock).  
Finally, to investigate whether the interaction of a variety of protein aggregates with cells 
triggers fluid phase uptake (Figure 5.12), NSC-34 cells were incubated in the presence of 
both Httex146Q, α-synuclein, α-lactalbumin, and TDP-43 with 10 kDa 647-dextran and 
assessed by confocal microscopy (Figure 5.12A) and flow cytometry (Figure 5.12B). 
Incubation with all protein aggregates including the model proteins α-lactalbumin fibrillar 
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and amorphous aggregates induced significant uptake of fluid (dextran- ALEXA-647), with 
significantly greater amounts of dextran detected in cells incubated with Httex146Q, TDP-43, 
α-lactalbumin and α-synuclein compared to cells compared to cells treated in the absence of 
protein aggregates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12 Htte x146Q, α-synuclein, TDP-43, α-lactalbumin RCM and amorphous protein 
aggregates trigger fluid phase uptake using fluorescently labelled dextran.  NSC-34 cells were 
incubated with PBS alone (mock) or 20 μg/ml of Httex146Q , α-synuclein, TDP-43, α-lactalbumin RCM and 
amorphous proteins for 30 min at 37°C, co-incubated with dextran Alexa-647 for 15 min, fixed with 4% PFA, 
permeabilised and labelled with Alexa Fluor 488 streptavidin. Slides were analysed by confocal microscopy. 
Outline of cells are indicated with white dashed lines. Bars represent 10 µm. Results are representative of at 
least n = 3. (B) Cells were firstly gated on forward (FSC) and side (SSC) scatter to exclude dead cells and the 
mean fluorescence intensities (MFI) of dextran Alexa-647 in NSC-34 cells was determined by flow cytometry. 
Results shown as means ± SD, n = 6; 
***
P < 0.001 or 
**
P < 0.01 compared to corresponding control. 
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5.4 Discussion 
The current study demonstrates that SOD1 aggregates can be internalised via 
macropinocytosis-like pathways into human primary neurons and more importantly human 
motor neurons derived from iPSCs. The addition of pharmacological inhibitors of 
macropinocytosis including EIPA and W56 disrupted the uptake of SOD1 aggregates into 
these cells. SOD1-mediated activation of macropinocytosis-like pathways in these primary 
cells induced membrane perturbations in the forms of ruffles and blebs, and subsequent fluid 
uptake, which are characteristic of macropinocytosis. The current study also confirmed for 
the first time that other protein aggregates associated with ALS, Huntington’s and Parkinson's 
diseases, including purified TDP-43, Httex146Q and α-synuclein protein aggregates 
respectively, trigger the activation of the Rho GTPase RAC1. This results in the formation of 
membrane ruffles on the cell surface and fluid phase uptake in NSC-34 cells, facilitating the 
entry of large fibrillary or amorphous protein aggregates. Together, the current study 
indicates that SOD1 aggregates can stimulate macropinocytosis in human neurons and 
suggests a role for macropinocytosis in the uptake of a protein aggregates more generally.  
Previous work had shown that exogenously applied misfolded mutant SOD1 could be taken 
up by cell lines and material found in conditioned media was shown to be internalised into 
human WT SOD1‐expressing murine primary spinal cord cultures, derived from embryonic 
spinal cord of transgenic mice (Grad et al., 2014). In the work presented here, the ability of 
human neurons to take up SOD1 aggregates was observed for the first time, supporting 
previous observations which suggest that extracellular misfolded or aggregated SOD1 may 
have an active role in the spread of pathology among cells in vitro and motor neurons in vivo 
(Ayers et al., 2014). Thus, SOD1 aggregates may contribute to disease progression via 
interactions with both the cell surface and internalisation into cells, which may occur in both 
fALS and sALS (Grad et al., 2014; Münch et al., 2011; Sundaramoorthy et al., 2013). 
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Furthermore, the uptake of purified TDP-43, Huntington and α-synuclein aggregates into 
NSC-34 motor neuron cells was observed similar to uptake of SOD1 in Chapter 2. This is 
consistent with cellular uptake of TDP-43 into microfluidic neuronal cultures as reported by 
Feiler et al (Feiler et al., 2015). In the context of Parkinson’s disease, cell culture studies have 
shown that extracellular α-synuclein in various forms (fibrils, oligomers, and monomers) can 
be internalised by cultured neuronal cells (Lee et al., 2008). Furthermore, α-synuclein is 
known to directly interact with lipids and membranes to facilitate its entry into neuronal cells 
(Lee et al., 2008). Similarly, in a Huntington’s disease model, large polyglutamine aggregates 
were shown to internalise into cultured cells (Yang et al., 2002). However, the precise 
mechanisms for entry of these proteins into cells remain to be determined. 
A role for macropinocytosis in the uptake of extracellular native and aggregated WT and 
mutant SOD1 into neuronal cells has been previously suggested (Grad et al., 2014; Münch et 
al., 2011; Sundaramoorthy et al., 2013). In these studies, cell lines were treated by the 
addition of small molecules that inhibit actin rearrangement, or Na
+
/H
+
 exchangers, Pak-1, 
PI3K, and PKC was reported to impair the uptake of SOD1 aggregates (Grad et al., 2014; 
Münch et al., 2011; Sundaramoorthy et al., 2013) consistent with macropinocytosis. In the 
current study, EIPA (inhibitor of Na+/H+ exchanger) which has previously been used as the 
main diagnostic test to identify macropinocytosis from other forms of endocytosis (West et 
al., 1989) and the RAC1 inhibitor W56 were used to confirm the involvement of 
macropinocytosis-like pathways in the uptake of SOD1 aggregates into human neurons. EIPA 
and RAC1 W56 inhibited the uptake of SOD1 aggregates into human iPSC derived motor 
neurons and primary neurons, similar to the study in Chapter 2 and previous observations 
(Grad et al., 2014; Münch et al., 2011; Sundaramoorthy et al., 2013). Similarly, the level of 
TDP-43 and Httex146Q uptake into NSC-34 cells were significantly suppressed by EIPA. 
Other fibrils such as Tau associated with Alzheimer’s disease have also been shown to enter 
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cells via macropinocytosis (Holmes et al., 2013). Taken together, these data suggest that 
SOD1, TDP-43 and Httex146Q and Tau are taken up by a similar mechanism, consistent with 
a generic mechanism of protein aggregate uptake. However, in the current study while α-
synuclein aggregates triggered ruffling and fluid uptake, characteristic of macropinocytosis, 
the uptake of α-synuclein was not significantly affected by EIPA. This might suggest the 
involvement of distinct pathways, or it could suggest a higher concentration of EIPA is 
needed in this model, as α-synuclein aggregates are small in size and could potentially be 
interacting and internalising in a different manner. However, future investigations into the 
role of α-synuclein, and indeed Httex146Q, α-syn and TDP-43- aggregates in the induction of 
macropinocytosis is clearly warranted. 
Triggering the activation of macropinocytosis leads to the entry of large amounts of solute, 
and because of the large size of macropinosomes macromolecules or particles too large for 
other forms of endocytosis are able to enter the cell (Swanson and Watts, 1995). Activation 
of macropinocytosis has been reported to induce a number of downstream signaling events 
including the activation of the Rho GTPase, RAC1 (Ridley et al., 1992), which contributes to 
the modulation of actin-mediated membrane ruffle formation in the form of lamellipodia, 
circular-shaped membrane extensions (ruffles) and large plasma membrane extrusions 
(blebs), macropinosome closure forming large intracellular vacuoles (0.5–10 μM) and 
membrane trafficking (Lanzetti et al., 2004; Mercer and Helenius, 2012). In the current study, 
SOD1, TDP-43, Httex146Q and α-synuclein aggregate-mediated activation of 
macropinocytosis thus internalisation into human primary neurons or NSC-34 cells 
respectively, was demonstrated. Incubation with SOD1, TDP-43, Httex146Q and α-synuclein 
aggregates induced membrane protrusions, including macropinocytic ruffling and systemic 
blebbing, consistent with the formation macropinosomes at the plasma membrane. Thus, it is 
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likely that motor neurons internalise extracellular aggregates directly via dynamic membrane 
rearrangements that eventually form large endocytic macropinosomes. 
Activated RAC1 has previously been identified as an important and central player in 
triggering membrane ruffles and blebbing (Mercer and Helenius, 2009) associated with virus 
entry into cells, and has been found to do so by activating downstream effectors of actin 
polymerisation (Sanchez et al., 2012). While the precise role of PKC in virus entry is still 
unclear, its activation with PMA (as used in this current study and in Chapter 2) can induce 
ruffling and fluid uptake in the absence of ligands that bind the cell surface (Swanson, 1989). 
The activation of RAC1 by TDP-43, Httex146Q and α-synuclein aggregates and subsequent 
membrane ruffling was supported by results presented in the current study. Although SOD1-
mediated activation of RAC1 in human iPSC derived motor neurons and primary neurons 
was not directly investigated in the current study, inhibition of RAC1 supressed the uptake of 
SOD1 aggregates into these cells, thus suggesting a role for RAC1 activation in aggregate 
entry. Of note, the study in chapter 1 confirmed that activation of RAC1 is upstream of 
membrane ruffling, thus consistent with triggering the increased perturbation in the plasma 
membrane of human iPSC derived motor neurons and primary neurons upon incubation with 
SOD1 aggregates.  
Macropinocytosis is a form of fluid phase endocytosis, characterised by internalisation of 
extracellular fluids and solutes at whatever concentrations they are found in the extracellular 
medium, rather than concentrating ligands at the cell surface (Swanson and Watts, 1995). The 
data presented here shows that the activation of macropinocytosis mediated by SOD1 
aggregates in human iPSC derived motor neurons and primary neurons, and TDP-43, 
Httex146Q and α-syn in NSC-34 cells induced fluid uptake (dextran-Alexa 647 to quantify 
fluid-phase endocytosis), coinciding with the formation of membrane ruffling. Similarly, 
previous work has demonstrated that incubation with tau fibrils increased dextran uptake, 
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consistent with activation of macropinocytosis (Holmes et al., 2013). The model proteins α-
lactalbumin RCM and amorphous proteins were also able to induce membrane perturbations 
that facilitate their cellular uptake in a similar manner to that of SOD1, suggesting that a 
broad range of aggregated proteins, both amorphous and amyloid-like, are able to induce 
membrane perturbations that facilitate their cellular uptake.  
In addition to TDP-43, Httex146Q and α-synuclein aggregate, various viruses, such as the 
vaccinia virus, adenovirus 3, herpes simplex virus 1 and HIV, utilize macropinocytosis to 
gain entry to cells. This phenomenon is likely to be due to the fact that macropinosomes are 
not restricted in size, enabling even large virions to be internalised, and that many cell types, 
not just professional phagocytes (such as macrophages), have the ability to activate the 
macropinocytosis pathways (Swanson and Watts, 1995). Indeed, macropinocytosis can be 
activated in neurons by interactions with large viral particles (Kalia et al., 2013). Of note, 
amyloid fibrils including those associated with Alzheimer's disease (Aβ1-40) and Parkinson’s 
disease (α-synuclein) and can enhance human immunodeficiency virus type 1 infection 
(Munch et al., 2007; Wojtowicz et al., 2002). Thus, it is interesting to speculate that this 
behaviour could be due to the potent ability of such aggregates to stimulate macropinocytosis 
and facilitate increased viral uptake. Recently, accumulating evidence suggests that the 
transcellular propagation of a wide range of disease-associated proteins, including SOD1, 
TDP-43, huntingtin with poly-Q repeats, α-synuclein, Aβ, tau mediate the progression of 
disease in a prion-like manner (reviewed in Ayers et al., 2016). Likewise, cellular uptake of 
the pathological prion protein has been reported to occur via by stimulated lipid-raft mediated 
macropinocytosis (Wadia et al., 2008) 
In conclusion, this study represents the first report of SOD1 mediated activation of 
macropinocytosis in human neurons, consistent with the notion that protein aggregates could 
be an active part of ALS disease progression, possibly through secondary nucleation (Buell et 
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al., 2014), or another prion-like aggregate propagation process. In addition, the current study 
highlights the ability of neurons to undergo stimulated macropinocytosis. Furthermore, the 
current study suggests that aggregate induction of macropinocytosis may be a more generic 
principle and not restricted to one type of aggregate (Holmes et al., 2013). While further 
investigations are required to determine the exact mechanisms of TDP-43, huntingtin and α-
synuclein uptake in vivo, additional mechanisms may also operate to facilitate their entry. 
Overall, the data is consistent with protein aggregates exploiting macropinocytosis as a novel 
route for entry into cells. It may therefore prove important to elucidate intracellular pathways 
that result in macropinosome formation and closure to generate effective therapeutic targets 
for halting the propagation of aggregation in these disorders. 
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6.1 Overview 
Amyotrophic lateral sclerosis (ALS) is a devastating neuromuscular degenerative disease that 
currently has no effective treatments or therapeutics. ALS is characterised by a focal onset of 
motor neuron loss, followed by contiguous outward spreading of pathology throughout the 
nervous system, resulting in paralysis and death within a few years after diagnosis. The 
aetiology of ALS is poorly defined and the complexity of the pathogenic mechanisms 
responsible for disease initiation and progression are not completely understood. However, 
multiple factors and cellular pathways including; protein aggregation and seeding of 
endogenous native proteins, aberrant secretion and the subsequent internalisation of 
aggregated proteins by neighbouring cells are implicated in disease pathogenesis. Both 
copper-zinc superoxide dismutase 1 (SOD1) and the 43-kDa trans-activating response region 
DNA-binding protein (TDP-43) have been implicated in these disease mechanisms, with 
recent evidence demonstrating a role for macropinocytosis in ALS disease progression. Thus, 
this thesis aimed to examine the prion-like activity of SOD1 and TDP-43, and determine the 
role of macropinocytosis in the propagation of ALS pathology, in cell lines and human 
neurons. From this, potential therapeutic targets may be identified and strategies developed. 
6.2 Conclusions and Significance 
The work presented in this thesis suggests that aggregates of SOD1 can stimulate 
macropinocytosis and result in the subsequent prion-like propagation of misfolding, both 
findings that may help explain patterns of ALS disease progression. Misfolded SOD1 is 
capable of transferring between neuronal cells, through release from cells via active and 
passive mechanisms and uptake via macropinocytosis–like pathways. In Chapter 2, the 
uptake of SOD1 aggregates by the murine motor-neuron like cell line (NSC-34) was 
confirmed. Furthermore, Chapter 2 demonstrated that inhibiting key regulators of 
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macropinocytosis in NSC-34 motor neurons, using pharmacological inhibitors significantly 
reduced the uptake of SOD1 aggregates into NSC-34 cells. This is consistent with previous 
evidence in the same and similar cell lines (N2a neuroblastoma cells) using misfolded SOD1. 
In these previous studies, similar pharmacological inhibitors of macropinocytosis resulted in 
a significant reduction in SOD1 internalisation (Grad et al., 2014; Münch et al., 2011; 
Sundaramoorthy et al., 2013) and subsequent induction of endoplasmic reticulum (ER) stress 
in neuronal cells (Sundaramoorthy et al., 2013). Although ER stress was not directly 
investigated in the current study, expression of misfolded WT and mutant SOD1 have been 
observed to induce ER stress, and when prolonged can promote and pro-apoptotic pathways 
in motor neurons reminiscent of ALS pathology (Nishitoh et al., 2008; Sundaramoorthy et al., 
2013).  
Furthermore, although these studies suggest a role for stimulated macropinocytosis in SOD1 
uptake, the exact mechanisms that underlie internalisation via macropinocytosis are 
unknown. It is therefore possible that misfolded SOD1 may trigger macropinocytosis through 
a direct interaction with receptors on the cell surface. Therefore, further analysis into the 
specific pathways leading up to the activation of macropinocytosis will assist in identifying 
how SOD1 utilises macropinocytosis for entry into cells. Incubation of NSC-34 cells with 
SOD1 aggregates induced the activation of the signalling molecule RAC1 which in turn 
resulted in the induction of membrane perturbations in the form of ruffles and blebs in the 
plasma membrane and subsequent fluid-phase uptake into NSC-34 cells was also observed. 
Given that there is no evidence of activated macropinocytosis in the absence of aggregates, it 
is therefore reasonable to conclude that aggregated SOD1 triggered these signaling pathways 
to activate a macropinocytosis-like pathway. The above represents new evidence for the 
SOD1 aggregate mediated activation of macropinocytosis in ALS, however viruses have been 
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shown in prior studies to activate these same macropinocytosis-like pathways to facilitate 
cellular infection (Sanchez et al., 2012). 
The murine motor neuron cell line NSC-34 is a hybrid cell line originally developed by 
fusing mouse derived neuron-enriched primary embryonic spinal cord cells and N18TG2 
neuroblastoma cells (Cashman et al., 1992). Although the NSC-34 cell model may provide 
information that may not be completely applicable to human ALS disease, it is likely that 
misfolded toxic SOD1 proteins may also activate macropinocytosis in a similar manner in 
vivo to facilitate their entry into motor neurons. For decades, transgenic rodent models of 
ALS have been widely available for use and have provided important information on a range 
of areas including pathogenesis and disease progression in ALS disease. However, given that 
there are differences between humans and rodents, particularly genetically engineered rodents 
which develop ALS-like disease phenotypes, other physiologically relevant models should be 
used to strengthen the validity of the data obtained. The development of reprogramming 
biology and humanised models of ALS have been established in recent years to allow for 
complementary, and arguably more relevant, models. The generation of patient specific 
induced pluripotent stem cells (iPSCs) derived from reprogrammed somatic cells from a 
range familial and sporadic ALS patients now represent an effective model disease model of 
ALS (Hedges et al., 2016; Lee and Huang, 2015). A range of disease-relevant cell types 
including neurons and motor neurons can be differentiated from human induced pluripotent 
stem cells and used to study pathogenic mechanisms and elucidate specific drug targets. 
Humanised models of ALS including iPSC derived motor neurons and human primary 
neurons were therefore used to investigate the role of SOD1 in triggering macropinocytosis 
(Chapter 5). In Chapter 5, internalisation of exogenously added WT and mutant SOD1 
aggregates were also shown to be reduced in the presence of pharmacological inhibitors that 
interfere with regulators of the macropinocytosis pathway and signaling molecules. In 
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addition, SOD1 aggregates induced membrane ruffling and blebbing in the plasma membrane 
and subsequent fluid uptake into human neurons coinciding with the activation of 
macropinocytosis. Although the activation of the signalling molecule RAC1 was not 
investigated, inhibition of RAC1 reduced the uptake of SOD1 aggregates consistent with a 
role for RAC1 activation in this process. Although these human models provide relevant 
insight into the mechanisms of exogenous SOD1 aggregate uptake, future studies could focus 
on investigating the role of macropinocytosis in SOD1 internalisation in animal models, 
including zebra fish which provide many advantages such as they are transparent and 
therefore can visualise fluorescence in real time and are easy to handle and house. 
Given the consistent structure and large size of most protein aggregates, it is likely that 
similar mechanisms are used by neurons to engulf such large aggregates. Intuitively, the large 
size of the protein aggregates argues against neuronal entry by most forms of endocytosis 
given their size limitations. Therefore, the process of macropinocytosis could potentially 
explain the uptake of such large structures. Thus, it reasonable to speculate that a wide range 
of proteins associated with other common neurodegenerative diseases including TDP-43, α-
synuclein and fibrillar polyQ aggregates (e.g. Huntingtin protein) in ALS, Parkinson’s and 
Huntington’s disease respectively, may also trigger the activation of macropinocytosis in 
neuronal cells. In Chapter 5, exogenously applied TDP-43, α-synuclein and Huntingtin (Htt-
46Q) protein aggregates were shown to be internalised by murine NSC‐34 motor neurons via 
activated macropinocytosis, as similarly observed for SOD1 aggregates. This is consistent 
with previous reports that implicate fluid-phase endocytosis in the cellular uptake of α-
synuclein and Tau (Alzheimer’s Disease) aggregates (Holmes et al., 2013; Lee et al., 2008).  
The panel of pharmacological inhibitors of macropinocytosis used in this study was sufficient 
for confirming the involvement of macropinocytosis, specifically the use of amiloride (EIPA) 
which is reported to specifically (in the context of other endocytosis pathways) inhibit 
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macropinocytosis (West et al., 1989) (Chapter 2 and Chapter 5). Given the effectiveness of 
EIPA, it may be worth investigating the effects of this drug in ALS mice or other animal 
models. However, it may also be worth utilising other available inhibitors specific to 
macropinocytosis or possibly developing new drugs for future experiments, to identify select 
processes that may be directly involved in the uptake of aggregates into neuronal cells among 
proteinopathies. However, macropinocytosis is important in a range of physiological 
processes, including its contribution to antigen presentation by the immune system (Kerr and 
Teasdale, 2009). Therefore a side effect of inhibiting macropinocytosis could be 
compromised immune function. 
In addition, given that this study presents for the first time, evidence for the activation of 
macropinocytosis mediated by aggregates of SOD1, TDP-43, α-synuclein and Huntingtin 
proteins, it will be interesting to determine whether these proteins interact with a specific 
receptor upon cell contact and whether this receptor is the same among proteinopathies. 
Although there is no evidence in the context of protein aggregate activated macropinocytosis, 
previous work would suggest that receptor tyrosine kinases are involved in activation of 
macropinocytosis (Kerr and Teasdale, 2009). Activation of receptor tyrosine kinases causes 
an increase in actin polymerisation at the cell surface, resulting in an elevation in actin-
mediated ruffling and therefore an increase in macropinosome formation, which is the 
mechanism distinguishing it from other endocytic pathways (Kerr and Teasdale, 2009). This 
cell surface receptor triggering activation of macropinocytosis may therefore represent a 
therapeutic target. Recent work suggests heparan sulfate proteoglycans are involved in the 
entry of tau aggregates, but how this relates to activation of macropinocytosis and to entry of 
other neurodegenerative disease associated aggregates is unclear (Holmes et al., 2013). In 
addition to this, inhibition of RAC1 activity inhibits ruffle formation irrespective of receptor 
tyrosine kinase signaling (Lanzetti et al., 2004). These are two examples of pathways that 
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could potentially be exploited to slow or stop the progression of toxic protein aggregates that 
enter cells via macropinocytosis. Furthermore, since macropinocytosis is incompletely 
understood, it is possible that different types of macropinocytosis pathways may exist, and 
therefore it will be interesting to investigate whether these proteins use the same or different 
pathways and how they induce relevant responses in varying neuronal cells. 
The ability of the SOD1 aggregates to escape membrane bound compartments and enter into 
the cytosol is consistent with prion-like activity. By entering through macropinosomes, SOD1 
aggregates can escape delivery into the endosomal compartments potentially due to the 
‘leaky’ nature of macropinosomes, which is attributed to their lack of physical structure 
(Conner and Schmid, 2003). Although the precise mechanism by which these SOD1 
aggregates escape macropinosomes and the relationship between escape and induced 
pathology is currently unknown. Given this, it may be worth investigating how SOD1 
aggregates gain access to the cytosol and whether these aggregates interact with endogenous 
proteins using real-time imaging techniques including Fluorescence Resonance Energy 
Transfer (FRET) Microscopy which can be used to investigate molecular interactions 
between SOD1 aggregates and endogenous proteins in real-time. 
The release of SOD1 into conditioned media was observed from cultured NSC-34 cells 
transiently expressing SOD1 proteins, coinciding with cell death (Chapter 3). However, how 
the protein aggregates relate to toxicity is currently unknown and it will therefore be 
interesting to determine whether misfolded and aggregated SOD1 proteins can directly 
induce cell death or whether other factors are operating simultaneously. These factors include 
deficient protein quality control, aberrant RNA metabolism, oxidative stress, endoplasmic 
reticulum stress, glutamate excitotoxicity, mitochondrial dysfunction, fragmentation of the 
Golgi apparatus, axonal transport defects and neuroinflammation. Furthermore, it is unknown 
whether the secreted SOD1 proteins were mediated by cell death or by active secretion 
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mechanisms. It is possible that both active and passive mechanisms of SOD1 secretion may 
have occurred, via cell death and exosomes respectively, as previously reported (Grad et al., 
2014). Incubation of naïve neuronal cells with these conditioned media containing 
extracellular WT and mutant SOD1 was shown to be internalised by murine NSC-34 motor 
neurons. Toxicity and apoptotic cell death have been similarly observed in NSC-34 cells, 
which have taken up extracellular misfolded and aggregated WT and mutant SOD1 protein 
(Sundaramoorthy et al., 2013).  
The prion-like propagation of a range protein aggregates mentioned above associated with 
neurodegenerative diseases is a hypothesis gaining much attention. Prior studies suggests that 
injection of brain/spinal cord extracts from symptomatic transgenic mice expressing human 
SOD1, Tau, or α-synuclein can seed pathology in the sites of injection and spread to other 
regions of the nervous system (Ayers et al., 2014; Clavaguera et al., 2009; Mougenot et al., 
2012). Moreover, cell culture experiments also show that insoluble material from brain tissue 
can seed aggregation of neuropathological TDP-43, whose cytoplasmic accumulation is 
associated with ALS (Furukawa et al., 2011). However, only until very recently has ALS 
been implicated in the prion-like paradigm. 
Cell-to-cell transfer of SOD1 aggregates between murine NSC-34 cells was observed here in 
vivo (Chapter 3). In addition, the ability of WT and mutant SOD1 as well as TDP-43 to 
induce the misfolding of native soluble proteins was quantified using a novel technique for 
measuring inclusions; flow cytometric characterisation of inclusions and trafficking (FloIT) 
(Chapter 3 and 4). Specifically, FloIT can be used to rapidly quantify cytosolic protein 
inclusions, including small inclusions and can be used to investigate the co-aggregation of 
different proteins into inclusions. Our data therefore, demonstrates the seeding of aggregation 
in a prion-like manner. Consistent with this, recent work provides striking evidence that this 
may indeed drive disease progression as focal injection of spinal cord homogenates from 
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symptomatic G93A SOD1 triggers progressive motor neuron disease in mice expressing 
G85R SOD1-YFP below the threshold for disease (Ayers et al., 2014). Furthermore, fibrils of 
TDP-43 can induce templated aggregation of TDP-43 in cells expressing WT TDP-43 or 
TDP-43 lacking nuclear localization signal (Shimonaka et al., 2016).  
In vivo, aggregates of SOD1 were shown to induce TDP-43 mislocalisation NSC-34 cells and 
rapid fragmentation consistent with TDP-43 pathology observed in sporadic disease. 
Although the exact mechanism for this observation was not determined, it is likely that the 
proteotoxic stress induced by aggregate uptake was sufficient to trigger the mislocalisation of 
TDP-43. To the best of our knowledge, SOD1 induced TDP-43 pathology has not yet been 
reported in humans, and the mislocalisation of TDP-43 in SOD1 mouse models is 
contradictory (Shan et al., 2009; Turner et al., 2008) and therefore future investigations into 
the mechanisms and role of SOD1 aggregates in the formation of pathological TDP-43 are 
therefore warranted. This, however, provides a potential mechanistic link between sporadic 
and familial ALS cases. Interestingly, TDP-43 aggregates are present in other 
neurodegenerative diseases such as Huntington’s and Alzheimer’s disease and may reflect the 
proteotoxic stress in these diseases. 
The use of WT and mutant forms of SOD1 as well as other pathological proteins including 
TDP-43 has been largely informative in the current study, given that these two proteins have 
been largely implicated in ALS. However, the use of one mutant form of the SOD1 protein 
(SOD1
G93A
) and TDP-43 (TDP-43
G127X
) may present a limitation of the study. Although the 
G93A mutation is one of the more common and well characterised mutations used widely as 
a model for familial ALS, future work should focus on a wider range of SOD1 mutations and 
possibly more mutations in TDP-43 protein. 
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6.3 Final remarks 
Overall, this thesis demonstrated that misfolded SOD1 and other protein aggregates 
associated with other common neurodegenerative disease including TDP-43, α-synuclein and 
Huntingtin aggregates are capable of entering into NSC‐34 motor neurons and that 
macropinocytosis plays a role in allowing the passage of protein aggregates into naïve cells. 
The SOD1-mediated activation of macropinocytosis on these cells induced actin dependant 
ruffling and blebbing in the plasma membrane triggered active RAC1 which lead to the 
internalisation of the aggregates. Once internalised into macropinosomes, the aggregates were 
capable of escaping into the cytosol, where the seeding of aggregation occurred, as detected 
using FloIT. Furthermore, the release of SOD1 aggregates from neuronal cells via passive 
and/or active mechanisms including cell death or potentially exosomes were observed and 
this may represent an early event in ALS disease. These extracellular (released) aggregates 
were able to internalise into other neighbouring motor neurons that may be more susceptible 
to cell damage and/or death, propagating cellular stress and aggregation from cell to cell, 
seeding aggregation consistent with previous evidence (Figure 6.1) (Grad et al., 2014; Münch 
et al., 2011; Sundaramoorthy et al., 2013).  
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Figure 6.1 Summary of important findings in this study and how they may explain the 
role of macropinocytosis and SOD1 and TDP-43 protein aggregates in the pathogenic 
disease cycle of amyotrophic lateral sclerosis . (i) In ALS, SOD1 or TDP-43 may form spontaneous 
aggregates under non-physiological conditions or contain newly formed aggregates from seeded aggregation 
reaction in motor neurons. (ii) These aggregates can be released from motor neurons either via cell death 
(passive) or via exosomes (active) mechanisms. (iii) Once released into the extracellular environment, these can 
internalise into neuronal cells via the activation of macropinocytosis, and enter through newly formed 
macropinosomes, a process exploited by viruses. (iv) These aggregates may then escape these membrane bound 
vesicles and enter into the cytosol (v) to potentially seed the aggregation of endogenous soluble proteins. 
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Understanding neuron specific macropinocytosis mechanisms will be vital in identifying a 
target to slow disease progression. In particular, the intracellular pathways that result in 
activation of macropinocytosis, the formation and closure of macropinosomes, and 
importantly potential disintegration of macropinosomes must be examined. Lastly, while the 
ability of cellular uptake of misfolded SOD1 to induce TDP-43 pathology may be due to 
cellular stress rather than a specific result of SOD1 misfolding, this notion further supports 
the complex nature of ALS disease. However further study is required to decipher the 
mechanisms involved in these interactions, and potentially identify other proteins or 
processes that may be involved.  
Given the prion-like properties of SOD1 and TDP-43 aggregates, an attractive therapeutic 
target would be to block the cell-to-cell propagation. One way of doing this is to target the 
aggregate entry mechanism. In an analogous situation, mechanisms underpinning Ebola virus 
entry via macropinocytosis are being scrutinized, with promising compounds targeting 
endocytosis and escape of viral particles from endosomes proving successful in mice (Sakurai 
et al., 2015). Macropinocytosis may be a viable target given that other cell types such as 
microglia that clear protein aggregates appear to be via different pathways (Roberts et al., 
2013). It may be possible then to redirect aggregates from entering neurons by supressing 
macropinocytosis in pathological conditions while maintaining receptor mediated phagocytic 
pathways utilized by microglia to engulf extracellular protein aggregates. 
Overall, the work presented in this thesis presents data that is consistent with the notion that 
protein aggregates could be an active part of ALS disease progression, possibly through 
secondary nucleation (Buell et al., 2014), or another prion-like aggregate propagation 
process. It presents novel data that now implicates the activation of macropinocytosis, a 
process used by viruses during infection. Therefore, a better understanding of the 
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pathological mechanisms involved and identifying targets may lead to halting the passage of 
the toxic aggregates in a strategy analogous to drugs blocking viral entry. 
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